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ABSTRACT 
 
Traumatic brain injury (TBI) is an important cause of morbidity and mortality. 
The objectives of this study are to determine the links, if any, between selected single 
nucleotide polymorphisms (SNPs) with 6 month post-TBI outcome, and to identify serum 
protein biomarkers that may be utilized to detect and grade the severity of TBI.  
A cross sectional cohort of 205 hospitalized TBI patients was prospectively 
studied for the SNPs in the genes of the Apolipoprotein E (APOE) and its promoter 
region, Catechol-O-Methyl Transferase (COMT), Dopamine D2 receptor (DRD2), 
Dopamine D3 receptor (DRD3), Ciliary Neurotrophic Factor (CNTF), Brain Derived 
Neurotrophic Factor (BDNF) and Glial cell Derived Neurotrophic Factor (GDNF) using 
patients blood DNA. The Glasgow Coma Score on admission, and Glasgow Outcome 
Scale at six months were determined in this cohort and correlated with the findings. A 
standard iTRAQ protocol was used to identify potential serum protein markers using 
serum pools from a separate cohort of mild, moderate and severe cases of TBI. Potential 
peptide candidates were analyzed on a “5800 MALDI TOF/ TOF mass spectrometer” and 
identified using the “ProteinPilot 4.0” software. 
Our analysis showed that possession of at least one APOE ε4 allele (OR: 5.5, 95% 
CI: 2.8-10.7, p= 0.01), COMT AA genotype (OR: 18.6, 95% CI: 5.97-58.03, p= 0.01) or 
at least one CNTF A allele (OR: 3.7, 95% CI: 1.88-7.36, p= 0.01) were significantly 
associated with unfavorable outcome at 6 months post-TBI. In the logistic model, the 
GCS alone significantly predicted unfavorable outcome in our TBI cohort (R2 = 30.8, 
p=0.01). However, GCS paired with the status of APOE ε4 allele (R2 = 60.9; APOE ε4 
allele- OR: 8.0, 95% CI: 3.6-18.0, p= 0.01; GCS- OR: 5.0, 95% CI: 2.7-9.1, p= 0.01), 
GCS paired with COMT AA genotype (R2 = 60.61; COMT AA genotype- OR: 18.96, 
95% CI: 5.48-65.56, p= 0.01; GCS- OR: 3.95, 95% CI: 2.17-7.17, p= 0.01) or GCS paired 
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with CNTF A allele (R2 = 46.15; CNTF A allele- OR: 4.55, 95% CI: 2.10-9.86, p= 0.01; 
GCS- OR: 4.28, 95% CI: 2.42-7.58, p= 0.01) were  better predictors for unfavorable 
outcome compared with GCS alone. Unfavorable outcome after TBI was not associated 
with alleles of SNPs of the APOE promoter, DRD2 gene, DRD3 gene, BDNF gene and 
GDNF gene.  
We identified 7 biomarkers to be increased in all grades (mild, moderate and 
severe) of TBI. Two of these markers (“Serum Amyloid- A” and “C- Reactive Protein”) 
were markers for general injury and inflammation. Five markers appear to be specifically 
increased in TBI (“Leucine- Rich alpha- 2 Glycoprotein- 1”, “Lipopolysaccharide 
Binding Protein”, “Fibronectin”, “Vitronectin” and “Alpha- 1 antichymotrypsin”). 
“Apolipoprotein E” and “Zinc Alpha- 2 glycoprotein” were increased only in severe TBI. 
Conversely, “Gelsolin” was decreased in all grades of TBI, whereas, “Kininogen” was 
decreased in moderate and severe TBI. If validated, some or all of these protein markers 
may aid in the detection of TBI, including mild TBI, in conjunction with other 
conventional diagnostic methods. Our findings suggest that certain serum protein markers 
and SNPs may be useful to aid clinicians in the diagnosis and grading of TBI, and for 
prediction of post-TBI outcome, respectively.   
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ABSTRAK 
 
Trauma Otak: Pengajian Mengenai Biomarker Serum Untuk Diagnosis Dan 
Polimorfisme Nukleotida Untuk Meramalkan Pemulihan 
 
Kecedaraan otak merupakan punca utama kesakitan dan kematian. Objektif kajian 
ini adalah untuk menentukan hubungan antara beberapa polimorfisme nukleotida tunggal 
dengan pemulihan pada bulan yang keenam dan mengenal pasti penanda protein serum 
yang boleh digunakan untuk mendiagnosis dan menggred trauma otak. 
Kami mengkaji 205 pesakit trauma otak di hospital. Polimorfisme nukleotida 
tunggal daripada gene Apolipoprotein E (APOE) dan promoter, Catechol-O-Methyl 
Transferase (COMT), Dopamine D2 receptor (DRD2), Dopamine D3 receptor (DRD3), 
Ciliary Neurotrophic Factor (CNTF), Brain Derived Neurotrophic Factor (BDNF) dan 
Glial cell Derived Neurotrophic Factor (GDNF) telah digenotype menggunakan DNA 
yang diekstrak daripada darah pesakit. Glasgow Coma Score (GCS) pada kemasukan, dan 
Glasgow Outcome Scale pada bulan yang keenam ditentukan; dan perkaitan dengan 
polimorfisme nukleotida tunggal ditentukan. Teknik iTRAQ telah digunakan untuk 
mengenal pasti protein serum untuk TBI daripada pesakit trauma otak ringan, sederhana 
dan serius dan sampel kawalan. Akhirnya, peptida dianalisis pada “5800 MALDI TOF/ 
TOF mass spectrometer” (Applied Biosystems) dan dikenal pasti menggunakan 
ProteinPilot 4.0. 
Analisis menunjukkan, allele APOE ε4, COMT AA genotype dan allele CNTF A 
dapat meramal pemulihan pesakit yang mengalami kecederaan otak. Kehadiran sekurang- 
kurangnya satu allele APOE ε4 (OR: 5.5, 95% CI: 2.8-10.7, p= 0.01), COMT AA 
genotype (OR: 18.6, 95% CI: 5.97-58.03, p= 0.01) atau kehadiran sekurang- kurangnya 
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satu allele CNTF A (OR: 3.7, 95% CI: 1.88-7.36, p= 0.01) adalah sangat berkait dengan 
pesakit yang tidak pulih dengan baik. Dalam model logistik, GCS sendiri dapat meramal 
samaada seorang pesakit tidak akan pulih dengan baik selepas kecederaan otak (R2 = 30.8, 
p=0.01). Tetapi, model tersebut dapat ramal dengan lebih baik sekiranya GCS 
digabungkan dengan status allele APOE ε4 (R2 = 60.9; Allele APOE ε4- OR: 8.0, 95% 
CI: 3.6-18.0, p= 0.01; GCS- OR: 5.0, 95% CI: 2.7-9.1, p= 0.01), GCS digabungkan 
dengan COMT AA genotype (R2 = 60.61; COMT AA genotype- OR: 18.96, 95% CI: 
5.48-65.56, p= 0.01; GCS- OR: 3.95, 95% CI: 2.17-7.17, p= 0.01) atau GCS digabungkan 
dengan status allele CNTF A (R2 = 46.15; Allele CNTF A- OR: 4.55, 95% CI: 2.10-9.86, 
p= 0.01; GCS- OR: 4.28, 95% CI: 2.42-7.58, p= 0.01). Pemulihan yang tidak baik tidak 
berkaitan dengan polimorfisme nukleotida pada gene APOE promoter, gene DRD2, gene 
DRD3, gene BDNF dan gene GDNF.  
Kami mengenalpasti 7 biomarker meningkat dalam semua gred kecederaan otak. 
Dua daripadanya (“Serum Amyloid A” dan “C- Reactive protein”) turut meningkat dalam 
inflamasi dan kecederaan biasa yang lain. Lima biomarker didapati meningkat secara 
spesifik selapas kecederaan otak (“Leucine Rich alpha-2 Glycoprotein-1”, 
“Lipopolysaccharide Binding Protein”, “Fibronectin”, “Vitronectin” dan “Alpha- 1 
antichymotrypsin”). “Apolipoprotein E” dan “Zinc Alpha- 2 glycoprotein” hanya 
meningkat dalam kecederaan otak yang serius. Manakala, aras “Gelsolin” dalam serum 
menurun selepas semua gred kecederaan otak, dan aras “Kininogen” hanya menurun 
dalam kecederaan tahap sederhana dan serius. Jika disahkan, biomarker- biomarker ini 
dapat memastikan kewujudan kecederaan otak dalam seseorang individu termasuk 
kecederaan otak yang ringan, dan dapat mendiagnosis dan menggred kecederaan otak, 
supplemen kepada kaedah mendiagnosis sedia ada yang lain. 
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CHAPTER 1 
INTRODUCTION 
 
Traumatic brain injury (TBI) occurs when an external force damages the brain 
and can result from motor vehicle accidents, from falls or from blunt force assault. TBI 
is one of the major health and socioeconomic problems in Malaysia and can be considered 
a “silent epidemic”. It is the prime cause of death for people who are below 45 years old 
of age (Moppett, 2007) and motor vehicle accidents are considered as the major cause of 
TBI. Based on statistics, the death rate due to motor vehicle accident in Malaysia is one 
of the highest in the world with approximately 22 deaths per 100, 000 inhabitants (Liew 
et al., 2009). Currently there are only seven general hospitals and three university 
hospitals in Malaysia with neurosurgical services to serve the entire population of 30 
million. With such inadequate neurosurgical facilities and intensive care units in 
Malaysia, there is an alarming and critical lack of services to cater for the large number 
of TBI patients (Liew et al., 2009).    
The pathophysiology of TBI is complex, and outcome depends on the type, 
severity and location of injury. Primary brain injury is induced by direct impact to the 
brain parenchyma leading to focal or diffuse tissue distortion, destruction, tearing, and/or 
hemorrhage. As a result of primary brain injury, neurons can die by necrosis caused by 
membrane disruption, irreversible metabolic disturbances and excitotoxicity (Chesnut et 
al., 1993). Primary brain injury in the brain can be fatal or give rise to severe disability 
due to neuronal destruction. A cascade of events, triggered either immediately after TBI 
or in the following hours or days, could lead to cerebral ischemia, cerebral edema, 
hematoma formation, hypoxia and hypotension (Chesnut et al., 1993; Marmarou et al., 
1991). These conditions are collectively known as secondary brain injury. In contrast to 
primary brain injury where neuronal death is mainly caused by necrosis, secondary brain 
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injury is marked mainly by neuronal apoptosis. Neuronal apoptosis involves the Caspase 
cascade and release of apoptogenic factors from mitochondria and lysosome which leads 
to systematic fragmentation of cellular DNA, collapse of nuclear structure and 
cytoskeletal disintegration. This is followed by the formation of membrane wrapped 
apoptotic bodies (Clark et al., 2001; Clark et al., 1997) and exposure of phosphatidyl-
serine on the cell membrane surfaces and subsequently detection and engulfment by 
microglia (Borisenko et al., 2003).   
Expression studies have shown that several genes are involved in the 
pathophysiology of secondary brain damage. Single nucleotide polymorphisms (SNPs) 
of various genes have been implicated to dramatically worsen primary damage, leading 
to the activation of a cascade of neuronal and axonal pathologies, which in turn could 
impact on the patient's overall clinical outcome. To date, the association between SNPs 
in the APOE gene and its promoter with outcome after TBI have been most extensively 
studied. Some SNPs of genes involved in dopamine systems, and neurotropic factors may 
have the potential to influence the outcome after TBI. The associations between outcomes 
after TBI with these SNP’s in our local population have not been studied before. Indeed, 
there is insufficient data in Asian populations to compare with data derived from Western 
populations.  
There is also considerable interest to develop protein markers that can be used to 
confirm the presence of TBI in patient with polytrauma and to distinguish and grade the 
severity (mild, moderate or severe) of TBI. If a reliable protein marker for TBI could be 
found that appears soon after TBI, is easily measurable in blood, has an absolute value 
proportional to the extent of brain and has a potential for early prognosis, TBI 
management could conceivably be improved. Unfortunately, to date an ideal TBI protein 
marker has yet to be found. Traditional biomarker identification rely on the ELISA 
method and/or high-resolution protein separation by 2D gels using dyes, fluorophores or 
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radioactivity to visualize and quantify the relative abundance of proteins (Bantscheff, 
Lemeer, Savitski, & Kuster, 2012; Schulze & Usadel, 2010). Unfortunately, many 
samples are required for ELISA, and image analysis of 2D gels is labour intensive and 
often subjective. Mass spectrometry-based proteomics has emerged as a new technology 
over the last decade to perform large-scale analysis of proteins, and has become routine 
in many types of biomarker analysis (Schulze & Usadel, 2010), including TBI 
(Hergenroeder et al., 2008). 
The general objectives of this study are to determine the associations between 
selected SNPs with outcome after TBI and to identify serum protein biomarkers that can 
be utilized to diagnose and grade the severity of TBI.  
 
The specific objectives are: 
1. To determine the association between polymorphisms in the APOE gene and 
promoter, and outcome after TBI.  
2. To determine the association between polymorphisms in the genes modulating 
dopamine system and outcome after TBI. 
3. To determine the association between polymorphisms in the genes modulating 
neurotropic factors and outcome after TBI. 
4. To identify serum biomarkers in mild, moderate and severe TBI by mass 
spectrometry. 
5. To determine the association between serum biomarkers and severity of the 
TBI. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Glasgow Coma Scale 
 
Consistent and precise recording of neurological observations is important to 
establish the patient’s neurological status after brain injury. The Glasgow Coma Scale 
(GCS) was introduced in 1974 with the aim of standardizing the assessment of the level 
of consciousness in head injury patients (Teasdale & Jennett, 1974). It has been used 
mainly in evaluating prognosis, comparing different groups of patients and for monitoring 
the neurological status. Traditionally, GCS based on the clinical presentation on 
admission, is the gold standard to classify patients into mild, moderate or severe brain 
injury. 
Table 2.1 shows the GCS scores and their definitions. The GCS is divided into 
three sections: “eye opening”, “verbal responses” and “motor responses”. The patient is 
assessed and scored in each area and the scores are then added together to give the 
patient’s GCS score - “The highest possible score is 15; the lowest is 3. A patient who is 
fully aware and orientated will score 15; a lower score will reflect a lower level of 
consciousness. It is important to stress that for clinical use, the three separate scores (eye 
opening, verbal responses and motor responses) rather than the total sum score more 
effectively reflects the patients’ clinical status. A cumulative score of 14-15 is classified 
as mild TBI, 9-13 as moderate TBI and ≤ 8 as severe brain injury” (Baalen et al., 2003; 
Teasdale & Jennett, 1974, 1976). 
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Table 2.1: Glasgow Coma Scale with scores (Baalen et al., 2003; Teasdale & Jennett, 
1974, 1976). 
Eye opening 1 
4 “Spontaneous.  Indicates arousal, not necessarily awareness” 
3 “To speech.  When spoken to – not necessarily the command to open eyes” 
2 “To pain. Applied to limbs, not face where grimacing can cause closure” 
1 “None” 
  
Motor response 2 
6 “Obeys commands. Exclude grasp reflex or postural adjustments” 
5 “Localises.  Other limb moves to site of nailbed pressure” 
4 “Withdraws. Normal flexion of elbow or knee to local painful stimulus” 
3 “Abnormal flexion. Slow withdrawal with pronation of wrist, adduction of 
shoulder” 
2 “Extensor response.  Extension of elbow with pronation and adduction” 
1 “No movement” 
  
Verbal responses 3 
5 “Orientated.  Knows who, where, when; year, season, month” 
4 “Confused conversation.  Attends & responds but answers muddled/wrong” 
3 “Inappropriate words. Intelligible words but mostly expletives or random” 
2 “Incomprehensible speech.  Moans and groans only – no words” 
1 “None” 
 
1 “Eye opening- this should be spontaneous when the patient is approached. If the patient’s eyes do not open spontaneously, determine 
whether they open to speech or painful stimuli. If the eyes are open, do not assume that the patient is fully aware and orientated to 
their surroundings. Some patients with head injuries may have spontaneous blinking and eye movement; this does not indicate full 
consciousness.” 
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Table 2.1, Continued: Glasgow Coma Scale with scores (Baalen et al., 2003; Teasdale 
& Jennett, 1974, 1976). 
 
2 “Motor response- this is assessed by giving the patient some simple commands, for example ‘squeeze my hand (both sides)’, ‘lift 
your legs up off the bed’, and ‘show your tongue’. The strength of the patient’s limbs should be noted- it is essential to observe for 
weaknesses. When a patient does not respond to simple commands then response to painful stimuli is assessed. The practice of 
pinching the patient and/or using a pinprick test is no longer recommended for assessing motor response and should not be used during 
a neurological evaluation. There are three recognised stimuli that can be used when assessing motor response:  
a. Trapezium squeeze- use the thumb and two fingers to squeeze and twist the muscle;  
b. Supraorbital pressure- run a finger along the bony rim above the eye. This is not recommended if the patient has facial 
fractures;  
c. Sternal rub- using the knuckles of a clenched fist, apply pressure along the sternum.” 
3 “Verbal response- this determines state of consciousness. Patients who are fully orientated will know their name, where 
they are, the date and year. A confused patient may be able to hold a conversation, but when asked questions may give replies which 
are incorrect or inapt. They may use inappropriate words, which do not make sense to the assessor, or they may make incomprehensible 
sounds such as moans or groans. Some stimuli may be required to obtain a response from the patient- this type of patient is not aware 
of their surroundings”  
.  
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After four decades, the GCS is now internationally recognized as an efficient 
assessment of consciousness. The scale progressively occupied a central role in clinical 
guidelines and an integral component of scoring systems for patients with TBI (G. 
Teasdale et al., 2014). 
 
2.2 Glasgow Outcome Scale 
 
Head injury is associated with significant morbidity and mortality. The Glasgow 
Outcome Scale (GOS) is one of several ways of measuring the outcome after head injury 
(Jennett & Bond, 1975). Table 2.2 shows the GOS scales and their definitions. It is a 
global scale for functional outcome that groups patient status into one of five categories: 
“Dead, Persistent vegetative state, Severe disability, Moderate disability or Good 
recovery”. The GOS is the most widely used and accepted measure of outcome following 
head injury and provides an overall assessment suitable for the comparison of outcomes 
(Wade, 1992). It is a simple, reliable means of describing recovery (Jennett & Bond, 
1975) that is quick to administer, broadly applicable and has clinically relevant categories 
(Wilson, Pettigrew, & Teasdale, 2000). It has been adopted widely for use in clinical trials 
(Hellawell, Signorini, & Pentland, 2000; Wade, 1992; Wilson et al., 2000). 
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Table 2.2: Glasgow Outcome Scale (Jennett & Bond, 1975) 
1 Death “dead” 
2 Persistent vegetative 
state 
“wakefulness without awareness; absence of speech or 
evidence of mental function in a patient who appears awake 
with spontaneous eye opening” 
3 Severe disability “conscious but dependent; patient requires assistance to 
perform daily activities and cannot live independently” 
4 Moderate disability “independent but disabled; patient unable to return to work 
but otherwise able to independently perform the activities of 
daily living” 
5 Good recovery “reintegrated but may have non disabling sequelae; able to 
return to work but not necessarily at the same level; may 
have minor neurological or psychological impairments” 
 
 
When an evaluation is to be done mainly depends on the aim for which it is being 
conducted. If the evaluation is done to measure mortality, it should be assessed at the time 
of discharge, since most deaths occur in the first week. Since some patients continue to 
improve over the years, it has to be noted that estimation of ultimate outcome might be 
tedious. Continuing a follow-up over years is very tedious and impractical to evaluate 
outcome of an acute condition. Studies using a 5-point outcome scale have shown that 
most patients reached their final point by six months, although it is undeniable that small 
number of patients will continue to improve within a category (Teasdale, 1982). Thus, 
most international studies emphasises outcome evaluation at 6 month. 
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The assignment of an individual to an outcome category should be based on the 
results of a structured interview focused on social and personal functional abilities 
(Jennett & Bond, 1975).  An interrater reliability study of the structured interview for the 
GOS yielded a weighted kappa value of 0.89. Hence, GOS assessment using a standard 
format with a written protocol is practical and reliable (Wilson, Pettigrew, & Teasdale, 
1998). This has increased the reliability of postal and telephone administration to 
determine a GOS rating (Wilson et al., 2002). Each interview incorporates a means for 
including information regarding pre-injury status, thereby providing a means for 
determining the effect of the sequelae of head injury on outcome separate from the effects 
of pre-existing conditions or circumstances (Pettigrew, Wilson, & Teasdale, 1998; 
Wilson et al., 1998). The final rating is based on the lowest category of outcome 
indication in the interview (Wilson et al., 2000). 
 
2.3 Genetic and serum protein biomarkers for TBI  
 
Interest for genetic and serum biomarkers in TBI had been rapidly increasing in 
the past several decades. Mainly because individuals with seemingly very similar injuries 
often have vastly different outcomes, it is believed that genetic factors may explain, in 
part, different recovery trajectories. As genetic and genomic technologies have improved, 
genetic analysis has become more accessible and increasingly used to study outcomes 
after TBI. SNPs are genetic variants that arises from a difference in a single base pair in 
the deoxyribonucleic acid. SNPs may be located in critical areas in genes and so may 
ultimately lead to changes in proteins that may be important in certain disease specific 
pathways. On the other hand, serum protein markers of TBI are also gaining interest. 
Serum protein markers are protein molecules which may be increased or decreased as a 
response to TBI. Alterations in levels of serum proteins within 24 hours in patients with 
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mild, moderate and severe TBI may be useful as an adjunct to detect and even grade TBI, 
especially in the polytrauma setting. Especially in mild TBI, as the patients’ GCS scores 
are normal, and neuroimaging investigations such as the CT scan or brain MRI may not 
show evidence of injury. These biomarkers allow a quantitative diagnostic, even for 
patients who cannot be evaluated by GCS due to intubation, ventilation and/or sedation. 
Although quite a number of research studies had been conducted, the effort to 
identify good genetic and serum protein markers still goes on. Confounding factors 
include varying degrees of secondary damage to the brain after the primary injury. The 
location and extent of tissue damage may not correspond with outcome because a small 
area of damage to an eloquent area could give rise to a more unfavorable outcome 
compared to a larger area of injury to a less critical area. In addition, restriction of brain 
tissue proteins flowing into the circulation by the blood brain barrier, and combination of 
TBI with trauma to extracranial organs increases the difficulty to find a sensitive and 
specific protein marker for TBI (Feala et al., 2013; Mondello et al., 2011).  
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2.4 SNPs as biomarkers of TBI  
 
The majority of genetic biomarker studies in TBI have been ‘candidate SNP 
association studies’. Expression studies had shown that numerous genes are associated in 
the pathophysiology of TBI. The SNPs of APOE gene and its promoter, candidate SNPs 
of dopamine systems and candidate SNPs of neurotropic factors are postulated to 
prospectively influence TBI outcome. Studying SNPs offers hope for the possible 
development of new patient management and therapeutic strategies. 
 
2.4.1 Apolipoprotein E (ApoE) 
 
ApoE is a 299 amino acid protein with a relative molecular mass of 34 KDa. ApoE 
is the major apolipoprotein in the human cerebrospinal fluid. It exists as small spherical, 
discoidal lipoprotein, often packed together with cholesterol and phospholipid to form 
lipid-protein complexes, which are then released into the extracellular space. These 
complexes bind to ApoE receptors on the surfaces of nerve cells and are internalised into 
the cell.  
In the peripheral nervous system, ApoE is synthesized primarily by the glia cells 
surrounding motor and sensory neurons, and in non-myelinated Schwann cells. Large 
quantities of ApoE are also secreted by resident macrophages and those recruited to 
injured peripheral nerves, which accumulates in the extracellular matrix of the 
regenerating nerve and degenerating stump (Mahley, 1988). It was initially observed that 
ApoE concentration increases 200-fold in an injured rat sciatic nerve (Boyles et al., 1989; 
Ignatius et al., 1986; Ignatius, Shooter, Pitas, & Mahley, 1987) and then returns to 
baseline by 8 weeks when sciatic nerve regeneration was largely complete. Studies of 
peripheral nerve injury in ApoE -/- mice suggested that normal regeneration can occur 
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without ApoE (Popko, Goodrum, Bouldin, Zhang, & Maeda, 1993). However, 
ultrastructural examination revealed a reduced number of axons, and defects in their 
morphology (Fullerton, Strittmatter, & Matthew, 1998). 
In the central nervous system (CNS), astrocytes are the major cells that produce 
ApoE (Boyles et al., 1985; Pitas et al., 1987). However, under pathological and 
physiological conditions, CNS neurons also express ApoE (Bao et al., 1996; Beffert & 
Poirier, 1996; Diedrich et al., 1991; Han et al., 1994; Harris et al., 2004; Metzger et al., 
1996; Xu et al., 1999; Xu et al., 1998; Xu, Schmechel, et al., 1999; Xu et al., 1996). 
Treatment with kainic acid induces ApoE synthesis in hippocampal neurons in rats 
(Boschert, Merlo-Pich, Higgins, Roses, & Catsicas, 1999), and ApoE is expressed in 
neurons in patients with cerebral infarcts (Aoki et al., 2003). It has been postulated that 
neuronal expression of ApoE is induced to promote neuron repair or protection (Huang 
et al., 2004; Mahley, 1988; Mahley & Huang, 1999; Mahley & Rall, 2000; Weisgraber, 
1994). 
 
2.4.1.1 ApoE isoforms and effects  
 
The APOE gene spans 3.7 kilobases, has four exons, and is located on the long 
arm (q) of chromosome 19 at position 13.2 (19q13.2) (Houlston, Snowden, Green, 
Alberti, & Humphries, 1989). ApoE are encoded by three alleles (ε2, ε3 and ε4) of the 
APOE gene (Roses, 1996) giving rise to 3 homozygous genotypes (APOE ε2/ε2, APOE 
ε3/ε3, and APOE ε4/ε4) and three heterozygous genotypes (APOE ε2/ε3, APOE ε3/ε4, 
and APOE ε2/ε4).  These three alleles arise due to SNPs at positions 112 and 158. The 
APOE ε2 allele have TGCs at both positions, APOE ε4 allele have CGCs at both positions, 
whereas APOE ε3 allele has TGC at position 112 and CGC at position 158, respectively.  
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Due to the SNPs, ApoE has three common isoforms (E2, E3 and E4): ApoE E2 (cysteine 
at both positions), ApoE E4 (arginine at both positions), whereas ApoE E3 has cysteine 
at position 112 and arginine at position 158, respectively. These small changes between 
the isoforms cause significant alterations in structure and function. 
ApoE has two structural domains: “a 22-kDa N-terminal domain (residues 1–191) 
containing the low-density lipoprotein receptor binding site (residues 136–150) and a 10-
kDa C-terminal domain (residues 216–299) containing the major lipid binding site 
(residues 240–270) (Mahley, 1988; Mahley & Huang, 1999; Mahley & Rall, 2000; 
Weisgraber, 1994; Weisgraber & Mahley, 1996). In ApoE E4, but not to the same extent 
as in ApoE E2 or ApoE E3, the two domains interact (Dong & Weisgraber, 1996; Dong 
et al., 1994). X-ray crystallographic studies indicate that arginine-112 in ApoE E4 allows 
the side chain of arginine-61 to extend away from the helical bundle (Dong et al., 1994) 
and interacts with glutamate-255 in the C-terminal region (Weisgraber, 1990). The side 
chain of arginine-61 in ApoE E3 and ApoE E2 has a different orientation (tucked between 
helices 2 and 3) (Wilson et al., 1991) and are much less likely to undergo domain 
interaction. Because of this, ApoE E4 is the least stable isoform. Furthermore, the 
denaturation pattern of ApoE E4 does not fit a two-state equilibrium (native versus fully 
unfolded), suggesting that ApoE E4 exists as a partially folded intermediate or a molten 
globule. These reactive intermediates have several pathophysiological activities (Dobson, 
2001; Ptitsyn, 1995), including altered intradomain interactions, increased lipid and 
membrane binding, membrane disruption, translocation across membranes, and increased 
susceptibility to proteolysis”.  
Consequently, ApoE E3 (and ApoE E2) seems to be more effective in the normal 
maintenance and repair of cells than ApoE E4, which may be in fact be detrimental to the 
process.  Isoform-specific effects of ApoE have been demonstrated on neurite extension 
culture systems (Bellosta et al., 1995; DeMattos, Curtiss, & Williams, 1998; Holtzman et 
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al., 1995; Nathan et al., 1994; Sun et al., 1998). In the presence of a source of lipid, ApoE 
E3 stimulates neurite outgrowth, whereas ApoE E4 does not. Astrocyte-derived ApoE 
E3, but not ApoE E4, also caused neurite extension in rat hippocampal neurons (Sun et 
al., 1998). ApoE E4 inhibition of neurite extension appears to be related to alterations in 
the cytoskeleton, that impacts on microtubule stability (Nathan et al., 1995). These effects 
may be mediated through tau (a microtubule stabilizing protein). ApoE E3, but not ApoE 
E4, binds to tau in vitro, and may protect tau from hyperphosphorylation, a process which 
inhibits the ability of tau to stabilize microtubules (Lovestone et al., 1996; Strittmatter et 
al., 1994; Tesseur et al., 2000).  
 
2.4.1.2 TBI and the APOE ε4 allele 
 
Despite great efforts to investigate the role of APOE gene on outcome after TBI, 
in most of these studies, its role remains equivocal. We believe it may be due to sample 
populations and varying prevalence of APOE 4 allele in the different study populations. 
Besides, in most studies, there is a case mix of mild to severe TBI patients (Chamelian, 
Reis, & Feinstein, 2004a; Pruthi et al., 2010), that could explain the divergent results of 
APOE polymorphism influence on TBI outcome. In order to generate robust data, a much 
larger sample is required, which might not be realistic.  
Teasdale et al. (1997) in a prospective evaluation of 89 patients with TBI, 
observed a 2-fold increase in unfavorable outcome at 6 months with 17 of 30 (57%) 
patients with APOE 4 allele who had unfavorable outcome compared with only 16 of 59 
patients (27%) without APOE 4 allele. “Death”, “vegetative state”, or “severe disability” 
was defined as unfavorable outcome using the GOS (G. M. Teasdale, Nicoll, Murray, & 
Fiddes, 1997). Several other clinical studies in adults with TBI support the notion that 
APOE 4 allele is associated with a poor prognosis and unfavorable outcome (Chiang, 
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Chang, & Hu, 2003; Friedman et al., 1999; Liaquat, Dunn, Nicoll, Teasdale, & Norrie, 
2002) (Table 2.3). Most of these reports document the association between APOE ε4 
allele and post-TBI outcome almost exclusively in Caucasian or white populations. Other 
studies suggested that APOE 4 allele has no impact on recovery from TBI (Alexander et 
al., 2007; Chamelian et al., 2004a; Diaz-Arrastia et al., 2003; Millar, Nicoll, Thornhill, 
Murray, & Teasdale, 2003; Nathoo, Chetry, van Dellen, Connolly, & Naidoo, 2003; 
Pruthi et al., 2010; G. M. Teasdale, Murray, & Nicoll, 2005; Willemse-van Son, Ribbers, 
Hop, van Duijn, & Stam, 2008). In a South African black population with a relative high 
frequency of APOE ε4 allele, APOE ε4 allele was not found to have a significant effect 
on TBI outcome (Nathoo et al., 2003). Yet other studies showed insignificant association 
between APOE genotype with outcome in mild TBI (Chamelian et al., 2004a; Sundstrom 
et al., 2004). Thus, further research to study the association between TBI outcome and 
APOE polymorphism is needed, particularly in non-caucasian racial groups.  
 
 
 
16 
  
Table 2.3: Baseline variables of studies on the association between APOE genotype and TBI outcome 
Author and Year Country 
Outcome 
Evaluation 
Method (Blinded 
to APOE 
genotype) 
Sample Size GCS OUTCOME 
            Non APOE4 allele carrier APOE4 allele Carrier 
    Mild Moderate Severe Unfavorable Favorable Unfavorable Favorable 
(G. M. Teasdale et al., 1997) United Kingdom 
Direct Interviews 
(Yes) 
89 48 19 22 16 43 17 13 
           
(Friedman et al., 1999) Israel 
Direct Interviews 
(Yes) 
69 X X X 29 13 26 1 
           
(Liaquat et al., 2002) United Kingdom 
No Info  
(Yes) 
129 53 26 50 
92 patients, 21% have poor 
outcome (~19) 
37 patients, 43% with poor 
outcome (~16) 
         
(Diaz-Arrastia et al., 2003) South Africa 
Phone interviews  
(Yes) 
106 58 13 35 10 19 21 56 
           
(Millar et al., 2003) United Kingdom 
No Info  
(Yes) 
396 27 21 272 73 206 28 88 
           
(Chiang et al., 2003) Taiwan 
Direct Interviews 
(Yes) 
100 36 24 40 20 61 10 9 
           
(Nathoo et al., 2003) United States of America 
No Info  
(Yes) 
110 59 31 20 10 55 11 34 
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Table 2.3, Continued: Baseline variables of studies on the association between APOE genotype and TBI outcome 
Author and Year Country 
Outcome 
Evaluation 
Method (Blinded 
to APOE 
genotype) 
Sample Size GCS OUTCOME 
            Non APOE4 allele carrier APOE4 allele Carrier 
    Mild Moderate Severe Unfavorable Favorable Unfavorable Favorable 
(Chamelian et al., 2004a) Canada 
No Info  
(Yes) 
90 X X X X X X X 
           
(G. M. Teasdale et al., 2005) United Kingdom 
Direct Interviews 
(Yes) 
984 513 178 267 215 445 118 206 
           
(Alexander et al., 2007) United States of America 
Direct Interviews 
(Yes) 
123 X X X 97 without APOE E4 allele 26 with APOE E4 allele 
         
(Willemse-van Son et al., 2008) Netherlands 
Direct Interviews 
(Yes) 
79 X X X 13 43 2 12 
           
(Pruthi et al., 2010) India 
Direct Interviews 
(Yes) 
73 X X X 11 50 0 12 
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2.4.1.3 APOE Promoter  
 
Three SNPs in the APOE promoter at positions -491 A/T, -427 C/T, and -219 G/T 
(also known as Th1/E47cs) have been variously reported to alter transcriptional activity 
of the APOE promoter due to differential binding of transcription factors (Artiga et al., 
1998; Lambert et al., 1998; Lambert et al., 1998). The -491T allele is associated with a 
diminished transcription, -427 polymorphism with an unaltered transcription and -219G 
allele with an enhanced transcription. The various allelic combinations for each position 
are: -491 AA or -491 AT or -491 TT; -427 CC or -427 CT or -427 TT; -219 GG or -219 
GT or -219 TT. These SNPs are also speculated to influence the outcome after TBI. 
Lendon et al. (2003) noted that poor recovery from TBI was more frequent among 
subjects with the TT genotype of -219 G/T compared to the GG and GT genotypes. 
However, no association was noted between unfavorable outcome and -491 A/T promoter 
polymorphism (Lendon et al., 2003). To date there is no study on -427 C/T promoter 
polymorphisms and outcome.  
 
2.4.2 SNPs in genes modulating the dopamine system 
 
Dopamine is an endogenous neurotransmitter that belongs to the catecholamine 
and phenethylamine families. When released at the presynaptic site of a neuron, it carries 
the signal through the synaptic cleft to reach the postsynaptic site of another neuron where 
it binds to dopamine receptors (mainly D1 to D5). Dopamine is the major 
neurotransmitter in the central dopaminergic pathways that plays an important role in 
motor function (the nigro-striatal pathway), motivated behavior, hormonal stasis (the 
tubero-infundibular pathway), cognition (meso-cortical pathway), mood homeostasis and 
reward circuitry (the meso-limbic pathway). It may also be involved in neural plasticity 
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and repair through effects on the brain derived neurotrophic factor (Guillin et al., 2004), 
and in recovery of motor function after TBI as seen in animal and human studies 
(Martinsson & Eksborg, 2004). 
The level of dopamine is carefully regulated in the central dopaminergic system. 
Moreover, dopaminergic systems are susceptible to injury and TBI associated 
dysregulation (Kobori, Clifton, & Dash, 2006; McAllister, Flashman, Sparling, & Saykin, 
2004) leads to increased level of dopamine, which is a potent excitotoxin to neurons. High 
levels of dopamine in the synaptic cleft are rapidly oxidized to form dopamine 
semiquinone/quinine. Oxidized dopamine via monoamine oxidase activity or redox 
cycling can induce the generation of hydrogen peroxide and superoxide that cause 
significant oxidative stress (Brunmark & Cadenas, 1988; Hastings, 1995; Olney et al., 
1990; Sinet, Heikkila, & Cohen, 1980; Williams & Castner, 2006). Furthermore, 
dopamine signaling at the dopamine D2 receptor can induce increases in intracellular 
Ca2+ release and activation of calcium dependent kinases and phosphatases important for 
cell death signaling (Azdad et al., 2009; Hernandez-Lopez et al., 2000; So et al., 2009). 
Many genetic studies have focused on SNPs in genes that modulate the dopamine 
system in neuropsychiatric disorders such as Parkinson’s disease, and treatment of 
schizophrenia with neuroleptics. The candidate SNPs that have been investigated include 
rs4680 (G/A) polymorphism in the Catechol-O-Methyl Transferase gene, rs1800497 
(C/T) polymorphism of the Dopamine D2 receptor gene and rs6280 (C/T) polymorphism 
in the dopamine D3 receptor gene. Relatively little work has been dedicated to correlating 
these SNPs with outcomes in TBI.   
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2.4.2.1 Catechol-O-Methyl Transferase 
 
Catechol-O-Methyl Transferase (COMT) is an enzyme involved in the catabolism 
of dopamine through methylation of dopamine and norepinephrine. The human COMT 
gene is located on chromosome 22q11.21–23. The rs4680 SNP in the COMT gene results 
in a change from G to A at position 472. The G allele codes for valine and A allele codes 
for methionine. The enzyme with valine is almost four times as active as methionine at 
normal body temperature. Under conditions of increased dopamine release, individuals 
with COMT A alleles may have less efficient neurotransmission and worse performance 
(Egan et al., 2001; Lachman et al., 1996; Syvanen, Tilgmann, Rinne, & Ulmanen, 1997). 
To date there is no study of the association of this SNP with functional outcome after 
TBI. However, a study which evaluated cognitive performance of 130 (indicate poor 
cognitive performance) individuals with TBI showed that GG homozygotes made more 
perseverative responses on the “Wisconsin Card Sorting Test”, while AA homozygotes 
had the least number of perseverative responses (Lipsky et al., 2005). 
 
2.4.2.2 Dopamine D2 receptor 
 
The human Dopamine D2 receptor (DRD2) gene is located on chromosome 
11q22–23, and consists of eight exons. Until 2004, rs1800497 which is a C to T SNP was 
thought to lie in a regulatory region of DRD2. The DRD2 T allele has been associated 
with a 40% decrease in the D2 receptors expression (Pohjalainen et al., 1998). In 2004, 
Neville et al. (2004) mapped rs1800497 to the last exon in the adjacent gene ANKK1. 
ANKK1 is a novel member of the serine/threonine kinase gene family with 11 ankyrin 
repeats (Neville, Johnstone, & Walton, 2004). Ankyrin repeats are involved in widely 
diverse processes, including protein-protein interactions and transcription initiation 
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(Hryniewicz-Jankowska, Czogalla, Bok, & Sikorsk, 2002; Lubman, Korolev, & Kopan, 
2004). It is likely that the ANKK1 gene is involved directly in dopaminergic signaling or 
in DRD2 transcription. To date there is no study which associates this SNP with 
functional outcome after TBI. However, a study by McAllister et al. (2005) of 39 patients 
with mild TBI showed that the T allele is associated with poorer performance in 
California Verbal Learning Test recognition task and the Continuous Performance Test. 
The study concluded that the T allele can affect cognitive outcome following mild TBI 
(McAllister et al., 2005). 
 
2.4.2.3 Dopamine D3 receptor 
 
The Dopamine D3 receptor (DRD3) gene is located on chromosome 3q13.3, and 
its coding sequence consists of six exons. The rs6280SNP in the DRD3 gene results in a 
change from C to T. Studies have shown that DRD3 C (glysine) confers an increased 
affinity for dopamine compared to DRD3 T (serine) (Wong, Buckle, & Van Tol, 2000). 
However, it is not known whether it affects outcome after TBI.  
 
2.4.3 SNPs in genes of neurotrophic factors 
 
Neurotrophic factors are small protein molecules that regulate growth and survival 
of neurons, associated with metabolic functions such as protein synthesis and synthesis 
of neurotransmitters that carry chemical signals which allow the neuron to communicate 
with other neurons or with other targets (muscles, glands, etc.). Because of these actions, 
neurotrophic factors play a significant role in the maintenance of neuronal function 
throughout an individual's entire lifetime (Huang & Reichardt, 2001; Thoenen, 1995). 
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Neurotrophic factors have been involved in the pathogenesis of some 
neurodegenerative disorders, and some factors have been proposed as potential treatments 
for these diseases on the basis of in vitro experiments and animal model studies (Moris 
& Vega, 2003). Many have studied brain-derived neurotrophic factor, glial cell-derived 
neurotrophic factor and ciliary neurotrophic factor on neuropsychiatric disorders such as 
Alzheimers’s disease, and in the treatment of schizophrenia (Huang et al., 2007; Lavedan, 
Volpi, Polymeropoulos, & Wolfgang, 2008; Voineskos et al., 2011; Xu et al., 2010). 
However, their impact on prognosis of TBI is still poorly investigated. 
 
2.4.3.1 Brain-derived neurotrophic factor 
 
Brain-derived neurotrophic factor (BDNF) is the most abundant neurotrophin in 
the brain (Barde, Edgar, & Thoenen, 1982; Leibrock et al., 1989). It plays an important 
role in the survival, differentiation, synaptic plasticity and outgrowth of peripheral and 
central neurons throughout adulthood (Huang & Reichardt, 2001; Poo, 2001).  
The rs6265 is an A to G polymorphism of BDNF gene.  The more common G 
allele encodes for valine, while the A allele encodes for methionine (Leibrock et al., 
1989). The SNP in the heterozygous form produces a mature protein that has altered 
intrinsic biological activity. This alteration affects intracellular processing and secretion 
of mature BDNF. Therefore, neuroplastic effect of BDNF in the heterozygous form is 
compromised, albeit in an unclear fashion, compared to the homozygous BDNF (Egan et 
al., 2003). BDNF is found abundantly in the hippocampus, an area which plays an 
important role in memory, attention, and speed of information processing (Farkas & 
Povlishock, 2007). 
 
23 
2.4.3.2 Glial-derived neurotrophic factor 
 
Glial-derived neurotrophic factor (GDNF) promote the survival and 
differentiation of dopaminergic neurons, protects dopamine neurons from some 
neurotoxins and enhances high-affinity uptake of dopamine (Lin, Doherty, Lile, Bektesh, 
& Collins, 1993; Xiao, Hirata, Isobe, & Kiuchi, 2002).  
The rs36119840 is an A to G polymorphism of the GDNF gene. GDNF is a 
glycosylated, disulfide-bonded, homodimer that is a distantly related member of the 
transforming growth factor-beta superfamily. In embryonic midbrain cultures, 
recombinant human GDNF promoted the survival and morphological differentiation of 
dopaminergic neurons and increased their high-affinity dopamine uptake (Lin et al., 
1993). However, the role and function of this polymorphism and how it affects the mature 
protein is unknown.  
 
2.4.3.3 Ciliary neurotrophic factor 
 
Ciliary neurotrophic factor (CNTF), which is expressed mainly by astrocytes is a 
member of the interleukin-6 family of cytokines that regulates neuro-inflammatory 
responses. CNTF was identified as a survival and differentiation factor for a variety of 
neuronal cell types, including motor, sensory and sympathetic neurons (Barres, Schmid, 
Sendnter, & Raff, 1993; Louis, Magal, Takayama, & Varon, 1993; Sendtner, Carroll, 
Holtmann, Hughes, & Thoenen, 1994). 
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The rs1800169 is a null mutation of the CNTF gene. The G to A transition 
produces a new splice acceptor site and the resulting mRNA codes for an aberrant protein 
(Barres et al., 1993; Louis et al., 1993; Sendtner et al., 1994; R. Takahashi et al., 1994). 
CNTF supports survival and/or differentiation of a variety of neuronal cell types including 
sensory, sympathetic, and motoneurons. Furthermore, nonneuronal cells, such as skeletal 
muscle cells, microglial cells, oligodendrocytes and liver cells, respond to exogenously 
administered CNTF, both in vitro and in vivo (Sendtner et al., 1994).  
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2.5 Serum Protein biomarkers 
 
Biomarkers arising from brain tissue after TBI will eventually find their way into 
the cerebrospinal fluid, and subsequently into the circulating blood, although in much 
lower levels.  Since collection of peripheral blood samples is much easier than collection 
of cerebrospinal fluid in clinical practice, many candidate biomarkers of TBI of interest 
have been assessed in serum. These biomarkers could indirectly reflect on the status of 
the brain (Wang et al., 2005). To date, research data on the potential usefulness of various 
serum biomarkers such as S100B protein, Glial Fibrillary Acidic Protein, Neuron Specific 
Enolase, Myelin Basic Protein, Fatty Acid-binding Proteins, Creatine Kinase Brain 
Isoenzyme, Inflammatory Markers, Oxidative Stress Markers, Markers of Vascular 
Injury, Heat Shock Proteins, and Neuroendocrine Markers are available. 
 
2.5.1 S100B protein 
 
The S100B is a 10.5 kDa, calcium binding protein which is synthesized and 
secreted by astrocytes. It is one of the most comprehensively studied biomarker of TBI. 
Serum S100B has been shown to be a sensitive marker for brain injury, which correlates 
with the severity of the injury (Herrmann et al., 2000; Savola et al., 2004). Elevated 
S100B is associated with secondary complications but only after complications have set 
in, not before. Hence, daily S100B levels cannot predict the occurrence of secondary 
complications, thus limiting its usefulness (Unden et al., 2007). A significant correlation 
was also demonstrated between the volume of contusion visible on computed tomography 
(CT) scan and increased serum S100B level (Herrmann et al., 2000; Raabe et al., 1998). 
In studies by Raabe et al. (1998) and Vos et al. (2004), S100B strongly predicted a poor 
outcome in patients with severe TBI (Raabe et al., 1998; Vos et al., 2004); and serum 
S100B levels at 24-hour post injury could also serve as a screening tool for the early 
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detection of patients at risk for brain death after severe TBI (Egea-Guerrero et al., 2013). 
It was also reported that serum S100B was increased in pediatric TBI (Berger et al., 2005). 
A higher S100B concentration was also associated with severe pediatric TBI with the 
lowest GCS score on admission (Piazza et al., 2007), and with a worse outcome (Berger, 
Beers, Richichi, Wiesman, & Adelson, 2007). However, early increase of this protein is 
not a reliable prognostic index of neurological outcome, since even very elevated values 
are compatible with complete neurological recovery (Piazza et al., 2007). Meanwhile, 
several studies have shown that S100B is not a TBI specific protein, having been reported 
to be elevated after bone fractures, thoracic contusions without fractures, burns and even 
after minor bruises (Anderson, Hansson, Nilsson, Dijlai-Merzoug, & Settergren, 2001). 
It is also not a specific marker of TBI if there is local ischemia and reperfusion of the 
kidney, liver and gut because local ischemia and reperfusion also cause an increase of 
S100B levels (Pelinka, Harada, et al., 2004). In the setting of polytrauma, interpretation 
is hard. 
 
2.5.2 Glial fibrillary acidic protein  
 
“Glial fibrillary acidic protein” (GFAP) is a brain-specific, monomeric 
intermediate filament protein expressed by astrocytes and comprises a major portion of 
the cytoskeleton. Missler et al. (1999) first documented that GFAP is released into the 
circulation very soon after TBI. They speculate that this provides an early indication of 
the volume of brain parenchyma involved in TBI (Missler, Wiesmann, Wittmann, 
Magerkurth, & Hagenstrom, 1999). Serum GFAP levels correlated significantly with the 
injury severity score and CT scan findings. In patients with lower GCS and larger 
contusions (Vos et al., 2004) and in patients with intracranial pressure of 25 mm Hg or 
more (Pelinka, Kroepfl, et al., 2004), serum GFAP levels were elevated. Serum GFAP 
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level reaches a peak on the first day of TBI and later drops gradually (Nylen et al., 2006). 
It is not released in the setting of polytrauma without TBI (Pelinka et al., 2004). Higher 
levels of serum GFAP were measured in patients who died  (Pelinka et al., 2004; Vos et 
al., 2004) or had a poor outcome at 6 months (Vos et al., 2004) or 1 year (Nylen et al., 
2006) post injury compared to those who were alive or had good outcomes. 
 
2.5.3 Neuron Specific Enolase 
 
“Neuron Specific Enolase” (NSE) is one of the five isozymes of a glycolytic 
enzyme. It was originally found to be expressed in neurons and later also identified in 
oligodendrocytes, neuroendocrine cells, erythrocytes and thrombocytes. Serum NSE 
levels were significantly elevated in patients with major head injury (Ross, Cunningham, 
Johnston, & Rowlands, 1996). NSE levels also correlated significantly with the injury 
severity score and CT scan findings (Skogseid, Nordby, Urdal, Paus, & Lilleaas, 1992; 
Vos et al., 2004). Patients with moderately severe to severe TBI (GCS score at the site of 
accident < or =12) (Herrmann et al., 2000) and those patients with larger contusions had 
higher serum NSE levels (Herrmann et al., 2000; Skogseid et al., 1992). In pediatric TBI, 
elevated serum NSE significantly predicts for intracranial lesions in children with blunt 
head trauma but it is neither sensitive nor specific enough to predict intracranial lesions 
in all patients (Fridriksson, Kini, Walsh-Kelly, & Hennes, 2000). Patients who died or 
had a poor outcome 6 months post injury had significantly higher NSE levels than those 
who were alive or had good outcome (Herrmann et al., 2001; Vos et al., 2004). However, 
recent findings showed that serum NSE level may also be elevated in non-traumatic 
conditions such as neuroendocrine bladder tumors, small cell lung cancer, neuroblastoma 
and stroke (Schoerkhuber et al., 1999). 
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2.5.4 Myelin Basic Protein  
 
“Myelin Basic Protein” (MBP) is a main and specific protein component of 
myelin. It has a molecular weight of 18.5 kDa. It was reported that serum MBP is 
increased in pediatric TBI and raised MBP level is mainly correlated with a worse 
outcome in children (Berger et al., 2005). However, it may also be released into the 
circulation in demyelinating disease (Ingebrigtsen & Romner, 2002). 
 
2.5.5 Fatty acid-binding proteins  
 
There are two types of “fatty acid-binding proteins” (FABP) expressed in various 
tissues, the “brain type” (B-FABP) and the “heart type” (H-FABP). B-FABP is found 
solely in the brain. Pelsers et al. (2004) showed that the highest concentrations of B-FABP 
and H-FABP is in the frontal lobe and pons, with the concentration of H-FABP at least 
10 times higher than B-FABP. B-FABP was not detected in serum from healthy donors 
whereas, the level of serum H-FABP was 6 mg/L. In the same study, they reported that 
serum B-FABP was increased in 68% and H-FABP was above its upper reference limit 
in 70% of the patients with mild TBI (n= 130). B-FABP and H-FABP were found to be 
more sensitive markers for mild TBI than S100B and NSE (Pelsers et al., 2004). In a 
recent study, serum H-FABP levels at 48 hour were inversely correlated with the outcome 
at 3 months and were able to predict mortality with 75% sensitivity and 93% specificity 
(Walder et al., 2013). 
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2.5.6 Creatine Kinase Brain Isoenzyme 
 
Creatine kinase brain isoenzyme (CKBB), synthesized by astrocytes, is an 
isoenzyme of creatine kinase. It has a molecular mass of 40 to 53 kDa. CKBB is released 
when there is anatomical injury to the brain. With a short half-life it is rapidly eliminated 
from circulation, hence it increases during the first few hours of trauma and rapidly drops 
unless there is continuous release. Furthermore, to be released into the circulation, blood 
brain barrier disruption is necessary (Schwartz, Bazan, Gage, Prihoda, & Gillham, 1989).  
In a study of 60 patients, Skogseid et al. (1992) found increased serum CKBB in 88% of 
the patients (n = 18) with moderate to severe head injury and in 23% of patients (n = 42) 
with minor head injury. They concluded that concentrations of CKBB correlated with the 
severity of injury as assessed clinically, and with the volume of contusion as estimated 
from CT scans (Skogseid et al., 1992). However, CKBB is also elevated in 
adenocarcinomas involving the prostate, ovary, gastrointestinal tract and breast, and small 
cell anaplastic carcinoma of the lung making CKBB not that specific for TBI (Schwartz 
et al., 1989). 
 
2.5.7 Inflammatory Markers 
 
Increased serum concentrations of “pro-inflammatory cytokines” and “anti-
inflammatory cytokines”, “chemokines”, and “acute phase reactant proteins” have been 
observed as potential markers for TBI. Pro-inflammatory cytokines (IL-1, TNF-α, IL-6), 
anti-inflammatory cytokines (IL-10, TGF-β), chemokines (ICAM-1, macrophage 
inflammatory protein [MIP-1, MIP-2], acute phase proteins (amyloid A, C-reactive 
protein) have been reported to change in various bodily fluids in response to TBI.   
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The candidate of much interest, IL-1β, is elevated in serum in both children and 
adults with TBI (Chiaretti et al., 2005; Singhal et al., 2002). The increase in IL-1β 
expression was correlated with head injury severity, and was indicative of poor clinical 
outcome in children (Chiaretti et al., 2005). These studies also showed that elevated IL-6 
was also associated with head injury severity in both children and adults (Chiaretti et al., 
2005; Minambres et al., 2003) and unfavourable outcome in children (Chiaretti et al., 
2005). Serum TNF-α was also upregulated after TBI and aids in stimulating neutrophil 
and recruit monocyte to the injury site to phagocytose cellular debris (Crespo et al., 2007; 
Goodman, Robertson, Grossman, & Narayan, 1990; S. A. Ross, Halliday, Campbell, 
Byrnes, & Rowlands, 1994). In severe TBI, it was found that TNF-α upregulation 
correlated with severity, but did not correlate with fatal outcome (Crespo et al., 2007). 
Sohrevardi et al. (2013) reported that on the 7th day of admission, serum IL-8 levels in 
patients with diffuse axonal injury had a negative correlation with GCS and GOS 
(Sohrevardi et al., 2013).  
Csuka et al. (1999) also reported that serum IL-10 were increased after severe TBI 
showing a peak during the first and second days followed by a lower rise in the second 
week (Csuka et al., 1999). IL-10 elevation in serum is a candidate  marker to predict 
which patient will develop intracranial hypertension and cerebral hypoperfusion (Stein et 
al., 2012). Although TGF-β is another candidate of much in interest in TBI, it could not 
be correlated with the extent of initial injury by CT scan or by GOS (Morganti-Kossmann 
et al., 1999). However, in a cohort of TBI patients who had diffuse axonal injury, the level 
of TGF-β was found to be increasing after admission and reached a maximum level on 
the 7th day (Sohrevardi et al., 2013).  
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Hergenroeder et al. (2008) reported that C-reactive protein is rapidly elevated after 
brain trauma and showed that it was a robust indicator of injury even at a very early 
timepoint of injury. However, C-reactive protein is also elevated when there is infection 
or other extracranial trauma (Hergenroeder et al., 2008).  
Since injury to other organs can also increase the serum level of inflammatory 
markers in the patient’s serum, these markers by themselves do not offer a high specificity 
for TBI. However, in certain circumstances in which selective TBI is suspected as in 
abusive TBI due to the shaken baby syndrome, these markers can be helpful to support a 
diagnosis of TBI (Berger et al., 2006). 
 
2.5.8 Oxidative Stress Markers 
 
The brain has a high oxygen demand and is very vulnerable to oxidative stress. 
During normal aerobic metabolism, superoxide radicals are constantly produced and 
scavenged by a number of antioxidant enzymes, including superoxide dismutase, 
glutathione reductase and catalase. Additionally, chemical antioxidants such as 
glutathione, ascorbic acid, and vitamin E are also likely to be involved in the 
detoxification of free radicals. Hypoperfusion and cell ischemia associated with TBI leads 
to oxidative stress arising from an increase in superoxide radicals. Superoxide radicals 
cause protein oxidation, lipid peroxidation and DNA damage (Griesbach, Hovda, Gomez-
Pinilla, & Sutton, 2008).  Lipid peroxidation of neuronal membranes which have an 
abundance of polyunsaturated fatty acids (Won, Kim, & Gwag, 2002), causes membrane 
dysfunction and cell death by lysis (Zink, 2001). Superoxide radicals can also injure 
endothelial cells, contributing to vasogenic and cytotoxic oedema (Finfer & Cohen, 
2001). When the brain is exposed to oxidative stress, activity and expression of 
antioxidant enzymes such as superoxide dismutase and catalase were shown to be 
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increased in animal models (Kucur et al., 2005). This has yet to be confirmed in human 
TBI cases. 
 
2.5.9 Markers of Vascular Injury 
 
The Von Willebrand Factor (VWF) is an adhesive glycoprotein that by interacting 
with components of the extracellular matrix and platelet receptors, stimulates onset and 
progression of thrombus formation at the site of vascular damage (Mendolicchio & 
Ruggeri, 2005).  VWF is an established marker of endothelial activation, a pro- 
inflammatory and pro-coagulant condition of injured endothelial cells lining blood 
vessels. Yokota et al. (2002) reported that elevated serum VWF suggests endothelial 
activation in severe head injury. They demonstrated that serum VWF in focal brain injury 
was significantly higher than in diffuse brain injury. In addition, the serum level of VWF 
may also be able to predict patients who develop delayed traumatic intracerebral 
hematoma (Yokota et al., 2002). This is supported by another study which showed a 
positive correlation between VWF levels with scores in the Marshall CT classification. 
The Marshall CT classification in this study groups TBI patients into four ordinal 
categories, based on the status of the mesencephalic cisterns, the degree of midline shift 
in millimeters, and the presence or absence of one or more surgical masses on the CT 
scan.  In this study, it was also suggested that an increase in VWF level following severe 
TBI may be a marker of unfavorable outcome, predicting mortality with a specificity of 
68% (De Oliveira et al., 2007). Another study in children with severe cranio-cerebral 
trauma also demonstrated significantly increased VWF (Becker et al., 1999).   
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Matrix metalloproteinases (MMPs) are zinc-dependent endopeptides that are vital 
for the degradation of extracellular matrix components such as collagen, fibronectins and 
elastins. During normal cell development activated metalloproteinases are needed for the 
extracellular matrix degradation to permit cell migration (Vu & Werb, 2000). Suehiro et 
al., studied patients with acute TBI and reported high serum levels of MMP-9. High levels 
of MMP-9 correlated with high levels of IL-6, suggesting that MMP-9 may be associated 
with post-TBI inflammatory events (Suehiro et al., 2004).  
Maier et al. (2007) showed an increase of the serum levels of Endothelin-1, a very 
potent vasoconstrictor peptide, in patients with severe TBI at the acute stage. They also 
reported that it was much more prominent among patients with subarachnoid hemorrhage 
(Maier, Lehnert, Laurer, & Marzi, 2007). 
 
2.5.10 Heat Shock Proteins 
 
Heat shock proteins (HSP) are chaperone molecules that protect cells from 
external stress. They play an important role in the protein folding and unfolding as well 
as in the assembly and disassembly of protein complexes. The Hsp70kDa family (HSPs 
are designated according to their molecular weights) regulates cerebral processes in 
normal or stress conditions. Pittet et al. (2002) showed that the Hsp72 (a member of the 
Hsp70 family) can be detected in the serum of patients with severe trauma within 30 
minutes after trauma and that high levels are associated with survival after severe trauma 
(Pittet et al., 2002). Another study reported that high serum Hsp70 may also be a 
promising outcome biomarker in severe TBI as male patients with fatal outcome had 
higher serum concentrations compared with survivors (da Rocha et al., 2005). 
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2.5.11 Neuroendocrine Markers 
 
Endocrine function may be affected by various inflammatory mediators, including 
cytokines and free radicals (Tanriverdi et al., 2006), part of the acute adaptive response 
to trauma. Medications such as glucocorticoids, narcotics or dopaminergic agents that 
may be administered at this stage may also influence endocrine function. Gonadotropin 
and somatotropin deficiency, followed by corticotropin and thyrotropin deficiency, and 
hyper- or hypoprolactinaemia are the most common alterations (Bondanelli, Ambrosio, 
Zatelli, De Marinis, & degli Uberti, 2005). Schneider et al., combined data from 19 
studies, which includes 1137 patients, and showed that the prevalence of hypopituitarism 
was greater in patients with severe compared to mild or moderate TBI  (Schneider, 
Kreitschmann-Andermahr, Ghigo, Stalla, & Agha, 2007). Tanreverdi et al., studied 52 
TBI patients (43 men and 9 women) and reported that 5.8% had thyroid stimulating 
hormone deficiency, 41.6% gonadotropin deficiency, 9.8% adrenocorticotropic hormone 
deficiency, and 20.4% had growth hormone  deficiency (Tanriverdi et al., 2006). Other 
studies reported cortisol hyporesponsiveness and hypogonadism as the most common 
deficiencies at the acute stage of TBI (Agha et al., 2004; Dimopoulou et al., 2004). 
Aldosterone levels were found to be high in patients with severe cerebral contusion, in 
patients whose CT scans showed a marked midline shift and disappearance of the 
perimesencephalic cistern, and in epidural hematoma. Moderately increased levels were 
found  in patients with a slight midline shift (Takahashi, Sato, & Tsuji, 1989). 
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CHAPTER 3 
APOE GENE AND ITS PROMOTER: INFLUENCES ON 6 MONTH OUTCOME 
AFTER TRAUMATIC BRAIN INJURY 
 
3.1 Introduction 
 
Apolipoprotein E (ApoE) is a polymorphic protein with three common isoforms 
(ApoE2, ApoE3, and ApoE4), which are encoded by three alleles (ε2, ε3 and ε4) of the 
Apolipoprotein E gene (APOE), respectively. These three alleles differ by single 
nucleotide changes at positions 112 and 158. APOE ε2 has TGC at both positions, APOE 
ε3 has TGC at position 112 and CGC at position 158, whereas APOE ε4 has CGC at both 
positions. ApoE is a major CNS lipoprotein synthesized by astrocytes (Mahley, 1988; 
Mahley, Innerarity, Rall, & Weisgraber, 1984) and has been suggested to play a role in 
neuronal homeostasis (Laws, Hone, Gandy, & Martins, 2003), particularly, mobilization 
of cholesterol into the CNS where it is required for neuronal plasticity (Moestrup, 
Gliemann, & Pallesen, 1992; Rebeck, Reiter, Strickland, & Hyman, 1993). ApoE is also 
postulated to be involved with neuronal repair by mediating the recycle of damaged cell 
membranes (Laws et al., 2003). The association between polymorphisms of APOE gene 
and its promoter with outcome is still not fully understood, particularly in Asian 
populations. Wide inter-ethnic variations in the APOE gene and its promoter were thought 
to be responsible for these inconsistent findings. In Malaysia, there are 3 major ethnic 
groups: Malay, Chinese and Indian. These ethnicities, especially the latter two, have 
migrated to Malaysia from China and India in the last century. In this study we attempted 
to determine if polymorphisms in the APOE gene and its promoter influence the outcome 
in a large cohort of multiethnic Malaysian patients with TBI.   
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3.2 Literature Review 
 
In a prospective evaluation of 89 patients with TBI, there was a 2-fold increase in 
unfavorable outcome at 6 months in patients with APOE 4 compared to patients without 
APOE 4. “Death”, “vegetative state”, or “severe disability” were defined as unfavorable 
outcomes using the GOS (G. M. Teasdale et al., 1997). Several other clinical studies 
concerning the severities and outcome of TBI in adults support the notion that APOE 4 
allele is associated with a poor prognosis and unfavorable outcome (Chiang et al., 2003; 
Friedman et al., 1999; Liaquat et al., 2002). Nonetheless, some contradicting evidence 
suggest that APOE 4 has no effect on recovery from TBI (Alexander et al., 2007; 
Chamelian et al., 2004; Diaz-Arrastia et al., 2003; Millar et al., 2003; Nathoo et al., 2003; 
Pruthi et al., 2010; G. M. Teasdale et al., 2005; Willemse-van Son et al., 2008). However, 
most of these reports document the effect of APOE ε4 on TBI outcome almost exclusively 
in white populations or those derived from Caucasians. Among a black population in 
South Africa with a relative high frequency of APOE ε4 allele, APOE ε4 allele was not 
found to have a significant effect on TBI outcome (Nathoo et al., 2003). Other studies 
showed that APOE genotype has little or insignificant effect on outcome in relatively mild 
injuries (Chamelian et al., 2004a; Sundstrom et al., 2004). Therefore, more research into 
the association between APOE polymorphism and outcome after TBI is needed, 
particularly in non-Caucasian racial groups.  
Recently, three upstream SNPs in the APOE gene promoter at positions -491 A/T, 
-427 C/T, and -219 G/T (also known as Th1/E47cs) have been reported. The various 
allelic combinations at each position viz., -491 AA or -491 AT or -491 TT; -427 CC or   
-427 CT or -427 TT; -219 GG or -219 GT or -219 TT, could alter transcription of APOE 
gene (Artiga, Bullido, Sastre, et al., 1998). Poor recovery from TBI was reported to be 
more frequent among subjects with the TT genotype of -219 G/T compared to the GG 
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and GT genotypes. However, no association was noted between unfavorable outcome and 
the -491 A/T promoter polymorphism (Lendon et al., 2003). To date, there is no study on 
-427 C/T promoter polymorphisms and outcome.  
 
3.3 Method 
 
3.3.1 Patient cohort 
 
“A total of 205 unpreselected and consecutive TBI patients admitted to the Neuro 
Intensive Care Unit, University of Malaya Medical Centre, were prospectively recruited 
for this study between Feb 2009 and June 2012. Baseline data including, gender, age, 
cause of TBI and clinical severity as indicated by the GCS, were recorded on admission. 
Injuries were graded as mild (GCS 15–14), moderate (GCS 13–9), and severe (GCS 8–3) 
(Teasdale & Jennett, 1974, 1976). Patients who had blood transfusions, and who had co-
morbidities such as polytrauma, hypertension, Alzheimer’s disease and other major 
systemic diseases that might interfere with TBI related disability, were excluded from the 
study. The Ethics Committee of the University Malaya Medical Centre had approved the 
study protocol” (Anada, Ganesan, Ramahsamay, & Wong, 2012).  
 
(Note: The incidents of TBI are high in Malaysia, however, these includes TBI 
accompanied with other major systemic injuries (Liew et al., 2009). The incidents of sole 
TBI incidents are relatively lower (300 cases per year) and a study of 200 subjects are 
sufficient for 80% sample power calculated using STATA statistical software.) 
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3.3.2 DNA extraction and purification  
 
“Two mls of EDTA blood were collected from each patient after written consent from 
patient or patient’s next of kin, and the blood samples were stored at -80°C until DNA 
extraction. Blood samples were washed in 1X standard saline citrate buffer at room 
temperature and digested for 1 hour using proteinase K and sodium-dodecyl-sulphate at 
55°C.  Digested products were purified using phenol-chloroform-isoamyl alcohol 
(25:24:1, pH 8.0, Sigma, USA) extraction method (Davis, Dibner, & Battey, 1986). The 
DNA was precipitated from the aqueous layer using 2M NaCI and cold absolute ethanol, 
air dried overnight, solubilised in 10:1 TE buffer and stored at -20°C for PCR. The purity 
and concentration of DNA were measured spectrophotometrically” (Anada et al., 2012). 
(Full details are found in Appendix B).  
 
3.3.3 PCR and sequencing 
 
“The APOE genotype and its promoter’s SNPs were determined by PCR amplification. 
For the APOE gene a sense primer 5’-CTG GAG GAA CAA CTG ACC CCG GTG- 3’ 
and anti- sense primer 5’-CAG GCG CTC GCG GAT GGC GCT GAG-3’ that flank the 
positions 112 and 158 were used (Appendix C). For the promoter region, sense primer 
5’-GGG GCT CCC CTG TGC TCA AG- 3’ and anti-sense primer 5’- TGT TCT CCC 
CCT GCC CCA GG- 3’ which flank positions -491, -427 and -219 were used (Appendix 
D). PCR was performed using Taq DNA Polymerase (Fermentas, Canada) with initial 
denaturation at 95ºC for 3 min, followed by 35 cycles of 60 sec of denaturation at 94ºC, 
45 sec of annealing at 68ºC, and 30 sec of extension at 72ºC. After 10 min of final 
extension at 72ºC, the PCR products were kept in 4oC. The PCR products were detected 
by electrophoresis in a 1.5% agarose gel, gel-purified as per manufacturer’s instruction 
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(Qiagen, USA) and sent for direct PCR sequencing (First BASE Laboratories, Malaysia). 
The sequence results were analysed with the Sequence Scanner (Version: 1.0, Applied 
Biosystems, USA)” (Anada et al., 2012).  
 
3.3.4 Outcome evaluation 
 
Functional outcome was measured by GOS. The GOS categorizes functional outcomes 
into five levels: “1, death”; “2, persistent vegetative state”; “3, severe disability”; “4, 
moderate disability” and “5, good recovery” (Jennett & Bond, 1975). These data were 
collected at 6 month post-injury during a face-to-face interview whenever possible or by 
phone when direct interview was not possible using a standard evaluation form (Appendix 
G). Data on mortality was collected from patients’ medical records. A GOS of 1, 2 and 3 
was categorized as unfavorable outcome, whereas 4 and 5 was categorized as favorable 
outcome. GOS assessment was done without prior knowledge of patient’s 
APOE/promoter or any other genotype results.  
 
3.3.5 Statistical analysis 
 
Analysis was performed using STATA, version 9.0. Independent T Test was used to 
compare variables within two groups. ANOVA was used to compare variables within 
three or more groups. Chi- square test, linear and logistic regression were used to 
determine association between variables. 
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3.4 Results 
 
3.4.1 Demography and genotype frequencies  
 
In this study of 205 cases of TBI (Table 3.1), the patients were predominantly 
male (86.8%), young (16-30 years old) and had moderate brain injury (GCS 9-13). 
Among our subjects, TBI was caused mainly by motor vehicle accidents, with 
motorcyclists recording the highest number of TBI cases (133/205 or 64.9%). This was 
followed by car drivers (6 subjects, 2.9%) and pedestrians (7 subjects, 3.4%). The second 
major cause of TBI was fall (25 subjects, 12.2%). Other causes of TBI were fall from a 
height (4 subjects, 2.0%) and assault (10 subjects, 4.9%). In this cohort, the cause of TBI 
for 16 subjects were unknown.   
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Table 3.1: Characteristics of 205 traumatic brain injury patients and APOE ε4 genotype. 
 
    
APOE Genotype No. of 
patients 
without ε4 
(n= 149) 
No. of 
patients 
with ε4 
(n= 56) 
Total 
    
    
Nature of accident    
MVA    
Motorcycle 94 39 133 
Car 5 1 6 
Other Vehicles 4 0 4 
Pedestrian 6 1 7 
Fall 17 8 25 
Fall from a height 3 1 4 
Assault 10 0 10 
Unknown 10 6 16 
    
Gender    
Male 131 47 178 
Female 18 9 27 
    
Age    
16-30 70 25 95 
31-45 37 17 54 
>45 42 14 56 
    
Outcome    
Favorable (GOS 4-5) 123 26 149 
Unfavorable (GOS 1-3) 26 30 56 
    
GCS    
14-15 29 12 41 
9-13 69 23 92 
<9 51 21 72 
    
 
Abbreviation: Motor Vehicle Accident (MVA), Glasgow Coma Score (GCS); Footnote: (1) For the subheading MVA, patient was 
using the vehicle when met with an accident; (2) A GOS of 1 (Death), 2 (Persistent Vegetative State) and 3 (Severe Disability) was 
categorized as unfavorable outcome 
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Each patient’s APOE genotype and promoter SNP was determined by PCR 
amplification and direct sequencing. Figure 3.1 and Figure 3.2 show the typical 
electrophoresis gel results of APOE and its promoter’s PCR products, respectively. These 
bands were excised, gel-purified and directly sequenced. The partial sequence 
electropherograms of APOE (Figure 3.1 to Figure 3.8) and its promoter region (figure 3.9 
to Figure 3.11) are as shown. A nucleotide was identified as homozygous if it has a single 
peak and a relative peak height in a single channel that exceeded a threshold. A nucleotide 
was identified as heterozygous if it has two peaks and the signal was approximately half 
the expected homozygous peak height.  
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Figure 3.1: Electrophoresis gel of the APOE PCR product for 3 patient samples. 
A sense primer 5’-CTG GAG GAA CAA CTG ACC CCG GTG- 3’ and anti- sense primer 
5’-CAG GCG CTC GCG GAT GGC GCT GAG-3’ that flank the positions 112 and 158 
of APOE gene produces a 320 base pair product. The DNA Blank PCR amplification was 
done by substituting DNA with ultrapure water. For the Positive Control, a previously 
sequence confirmed patient DNA was used. Sample 1-3 denotes PCR products for three 
different subjects.  
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Figure 3.2: Electrophoresis gel of the APOE Promoter region PCR product for a patient. 
A sense primer 5’-GGG GCT CCC CTG TGC TCA AG- 3’ and anti-sense primer 5’- 
TGT TCT CCC CCT GCC CCA GG- 3’ which flank positions -491, -427 and -219 of the 
APOE the promoter region produces a 680 base pair product. The DNA Blank PCR 
amplification was done by substituting DNA with ultrapure water. For the Positive 
Control, a previously sequence confirmed patient DNA was used. Sample 1 denotes PCR 
products for a subject. 
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Position 112 Position 158 
 
  
 
Figure 3.3: Partial sequence electropherograms of a subject with APOE ε2ε2 
genotype. 
A red peak indicates the presence of Thymine (T nucleotide) and blue peak indicates the 
presence of Cytosine (C nucleotide). The electropherogram showed a single red peaks at 
positions 112 and 158, thus the subject had homozygous T nucleotide at both positions 
112 and 158, indicating the APOE ε2ε2 genotype. 
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Position 112 Position 158 
 
 
 
 
Figure 3.4: Partial sequence electropherograms of a subject with APOE ε2ε3 
genotype. 
A red peak indicates the presence of Thymine (T nucleotide) and blue peak indicates the 
presence of Cytosine (C nucleotide). The electropherogram showed a single red peak at 
position 112 and overlapping double peaks at position 158, thus the subject had 
homozygous T nucleotide at both positions 112 and heterozygous C/T at position 158, 
indicating the APOE ε2ε3 genotype. 
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Figure 3.5: Partial sequence electropherograms of a subject with APOE ε2ε4 
genotype. 
A red peak indicates the presence of Thymine (T nucleotide) and blue peak indicates the 
presence of Cytosine (C nucleotide). The electropherogram showed overlapping double 
peaks at both positions 112 and 158, thus the subject had heterozygous C/T at both 
positions 112 and 158, indicating the APOE ε2ε4 genotype. 
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Figure 3.6: Partial sequence electropherograms of a subject with APOE ε3ε3 
genotype. 
A red peak indicates the presence of Thymine (T nucleotide) and blue peak indicates the 
presence of Cytosine (C nucleotide). The electropherogram showed a single red peak at 
positions 112 and a single blue peak at position 158, thus the subject have homozygous 
T nucleotide at position 112 and homozygous C nucleotide at position 158, indicating the 
APOE ε3ε3 genotype. 
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Figure 3.7: Partial sequence electropherograms of a subject with APOE ε3ε4 
genotype. 
A red peak indicates the presence of Thymine (T nucleotide) and blue peak indicates the 
presence of Cytosine (C nucleotide). The electropherogram showed overlapping double 
peaks at position 112 and a single blue peak at position 158, thus the subject have 
heterozygous C/T at position 112 and homozygous C nucleotide at position 158, 
indicating the APOE ε3ε4 genotype. 
 
50 
Position 112 Position 158 
 
  
 
Figure 3.8: Partial sequence electropherograms of a subject with APOE ε4ε4 
genotype. 
A red peak indicates the presence of Thymine (T nucleotide) and blue peak indicates the 
presence of Cytosine (C nucleotide). The electropherogram showed a single blue peak at 
positions 112 and 158, thus the subject have homozygous C nucleotide at both positions 
112 and 158, indicating the APOE ε4ε4 genotype. 
  
51 
 Position -491 
  
 AA AT TT 
 
 
   
 
Figure 3.9: Partial sequence electropherograms of the APOE promoter region at position 
-491. 
A red peak indicates thepresence of Thymine (T nucleotide) and a green peak indicates 
Adenine (A nucleotide). The electropherogram showed a single peak if the subject is 
homozygous at a polymorphism position (subject with homozygous T has single red peak 
and subject with homozygous A has a single green peak). The electropherogram showed 
two typical overlapping peaks if the subject is heterozygous AT.  
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 Position -427 
    
 CC CT TT 
 
 
   
 
Figure 3.10: Partial sequence electropherograms of the APOE promoter region at 
position -427. 
A red peak indicates the presence of Thymine (T nucleotide) and a blue peak indicate 
presence of Cytosine (C nucleotide). The electropherogram showed a single peak if the 
subject is homozygous at a polymorphism position (subject with homozygous T has a 
single red peak and subject with homozygous C has a single blue peak). The 
electropherogram showed two typical overlapping peaks if the subject is heterozygous 
CT.  
  
53 
 Position -219 
    
 GG GT TT 
 
 
   
 
Figure 3.11: Partial sequence electropherograms of the APOE promoter region at 
position -219. 
A red peak indicates the presence of Thymine (T nucleotide) and a black peak indicates 
presence of Guanine (G nucleotide). The electropherogram showed a single peak if the 
subject is homozygous at a polymorphism position (subject with homozygous T has a 
single red peak and subject with homozygous G has a single black peak). The 
electropherogram showed two typical overlapping peaks if the subject is heterozygous 
GT. 
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Fifty six patients (27.3%) had at least one copy of the APOE ε4 allele; the 
genotypes were: ε2ε4 (2.9%), ε3ε4 (21.5%) and ε4ε4 (2.9%). The other genotype 
frequencies were ε2ε2 (1.5%), ε2ε3 (10.7%), and ε3ε3 (60.5%) (Table 3.2).  
 
Table 3.2: APOE genotype frequencies in 205 TBI patients 
 
APOE 
Genotype 
Frequency % 
   
ε2ε2 3 1.5 
ε2ε3 22 10.7 
ε2ε4 6 2.9 
ε3ε3 124 60.5 
ε3ε4 44 21.5 
ε4ε4 6 2.9 
   
 
 
The frequencies of the polymorphisms found in the promoter region were: -491 
AA (81.5%), -491 AT (17.5%), -491 TT (1.1%); -427 TT (80.5%), -427 CT (18.1%), -
427 CC (1.7%) and -219 GT (47.8%), 219 TT (35.1%), -219 GG (17.3%) (Table 3.3).   
 
Table 3.3: APOE promoter genotype frequencies in 205 TBI patients 
 
APOE 
Promoter 
Frequency % 
   
-491 A/T   
AA 167 81.5 
AT 36 17.5 
TT 2 1.1 
   
-427 T/C   
TT 165 80.5 
CT 37 18.1 
CC 3 1.7 
   
-219 T/G   
GG 35 17.3 
GT 98 47.8 
TT 72 35.1 
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3.4.2 Outcome after TBI 
 
In our cohort of 205 patients (Table 3.4), 56 had unfavorable outcomes (GOS 1, 
2, 3) after 6 months. Thirty of these patients had at least one copy of the APOE ε4 allele, 
whereas, in the 149 patients with favorable outcomes, only 26 had at least one APOE ε4 
allele. Thus, overall, possession of an APOE ε4 allele appears to be significantly 
associated with an unfavorable outcome (OR: 5.5, 95% CI: 2.8-10.7, p= 0.01). 
 
Table 3.4: Post-TBI outcome stratified by severity and presence of APOE ε4 allele 
 
No. of 
patients with 
favorable 
outcome (%) 
No. of 
patients with 
unfavorable 
outcome (%) 
   
All TBI (n= 205)   
APOE ε4 allele 26 (17.4)  30 (53.6) 
No APOE ε4 allele 123 (82.6) 26 (46.4) 
Total 149 56 
   
Mild (n= 41)   
APOE ε4 allele 12 (32.4) 2 (50.0) 
No APOE ε4 allele 25 (67.6) 2 (50.0) 
Total 37 4 
   
Moderate (n= 92)   
APOE ε4 allele 12 (15.6) 11 (73.3) 
No APOE ε4 allele 65 (84.4) 4 (26.7) 
Total 77 15 
   
Severe (n=72)   
APOE ε4 allele 4 (11.4) 17 (45.9) 
No APOE ε4 allele 31 (88.6) 20 (54.1) 
Total 35 37 
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Stratified by severity (Table 3.4), in the 72 patients with severe TBI (GCS < 9), 
37 had unfavorable outcomes, 17 had at least one allele of APOE ε4, whereas, in the 35 
patients with favorable outcomes, only 4 had at least one APOE ε4 allele. Thus, in severe 
TBI, there was a significant association between unfavorable outcome and possession of 
APOE ε4 allele (p= 0.01). In the 92 patients who had moderate TBI (GCS: 9-13) (Table 
3.4), 15 had unfavorable outcomes, 11 of whom had at least one copy of the APOE ε4 
allele, whereas, in the 77 patients with favorable outcomes, only 12 had at least one APOE 
ε4 allele. Thus, similar to severe TBI, there appear to be a significant association between 
unfavorable outcome and possession of APOE ε4 allele in moderate TBI (p= 0.01). All 6 
patients who are homozygous for the ε4 allele had moderate TBI and unfavorable 
outcomes.  
In the 41 patients with mild TBI (GCS: 14-15) (Table 3.4), 4 patients had 
unfavorable outcomes, with 2 having at least one copy of the APOE ε4 allele, whereas, 
in the 37 patients with favorable outcome, 12 patients had at least one APOE ε4 allele. In 
contrast to severe and moderate TBI, there seem to be no significant association between 
unfavorable outcome and APOE ε4 allele in mild TBI (p= 0.34). 
We further explored the possibility that the APOE ε2 allele combined with APOE 
ε4 allele may mask the deleterious effects of APOE ε4 in TBI as previously described (S. 
D. Han et al., 2007; Nathoo et al., 2003; G. M. Teasdale et al., 1997). In 6 TBI patients 
in our cohort who had the ε2ε4 genotype, 5 (2 patients with mild TBI and 3 patients with 
moderate TBI) had favorable outcomes. Although the number of patients involved is 
small, if they were excluded from the statistical analysis, a stronger association between 
of APOE ε4 allele and unfavorable outcome (OR: 6.5, 95% CI: 3.2-13.2, p= 0.01) became 
apparent. 
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Analysis by the logistic model suggests that the GCS alone significantly predicts 
an unfavorable outcome in TBI (R2 = 30.8, p=0.01). However, GCS paired with 
possession of an APOE ε4 allele is a better predictor for unfavorable outcome compared 
with GCS alone (R2 = 60.9; APOE ε4 allele- OR: 8.0, 95% CI: 3.6-18.0, p= 0.01; GCS- 
OR: 5.0, 95% CI: 2.7-9.1, p= 0.01).  
As for the -491 A/T, -427 C/T and -219 G/T polymorphisms in the  APOE gene 
promoter, we did not find any association between unfavorable outcome and the presence 
of the -491 A allele, -427 C allele and -219 T alleles, or any other combinations (p > 0.01). 
We also did not find any association with unfavorable outcome when these 
polymorphisms were combined with possession of the APOE ε4 allele (p > 0.01).  
 
3.5 Discussion 
  
In this prospective cross sectional study, we found that APOE ε4 allele in patients 
with moderate and severe TBI were more likely to have an unfavorable global functional 
outcome at 6 months as measured with the GOS compared to patients without the APOE 
ε4 allele. 
Evidence from several other studies support our finding that possession of the 
APOE ε4 allele is a genetic determinant for unfavorable outcome after TBI (Chiang et al., 
2003; Friedman et al., 1999; Liaquat et al., 2002; Teasdale et al., 1997). Teasdale et al. 
(1997) was the first one to report this association in a prospective evaluation of 89 patients 
with TBI. The study reported that 17 (57%) of 30 patients with the APOE 4 allele had a 
2-fold increase in unfavorable outcome at 6 months compared with 16 (27%) of 59 
patients without the allele. This first study provided the impetus to better understand the 
role of APOE gene in the setting of TBI as it may be essential in the assessment of 
prognosis. Moreover, patients with TBI could be counseled about the imminent risks from 
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injury and of cognitive decline in later life (G. M. Teasdale et al., 1997). Meanwhile, 
Chiang et al. (2003) studied 100 subjects with TBI and documented that 10 of 19 patients 
(52.6%) with the APOE 4 allele had an unfavorable outcome compared with 20 of the 
81 (24.1%) patients without the allele (Chiang et al., 2003). A study of 69 subjects by 
Friedman et al. (1999) also showed a similar trend in which 26 of 27 subjects (96.3%) 
with the APOE 4 allele had an unfavorable outcome compared with 29 of 42 of those 
(69.0%) without the allele (Friedman et al., 1999). In addition, a recent meta-analysis 
(Zhou et al., 2008) indicated that although the presence of the APOE ε4 allele was not 
associated with the initial severity of brain injury after TBI, it was associated with 
increased risk of poor outcome at 6 months after injury. Most of these reports documented 
the effect of APOE ε4 on TBI outcome almost exclusively in white populations or those 
derived from Caucasians. The current study is the third from Asia to report an association 
between possession of APOE ε4 allele and unfavorable outcome after TBI. The other two 
studies mentioned above were from Israel (Friedman et al., 1999) and from Taiwan 
(Chiang et al., 2003).  
There are a few studies which have focused on the outcome in patient subgroups 
with APOE ε4 (Han et al., 2007; Nathoo et al., 2003; Teasdale et al., 1997). Of the ten 
patients with ε2ε4 genotype in the study by Nathoo et al. (2003) six had a good outcome 
(Nathoo et al., 2003). In the present study, we found that out of 6 patients with ε2ε4 
genotype 5 had good outcome. Although this appears to support the theory that APOE ε2 
allele is neuroprotective, we were unable to show statistical significance based on the 
small number of patients. 
The mechanisms underlying these associations are unclear at present but 
neuropathological studies have highlighted the importance of ApoE in the acute response 
to brain injury. Transgenic mice that express the human ApoE E4 isoform were associated 
with decreased synaptic plasticity (White, Nicoll, Roses, & Horsburgh, 2001), increased 
59 
mortality, increased size of brain injury and increased physical deficit compared to mice 
expressing the human ApoE E3 isoform (Sabo et al., 2000).  In particular, neuronal 
plasticity was impaired over a 90-day period after entorhinal cortex lesion (White et al., 
2001). Laskowitz et al. (2001) found that ApoE E4 isoform was less effective than either 
ApoE E2 or ApoE E3 at suppressing inflammatory cytokines in mouse and human 
microglial cultures (Laskowitz et al., 2001). ApoE isoform-specific brain inflammatory 
response was also recorded in transgenic mice expressing human ApoE E3 while ApoE 
E4 transgenic mice had a greater inflammatory response compared to ApoE E3 transgenic 
mice (Lynch et al., 2003). Isoform-specific effects of ApoE have also been demonstrated 
in neurite extension culture systems (Bellosta et al., 1995; DeMattos et al., 1998; 
Holtzman et al., 1995; Nathan et al., 1994; Sun et al., 1998). The observed inhibition of 
neurite extension by ApoE E4 appears to be related to alterations in the cytoskeleton, 
especially microtubule stability (Nathan et al., 1995). These effects may be mediated 
through tau (a microtubule stabilizing protein). ApoE E3, but not ApoE E4, binds to tau 
in vitro, and may protect tau from hyperphosphorylation, a process which inhibits tau’s 
ability to stabilize microtubules (Lovestone et al., 1996; Strittmatter et al., 1994; Tesseur 
et al., 2000).  
 Nonetheless, there are a few studies that suggest that is no association between 
APOE ε4 allele and unfavorable outcomes at 6 months post-trauma (Alexander et al., 
2007; Chamelian et al., 2004a; Diaz-Arrastia et al., 2003; Millar et al., 2003; Nathoo et 
al., 2003; Pruthi et al., 2010; Teasdale et al., 2005; Willemse-van Son et al., 2008). 
Teasdale et al, (2005) conducted one of the largest studies to date (U.K. based patient 
population) consisting of 1000 TBI patients. Their overall results revealed that 36% of 
APOE ε4 carriers had an unfavorable outcome (GOS 1, 2, 3) compared to 33% of non-
carriers of APOE ε4 (p=0.23) at six-month follow-up. However, they found that 
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possession of the APOE ε4 allele in children and young adults was associated with 
unfavorable outcomes (Teasdale et al., 2005).  
A study in an African population also failed to find a positive correlation between 
APOE ε4 allele and unfavorable outcome (Nathoo et al., 2003). Pruthi et al. (2010) also 
failed to find a positive correlation between presence of APOE ε4 allele and unfavorable 
outcome after TBI in 73 subjects from India, in which none of the 12 patients who had at 
least one APOE e4 allele had a poor outcome at six-month follow-up whereas 11(18%) 
patients without an APOE e4 allele had a poor outcome (Pruthi et al., 2010). Apparently, 
most of the studies which did not show association between unfavorable outcome and 
APOE ε4 allele either had only included mild and moderate TBI cases (excluding severe 
TBI) (Chamelian, Reis, & Feinstein, 2004b; Pruthi et al., 2010) or only included patients 
with contusion (Nathoo et al., 2003) or did not include death as an unfavorable outcome. 
In the current study we had included mild (GCS 15–14), moderate (GCS 13–9), and 
severe (GCS 8–3) cases (Teasdale & Jennett, 1974, 1976). Not surprisingly, mild TBI 
cases generally tend to have favorable outcomes whereas the severe TBI tend to have 
unfavorable outcomes. Thus, selectively excluding mild or severe TBI cases will bias the 
results toward unfavorable or favorable outcomes, respectively. We believe our study 
cohort which comprises all severity grades of TBI has less selection bias.  We have also 
included death as an unfavorable outcome since excluding this cases could likewise 
selectively bias the results.  
We did not find any association between polymorphisms of APOE promoter with 
unfavorable outcomes. In contrast, Lendon et al. (2003) in their study of 92 patients noted 
that poor recovery from TBI was more frequent among subjects with TT genotype of -
219 G/T compared to the GG and GT genotypes (Lendon et al., 2003). Nevertheless, this 
study also reported absence of association between -491 A/T promoter polymorphism and 
unfavorable outcome (Lendon et al., 2003). Apart from our study, to date we are not aware 
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of any other study on the impact of -427 C/T promoter polymorphisms on outcome. The 
role of polymorphisms in the APOE promoter are still unclear and further research is 
needed to understand underlying mechanisms especially on how these polymorphisms 
alter the transcription and eventually affect the APOE gene itself in TBI patients. 
Our findings and supportive evidence from other studies implies that in all TBI 
patients APOE genotype should be determined at admission especially in moderate/severe 
TBI.  It may be a useful tool to alert clinicians to the possibility of a poorer outcome and 
therefore greater attention to these patients may be warranted (Ost et al., 2008; Teasdale 
et al., 1997). With further research into the mechanisms by which ApoE impacts the 
CNS’s response to injury, ApoE may be a potential target for the development of future 
therapeutic intervention. Research findings supporting the use of ApoE and ApoE-
derived peptide administration in the recovery process following TBI support this idea. 
ApoE seems to have a direct neuroprotective role, as neuronal damage in the entorhinal 
cortex and global ischaemia in APOE deficient mice is ameliorated by intraventricular 
infusion of ApoE (Graham, Horsburgh, Nicoll, & Teasdale, 1999; Horsburgh, McCarron, 
White, & Nicoll, 2000). Horsburgh et al. (2000) found that ApoE-deficient and ApoE 
wild-type mice with global ischemia has improved outcome when intrathecal 
administration of ApoE protein was given (Horsburgh, McCulloch, et al., 2000). 
Intraventricularly administered ApoE mimetic peptide derived from the receptor-binding 
region in postnatal day 7 rats immediately before hypoxic-ischemic injury showed less 
brain injury than control animals (McAdoo et al., 2005). Lynch et al. (2003) found similar 
results with intravenously administered ApoE mimetic peptide (residues 133–149) given 
30 min after inducing TBI in mice. Animals receiving the peptide had improved 
functioning and reduction in the number of injured hippocampal neurons (Lynch et al., 
2003).  
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One of the limitations of this study is the small number of females so we were 
unable to analyze if gender differences could affect the outcome after TBI, especially in 
those who had at least one APOE ε4 allele. Although wide inter-ethnic variations in the 
APOE gene and its promoter are thought to be responsible for inconsistent findings in the 
literature, our sample size does not have enough power to confidently confirm how ethnic 
differences in Malaysia could affect the outcome after TBI. Since this is the first study in 
a Malaysian population and the impact of APOE ε4 over extended periods are less clear, 
larger patient cohorts and experimental studies are needed to fully explain how APOE ε4 
can unfavorably affect outcome after TBI. 
 
3.6 Conclusion 
 
Our findings show that presence of APOE ε4 allele is associated with poor 
outcome at 6 months after TBI, independent of polymorphisms in the promoter of the 
APOE gene.  In our patients, GCS combined with APOE ε4 allele status were better 
predictors for unfavorable outcome at 6 months after TBI compared with GCS alone. 
Although, the prevalence of APOE ε4 allele among Asian is marginally less compared to 
the Caucasian and African population, we believe its deleterious role in TBI is supported 
by our findings. Thus, we propose that APOE genotyping, in addition to routine clinical 
management may aid clinician in targeting TBI patients that may need much more 
intensive care by:  
 Providing adequate sedation that potentiates analgesics; provides anxiolysis; 
limits elevations of ICP related to agitation, discomfort, cough or pain; facilitates 
nursing care and mechanical ventilation; decrease O2 consumption, CMRO2, and 
CO2 production; improves patient comfort; and prevents harmful movements. 
63 
 Regular monitoring that include electrocardiography (ECG monitoring), arterial 
oxygen saturation (pulse oxymetry, SpO2), capnography (end-tidal CO2, PetCO2), 
arterial blood pressure (arterial catheter), central venous pressure (CVP), systemic 
temperature, urine output, arterial blood gases, and serum electrolytes and 
osmolality. 
 ICP monitoring for earlier detection of intracranial mass lesion, guidance of 
therapy and avoidance of indiscriminate use of therapies to control ICP, drainage 
of CSF with reduction of ICP and improvement of CPP, and determination of 
prognosis. 
 Controlling of systemic temperature as moderate systemic hypothermia at 32°C 
to 34°C, reduces cerebral metabolism and CBV, decreases ICP, and increases 
CPP.  
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CHAPTER 4 
SINGLE NUCLEOTIDE POLYMORPHISMS IN GENES THAT MODULATE 
THE DOPAMINE SYSTEM: INFLUENCES ON 6 MONTH OUTCOME AFTER 
TRAUMATIC BRAIN INJURY 
 
4.1 Introduction 
 
Dopamine is an endogenous chemical that transmits signals from one neuron to 
another. It is the major neurotransmitter in the central dopaminergic pathways that plays 
a critical role in motor function (the nigro-striatal pathway), motivated behavior, 
hormonal stasis (the tubero-infundibular pathway), cognition (meso-cortical pathway), 
mood homeostasis and reward circuitry (the meso-limbic pathway). Dopamine may also 
be involved in neural plasticity and repair through effects on brain derived neurotrophic 
factor (Guillin et al., 2004), and in motor function recovery after TBI as seen in animal 
and human studies (Martinsson & Eksborg, 2004). Dopaminergic systems are carefully 
regulated in the CNS and are vulnerable to injury and dysregulation in TBI (Kobori et al., 
2006; McAllister et al., 2004).  Dysregulation could lead to increased levels of dopamine, 
which is a potently excitotoxic to the neurons. Therefore, genes that influence central 
dopaminergic function may play important roles in modulating the outcome of TBI 
(McAllister et al., 2004). Relatively little work has been done to study the association of 
SNPs in genes that modulate the dopamine system with outcome after TBI, particularly 
in Asian populations (Lipsky et al., 2005; McAllister et al., 2005). In this current study, 
we investigated if rs4680 (G/A) polymorphisms in the Catechol-O-Methyl Transferase 
gene, rs1800497 (C/T) polymorphisms of the Dopamine D2 receptor gene and rs6280 
(C/T) polymorphisms in the dopamine D3 receptor gene could influence outcome in 
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patients with TBI.  We hypothesize that there may be some SNPs that could impact on 
post-trauma recovery. 
 
4.2 Literature Review 
 
SNPs in genes that modulate the dopaminergic system have the potential to 
influence coding for dopamine receptor subtypes (DRD1- DRD5), dopamine re-uptake 
(the dopamine transporter, DAT) and dopamine metabolism (COMT). These SNPs are 
able to change a wide array of critical human functions. Many studies focused on finding 
SNPs in genes that modulate the dopamine system have been done. These include studies 
in neuropsychiatric disorders such as Parkinson’s disease, and schizophrenia and its 
treatment with neuroleptics (M. F. Egan et al., 2001; Wong et al., 2000). The SNPs 
studied were rs4680 (G/A) polymorphisms in the Catechol-O-Methyl Transferase 
(COMT) gene, rs1800497 (C/T) polymorphisms of the Dopamine D2 receptor (DRD2) 
gene and rs6280 (C/T) polymorphisms in the dopamine D3 receptor (DRD3) gene as 
summarized in Table 4.1. 
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Table 4.1: SNPs in genes that modulate the dopamine system 
GENE 
CHROMOSOME 
LOCATION 
ROLE SNP REFERENCES 
COMT 22q11.21–23 Enzyme involved in 
breakdown of dopamine 
through the methylation of 
dopamine and 
norepinephrine 
1. rs4680 (G/A) 
2. The G allele codes for valine and A allele codes for 
methionine. 
3. The enzyme with valine is almost four times as active as 
the enzyme with methionine at normal body temperature. 
4. Under conditions of increased dopamine release, 
individuals with COMT A alleles may not able to 
breakdown dopamine efficiently. Increased level of 
dopamine, which is a potent excitotoxin to neurons may 
lead to less efficient neurotransmission and a worse 
performance. 
 
(Egan et al., 2001; 
Lachman et al., 
1996; Syvanen et 
al., 1997) 
DRD2 11q22–23 Postsynaptic receptor for 
dopamine 
1. rs1800497 (C/T) 
2. Dopamine signaling at the dopamine D2 receptor can 
induce increases in intracellular Ca2+ release and 
activation of calcium dependent kinases and phosphatases 
important for cell death signaling  
3. T allele has been associated with a 40% reduction in the 
expression of DRD2 receptors therefore individuals with T 
allele have better protection against cell death signaling. 
 
(Azdad et al., 
2009; Hernandez-
Lopez et al., 2000; 
Pohjalainen et al., 
1998) 
DRD3 3q13.3 Postsynaptic receptor for 
dopamine 
1. rs6280 (C/T). 
2. The C allele code Glycine and T allele code for serine 
3. DRD3 from the C allele confers an increased affinity for 
dopamine compared to the T allele 
4. It is not known whether it affects outcome after TBI. 
 
(Wong et al., 
2000) 
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4.3 Method 
 
This is a prospective cross sectional study of 205 hospitalized TBI patients from the same 
cohort described in Chapter 3 (3.3.1 Patient cohort, Page 37). The Glasgow Coma Score 
(GCS) on admission were determined as described (3.3.1 Patient cohort, Page 37) and 
Glasgow Outcome Scale (GOS) at six months was assessed as described (3.3.4 Outcome 
evaluation, Page 39). DNA was extracted from the patients’ blood as previously described 
(3.3.2 DNA extraction and purification, Page 38). The polymorphisms in the COMT gene, 
the DRD2 gene and the DRD3 gene were genotyped with the TaqMan genotyping assay 
(Applied Biosystems, Foster City, CA). Statistical analysis is detailed in Chapter 3 (3.3.5 
Statistical analysis, Page 39).  
 
4.3.1 TaqMan SNP Genotyping Assays 
 
The rs4680 (G/A) polymorphisms in the COMT gene, rs1800497 (C/T) polymorphisms 
of the DRD2 gene and rs6280 (C/T) polymorphisms in the DRD3 gene were genotyped 
with the TaqMan genotyping assay (Applied Biosystems, Foster City, CA) using the 
Real-time PCR 7500 Fast real-time polymerase chain reaction system (ABI7500 Fast; 
Applied Biosystems, Foster City, CA, USA). The assay-on-demand probes and primers 
were: C__25746809_50, C__7486676_10 and C__949770_10, for SNPs rs4680, 
rs1800497 and rs6280, respectively. The reaction volume was 10 μL, comprising 6 μL 
genotyping mix and 4 μL genomic DNA. The reaction conditions consisted of a pre-run 
at 95 °C for 10 min, following by 45 cycles of denaturation at 95 °C for 15 s and annealing 
step at 60 °C for 1 min.  
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4.4 Results 
 
4.4.1 Genotype frequencies  
 
Figure 4.1 shows the SNP genotyping scatter plots for the polymorphisms studied. 
In TaqMan SNP Genotyping Assays, the polymorphisms was determined by VIC/FAM 
fluorescence signal emitted by probes when it annealed and extended in the region of the 
interest in the DNA. If both alleles are homozygous either VIC or FAM fluorescence 
signal will be emitted by the probes. However if alleles are heterozygous both VIC and 
FAM fluorescence signal will be emitted together. The COMT homozygous G allele, 
DRD2 homozygous C allele and DRD3 homozygous C allele would emit FAM 
fluorescence signals only. The COMT homozygous A allele, DRD2 homozygous T allele 
and DRD3 homozygous T allele would emit VIC fluorescence signals only. Both VIC 
and FAM fluorescence signals would be emitted when COMT, DRD2, DRD3 alleles are 
heterozygous.   
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Figure 4.1: SNP genotyping scatter plot for rs4680 (G/A) polymorphism in the COMT gene, rs1800497 
(C/T) polymorphism in the DRD2 gene and rs6280 (C/T) polymorphism in the DRD3 gene. 
Red dots show FAM signals indicating that both alleles are homozygous, green dots show VIC signals 
indicating that both alleles are homozygous and blue dots show VIC and FAM signals indicating that 
alleles are heterozygous.  
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The genotype frequencies for rs4680 (G/A) polymorphism in the COMT gene, 
rs1800497 (C/T) polymorphism in the DRD2 gene and rs6280 (C/T) polymorphism in the 
DRD3 gene in our study population are summarized in Table 4.2. For the rs4680 (G/A) 
polymorphism in the COMT gene, the most common and predominant genotype was 
homozygous GG found in 50.2% of subjects, followed by heterozygous GA genotype 
(38.6%) and homozygous AA genotype (11.2%). For the rs1800497 (C/T) polymorphism 
of the DRD2 gene, 43.9% of the subjects were heterozygous CT. The rest were 
homozygous CC (20.5%) and homozygous TT (35.6%). For the rs6280 (C/T) 
polymorphism in the DRD3 gene, the most common genotype was homozygous TT 
(46.3%), heterozygous CT (39.5%) and homozygous CC 14.2%. 
 
Table 4.2: Genotype frequencies in 205 patients with TBI 
 No. of patients % 
COMT   
GG 103 50.2 
GA 79 38.6 
AA 23 11.2 
   
DRD2   
CC 42 20.5 
CT 90 43.9 
TT 73 35.6 
   
DRD3   
CC 29 14.2 
CT 81 39.5 
TT 95 46.3 
   
 
 
  
71 
4.4.2 Outcome after TBI 
 
Table 4.3 shows the frequencies of the COMT polymorphisms in patients further 
stratified by GCS. In general, the presence of COMT AA genotype was found to be 
significantly associated with an unfavorable outcome at 6 month after TBI (OR: 18.6, 
95% CI: 5.97-58.03, p= 0.01). Out of the 56 patients who had unfavorable outcomes, 19 
(33.9%) had the COMT AA genotype. In the 149 patients with favorable outcomes, only 
4 (2.7%) had the COMT AA genotype. Nineteen (82.6%) out of 23 patients who had the 
COMT AA genotype had unfavorable outcomes.  The various alleles of DRD2 gene and 
DRD3 gene were not associated with outcome after TBI (p > 0.01). 
 
Table 4.3: COMT genotype and outcome in 205 patients with TBI 
 
No. of 
patients with 
favorable 
outcome (%) 
No. of 
patients with 
unfavorable 
outcome (%) 
   
All TBI (n= 205)   
COMT GG 85 (57.0) 18 (32.1) 
COMT GA 60 (40.3) 19 (33.9) 
COMT AA 4 (2.7) 19 (33.9) 
Total 149 56 
   
Mild (n= 41)   
COMT GG 23 (62.2) 1 (25.0) 
COMT GA 14 (37.8) 1 (25.0) 
COMT AA 0 (0) 2 (50.0) 
Total 37 4 
   
Moderate (n= 92)   
COMT GG 40 (51.9) 5 (33.3) 
COMT GA 34 (44.2) 5 (33.3) 
COMT AA 3 (3.9) 5 (33.3) 
Total 77 15 
   
Severe (n=72)   
COMT GG 22 (62.9) 12 (32.4) 
COMT GA 12 (34.3) 13 (35.1) 
COMT AA 1 (2.9) 12 (32.4) 
Total 35 37 
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In the group of 72 patients with severe TBI (GCS <9), 37 had unfavorable 
outcomes, and 12 had the COMT AA genotype, whereas, in the 35 patients with favorable 
outcome, only 1 had the COMT AA genotype. Thus, there appear to be a significant 
association between unfavorable outcome and COMT AA genotype in severe TBI (2 = 
10.6, p= 0.01).  
In the 92 patients who had moderate TBI (GCS: 9-13), 15 had unfavorable 
outcomes, 5 of whom had the COMT AA genotype, whereas, in the 77 patients with 
favorable outcomes, only 3 had the COMT AA genotype. Again, there appear to be a 
significant association between unfavorable outcome and COMT AA genotype in 
moderate TBI (2 = 13.7, p= 0.01).  
In the 41 patients with mild TBI (GCS: 14-15), 4 patients had unfavorable 
outcomes, with 2 having the COMT AA genotype, whereas, in the 37 patients with 
favorable outcome, none had the COMT AA genotype. Thus, there is also a significant 
association between unfavorable outcome and COMT AA genotype in mild TBI (2 = 
19.4, p= 0.01).  
In the logistic model, GCS of the patients alone significantly predicts the 
unfavorable outcome in TBI (R2 = 30.83, p=0.01). However, GCS paired with status of 
COMT A allele appears to be a better predictor for unfavorable outcome in TBI compared 
with GCS alone (R2 = 60.61; COMT AA genotype- OR: 18.96, 95% CI: 5.48-65.56, p= 
0.01; GCS- OR: 3.95, 95% CI: 2.17-7.17, p= 0.01).  
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4.5 Discussion 
 
In this prospective cross sectional study of 205 patients with TBI, we have found 
that patients with the COMT AA genotype were associated with an unfavorable global 
functional outcome as measured by the GOS, for all grades of TBI. Unfavorable outcome 
after TBI was not associated with polymorphisms of DRD2 and DRD3 genes.  
COMT A allele results in low activity of the COMT enzyme. Under conditions of 
increased dopamine release due to dysregulation of the dopaminergic system after TBI, 
individuals who have COMT AA genotype may not be able to breakdown high levels of 
dopamine which have accumulated in the synaptic clefts (Egan et al., 2001; Lubman et 
al., 2004; Syvanen et al., 1997). High levels of dopamine in the synaptic cleft are rapidly 
oxidized to form dopamine semiquinone/quinine. Oxidized dopamine via monoamine 
oxidase (MAO) activity or redox cycling can induce the generation of hydrogen peroxide 
and superoxide causing significant oxidative stress (Brunmark & Cadenas, 1988; 
Hastings, 1995; Olney et al., 1990; Sinet et al., 1980; Williams & Castner, 2006). 
Furthermore, increased dopamine signaling at the dopamine D2 receptor can increase 
intracellular Ca2+ release and activation of calcium dependent kinases phosphatases that 
are important for cell death signaling (Azdad et al., 2009; Hernandez-Lopez et al., 2000; 
So et al., 2009). This is supported by studies in animal models of TBI, which showed that 
following ischemia there is a 500 fold increase in dopamine concentration within the 
striatum (Globus et al., 1988). This increase precipitates excitotoxic disruption and 
oxidative damage to dopaminergic cellular function (Wagner et al., 2005). It is possible 
that individuals with COMT AA genotype are at a higher risk of excitotoxic and oxidative 
damage to their neurons after TBI. Significant neuronal damage may profoundly and 
unfavorably affect recovery after TBI.       
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To date, there is no other study which has associated specific SNPs of the COMT 
gene with functional outcome after TBI. However, a COMT gene study which evaluated 
cognitive performance or executive functioning of individuals with TBI and their 
response on the “Wisconsin Card Sorting Test” appeared to show results different from 
ours. Based on 113 individuals tested, individuals homozygous for A allele made fewer 
perseverative responses (good response) on the “Wisconsin Card Sorting Test” (Mean: 
12.1 ± 5.1) than individuals homozygous for the G allele, who had the highest number of 
perseverative responses (mean: 20.0 ± 20.9). Heterozygotes made an intermediate 
number of perseverative responses (mean: 14.0 ± 10.9). Perseverative responding 
suggests problems with cognitive ﬂexibility when the individual has difﬁculty shifting or 
changing mental set (Lipsky et al., 2005). However, one cannot determine from these data 
alone that TBI played a role in the observed association between COMT polymorphism 
and executive performance. The lack of a healthy comparison group in their study limits 
the ability to examine a causative relationship between COMT genotype and executive 
performance following TBI.  
Failure to find an association between rs1800497 polymorphisms of DRD2 gene 
and outcome after TBI is not entirely unexpected. Although studies have found that the 
T allele of rs1800497 was associated with poorer performance on measures of response 
latency (“Gordon Continuous Performance Test reaction times”) and measures of 
episodic memory (“the California Verbal Learning Test - recognition trial”) (McAllister 
et al., 2005), recent findings suggest that rs1800497 polymorphisms is strongly linked to 
another allele of an as yet undiscovered functional SNP located on the DRD2 gene. In 
other words, every person with an rs1800497 T allele also has this undiscovered allele. 
Since we do not know of the presence of this allele, we end up mistakenly attributing 
causality to the rs1800497 T allele (McAllister, 2009). Further studies are needed to study 
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other SNP’s of DRD2 gene and its linkage with rs1800497 polymorphisms of DRD2 gene 
and unfavorable outcome after TBI.  
To date, there is no other study which associated specific SNP of DRD3 gene with 
functional outcome after TBI. However, Bombin et al. (2008) evaluated 84 patients with 
first- episode psychosis with a comprehensive neuropsychological battery of test. The 
study assessed attention, working memory, memory and executive functions. Their 
findings suggest that subjects homozygous for DRD3 C allele have poorer executive 
performance than subjects homozygous for T allele. This study did not find any 
significant differences in the other cognitive paradigms and postulated that rs6280 
polymorphism of the DRD3 gene could possibly to be involved solely with prefrontal 
cognition (Bombin et al., 2008). This might explain why no association was found 
between this polymorphism and executive functioning in our current study.   
There are several limitations of this study that should be noted in interpreting the 
results. Outcome after TBI is a complex interaction of the profile and type of brain injury, 
effects of injury to other areas, post-injury treatment and various psychosocial factors. 
Thus the contribution of a single polymorphism to outcome could be quite modest. 
Another weakness in this study was the low number of females that does not allow us 
enough power to confirm that role of gender in outcome. Since this is the first study in a 
Malaysian population and the effects of the COMT AA genotype over extended longer 
period are less clear, further studies are needed to explain and confirm the association of 
COMT AA genotype with unfavorable outcome after TBI. 
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4.6 Conclusion 
 
Our findings show that presence of COMT AA genotype is associated with poor 
outcome at 6 months after TBI. We also found that GCS paired with status of COMT AA 
genotype appears to be a better predictor for unfavorable outcome at 6 month after TBI 
compared with GCS alone.  There is no association between alleles of DRD2 gene and 
DRD3 gene with outcome after TBI.  
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CHAPTER 5 
SINGLE NUCLEOTIDE POLYMORPHISMS IN GENES THAT MODULATE 
THE NEUROTROPIC FACTORS: INFLUENCES ON 6 MONTH OUTCOME 
AFTER TRAUMATIC BRAIN INJURY 
 
 
5.1 Introduction 
 
Neurotrophic factors are small protein molecules that regulate growth and survival 
of neurons. They influence metabolic functions such as protein synthesis and the ability 
of the neuron to make the neurotransmitters for communication with other neurons or 
with other targets (e.g. muscles and glands). Hence, neurotrophic factors play a significant 
role in the maintenance of neuronal function throughout an individual's entire lifetime 
(Huang & Reichardt, 2001; Thoenen, 1995). Comparatively little work has been done to 
study the association between SNPs of neurotrophic factor genes with outcome after TBI, 
particularly in Asian populations. In the current study, we attempted to determine if 
rs1800169 (A/G) polymorphism of the ciliary neurotrophic factor gene (CNTF), rs6265 
(A/G) polymorphism of the brain-derived neurotrophic factor gene (BDNF) and 
rs36119840 (A/G) polymorphism of the glial cell-derived neurotrophic factor gene 
(GDNF) could influence outcome in patients with TBI. 
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5.2 Literature Review 
 
Neurotrophic factors can be grouped as Neurotrophins (Nerve Growth Factor, 
BDNF, neurotrophin-3, neurotrophin-4 and CNTF), Glial cell-line Derived Neurotrophic 
Factor family ligands (GDNF, neurturin, artemin, and persephin) and Neuropoietic 
Cytokines. Neurotrophic factors have been reported to contribute to the pathogenesis of 
some neurodegenerative disorders, and have been proposed as potential treatments for 
these diseases, based on evidence of in vitro experiments and animal model studies (Moris 
& Vega, 2003). Many genetic studies have focused on SNPs in neurotrophic factor genes 
in neuropsychiatric disorders such as Alzheimers’s disease and schizophrenia (Huang et 
al., 2007; Lavedan et al., 2008; Voineskos et al., 2011; Xu et al., 2010) to identify SNPs 
that may be associated with increased risk for disease. These SNPs studies include 
rs1800169 (A/G) polymorphism of the CNTF gene, rs6265 (A/G) polymorphism of the 
BDNF gene and rs36119840 (A/G) polymorphism of the GDNF gene as summarized in 
Table 5.1. 
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Table 5.1: Neurotrophic factors: Characteristics, function and SNPs 
GENE CHARACTERISTICS AND FUNCTION SNP REFERENCES 
    
CNTF 1. A member of the interleukin-6 family of 
cytokines  
2. It can rescue various types of adult CNS 
neurons in disease models, including striatal, 
cholinergic forebrain, dopaminergic 
midbrain and motor neurons   
3. CNTF stimulates gene expression, cell 
survival or differentiation in a variety of 
neuronal cell types such as sensory, 
sympathetic, ciliary and motor neurons  
4. Nonneuronal cells, such as oligodendrocytes, 
microglial cells, liver cells, and skeletal 
muscle cells, respond to exogenously 
administered CNTF, both in vitro and in vivo 
1. rs1800169 (G/A)  
2. It is a null mutation of the CNTF gene.  
3. The G to A transition introduces a new 
splice acceptor site and the resulting 
mRNA encodes a non- functional aberrant 
protein  
(Anderson, Panayotatos, Corcoran, 
Lindsay, & Wiegand, 1996; Arakawa, 
Sendtner, & Thoenen, 1990; Barres et 
al., 1993; Dale, Kuang, Wei, & Varon, 
1995; Emerich et al., 1997; Hagg, 
Quon, Higaki, & Varon, 1992; Hagg & 
Varon, 1993; Hagg, Varon, & Louis, 
1993; Lo, Li, Oppenheim, Prevette, & 
Houenou, 1995; Louis et al., 1993; 
MacLennan et al., 1996; Mitsumoto et 
al., 1994; Pun, Santos, Saxena, Xu, & 
Caroni, 2006; Sagot et al., 1995; 
Sendtner et al., 1994; Sendtner, 
Kreutzberg, & Thoenen, 1990; 
Sendtner et al., 1992; Simon, Jablonka, 
Ruiz, Tabares, & Sendtner, 2010; R. 
Takahashi et al., 1994; Zala et al., 
2004) 
 
BDNF 1. BDNF is found abundantly in the 
hippocampus area  
2. It plays an important role in memory, 
attention, and speed of information 
processing. 
1. rs6265 (A/G)  
2. The more common G allele encodes for 
valine, while the A allele encodes 
methionine.  
3. The heterozygous form of this SNP 
produces a mature protein that has altered 
intrinsic biological activity.  
(Egan et al., 2003; Farkas & 
Povlishock, 2007; Leibrock et al., 
1989) 
 
 
80 
Table 5.1, Continued: Neurotrophic factors: Characteristics, function and SNPs 
GENE CHARACTERISTICS AND FUNCTION SNP REFERENCES 
    
  4. This alteration affects intracellular 
processing and secretion of mature 
BDNF. 
5. Therefore, compared to the homozygous 
BDNF form, neuroplastic effect of 
heterozygous BDNF may be 
compromised but the mechanism is 
unclear.  
 
 
GDNF 1. GDNF is a glycosylated, disulfide-bonded 
homodimer that is a distantly related member 
of the transforming growth factor-beta 
superfamily.  
2. In embryonic midbrain cultures, recombinant 
human GDNF promoted the survival and 
morphological differentiation of 
dopaminergic neurons and increased their 
high-affinity dopamine uptake. 
1. rs36119840 (A/G) 
2. The role and function of this 
polymorphism and how it affects the 
protein is not clearly understood.  
(Lin et al., 1993) 
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5.3 Method 
 
This is a prospective cross sectional study of 205 hospitalized TBI patients from the same 
cohort described in Chapter 3 (3.3.1 Patient cohort, Page 37). The Glasgow Coma Score 
(GCS) on admission were determined as described (3.3.1 Patient cohort, Page 37) and 
Glasgow Outcome Scale (GOS) at six months was assessed as described (3.3.4 Outcome 
evaluation, Page 39). DNA was extracted from the patients’ blood as previously described 
(3.3.2 DNA extraction and purification, Page 38). The polymorphisms in the CNTF gene, 
the BDNF gene and the GDNF gene were genotyped with the TaqMan genotyping assay 
(Applied Biosystems, Foster City, CA). Statistical analysis is detailed in Chapter 3 
(Chapter 3; 3.3.5 Statistical analysis, Page 39).  
 
5.3.1 TaqMan SNP Genotyping Assays 
 
The rs1800169 (A/G) polymorphism of the CNTF gene, the rs6265 (A/G) polymorphism 
of the BDNF gene and the rs36119840 (A/G) polymorphism of the GDNF gene were 
genotyped with the TaqMan genotyping assay (Applied Biosystems, Foster City, CA) 
using the Real-time PCR 7500 Fast real-time polymerase chain reaction system (ABI7500 
Fast; Applied Biosystems, Foster City, CA, USA), and assay-on-demand probes and 
primers: C__11592758_10, C__648651_20 and C__7511603_10, for SNPs rs6265, 
rs36119840 and rs1800169, respectively. The reaction volume was 10 μL, comprising 
6 μL genotyping mix and 4 μL genomic DNA. The reaction conditions consisted of a pre-
run at 95 °C for 10 min, following by 45 cycles of denaturation at 95 °C for 15 s and 
annealing step at 60 °C for 1 min.  
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5.4 Results 
 
5.4.1 Genotype frequencies  
 
Figure 5.1 shows the SNP genotyping scatter plots for the polymorphisms studied. 
The polymorphisms were determined by VIC/FAM fluorescence signals emitted by 
probes when they annealed and extended in the region of the interest in the DNA. If both 
alleles are homozygous, either VIC or FAM fluorescence signal will be emitted by the 
probes. However, if alleles are heterozygous, both VIC and FAM fluorescence signals 
will be emitted together. The CNTF homozygous A allele, BDNF homozygous A allele 
and GDNF homozygous A allele emit FAM fluorescence signals. The CNTF homozygous 
G allele, BDNF homozygous G allele and GDNF homozygous G allele emit VIC 
fluorescence signals. Both VIC and FAM fluorescence signals were emitted when CNTF, 
BDNF, GDNF alleles were heterozygous.   
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Figure 5.1: SNP genotyping scatter plot for rs1800169 (A/G) polymorphism of CNTF gene, rs6265 (A/G) 
polymorphism of BDNF gene and rs36119840 (A/G) polymorphism of GDNF gene. 
Red dots show FAM signals indicating that both alleles are homozygous, green dots show VIC signals 
indicating that both alleles are homozygous and blue dots show VIC and FAM signals indicating that 
alleles are heterozygous. 
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The genotype frequencies for rs1800169 (A/G) polymorphism of CNTF gene, 
rs6265 (A/G) polymorphism of BDNF gene and rs36119840 (A/G) polymorphism of 
GDNF gene are summarized in Table 5.2. For the rs1800169 (A/G) polymorphism of the 
CNTF gene, the most common and predominant genotype was homozygous GG found in 
76.1% of subjects, followed by heterozygous AG genotype (22.9%) and homozygous AA 
genotype (1.0%). For the rs6265 (A/G) polymorphism of the BDNF gene, 47.8% of the 
subjects were heterozygous AG, 37.6% homozygous AA and 14.6% homozygous GG. 
For the rs36119840 (A/G) polymorphism of the GDNF gene, the only genotype found 
was homozygous GG (100%); the GDNF homozygous AA and heterozygous GG 
genotypes were not found. 
 
Table 5.2: Genotype frequencies in 205 patients with TBI 
 
No. of 
patients 
% 
   
CNTF   
AA 2 1.0 
AG 47 22.9 
GG 156 76.1 
   
BDNF   
AA 77 37.6 
AG 98 47.8 
GG 30 14.6 
   
GDNF   
AA 0 0 
AG 0 0 
GG 205 100 
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5.4.2 Outcome after TBI 
 
The outcome after TBI was not associated with different alleles of BDNF gene 
and GDNF gene, respectively (p > 0.01). Table 5.3 shows the frequencies of the CNTF 
polymorphisms in patients further stratified by GCS. In general, for all the grades of TBI, 
the CNTF A allele is significantly associated with an unfavorable outcome at 6 months 
after TBI (OR: 3.7, 95% CI: 1.88-7.36, p= 0.01). Of the total of 205 patients, 56 had 
unfavorable outcomes, 24 (42.9%) of whom had at least one copy of the CNTF A allele, 
whereas, in the 149 patients with favorable outcomes, only 25 (16.8%) had at least one 
CNTF A allele (Table 5.3).  
 
Table 5.3: CNTF genotype and outcome in 205 patients with TBI 
 
No. of 
patients with 
favorable 
outcome (%) 
No. of 
patients with 
unfavorable 
outcome (%) 
   
All TBI (n= 205)   
CNTF AA 2 (1.3) 0 (0) 
CNTF AG 23 (15.4) 24 (42.9) 
CNTF GG 124 (83.2) 32 (57.1) 
Total 149 56 
   
Mild (n= 41)   
CNTF AA 1 (2.7) 0 (0) 
CNTF AG 6 (16.2) 3 (75.0) 
CNTF GG 30 (81.1) 1 (25.0) 
Total 37 4 
   
Moderate (n= 92)   
CNTF AA 1 (1.3) 0 (0) 
CNTF AG 12 (15.6) 7 (37.8) 
CNTF GG 64 (83.1) 8 (62.2) 
Total 77 15 
   
Severe (n= 72)   
CNTF AA - (0) - (0) 
CNTF AG 5 (14.3) 14 (37.8) 
CNTF GG 30 (85.7) 23 (62.2) 
Total 35 37 
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In the 72 patients with severe TBI (GCS <9), 37 had unfavorable outcomes, and 
14 (37.8%) of these patients had at least one copy of the CNTF A allele, whereas, in the 
35 patients with favorable outcome, only 5 (14.3%) had at least one CNTF A allele. There 
appear to be a significant association between unfavorable outcome in severe TBI and the 
CNTF A allele (2 = 5.1, p= 0.01).  
In the 92 patients who had moderate TBI (GCS: 9-13), 15 had unfavorable 
outcomes, 7 (46.7%) of whom had at least one copy of the CNTF A allele, whereas, in 
the 77 patients with favorable outcomes, only 13 (16.9%) had at least one CNTF A allele. 
Again, there is a significant association between unfavorable outcome in moderate TBI 
and the CNTF A allele (2 = 6.5, p= 0.01).  
In the 41 patients with mild TBI (GCS: 14-15), 4 patients had unfavorable 
outcomes, with 3 (75%) having at least one copy of the CNTF A allele, whereas, in the 
37 patients with favorable outcome, only 7 (18.9%) patients had at least one CNTF A 
allele. Thus, there is a significant association between unfavorable outcome in mild TBI 
and CNTF A allele (2 = 6.2, p= 0.01).  
In the logistic model, GCS of the patients alone significantly predicts unfavorable 
outcome in TBI (R2 = 30.83, p=0.01). However, GCS paired with the presence of the 
CNTF A allele is a better predictor for unfavorable outcome in TBI compared with GCS 
alone (R2 = 46.15; CNTF A allele- OR: 4.55, 95% CI: 2.10-9.86, p= 0.01; GCS- OR: 4.28, 
95% CI: 2.42-7.58, p= 0.01). 
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5.5 Discussion 
 
In this cross sectional study, we have found that patients with the CNTF A allele 
had an association with unfavorable global functional outcomes (as measured by the 
GOS), compared to patients without the CNTF A allele. Unfavorable outcomes after TBI 
were not associated with alleles of BDNF and GDNF genes.  
In the setting of TBI, CNTF may be very vital for the regulation of excessive 
glutamate. Since TBI is associated with a massive release of glutamate (Bullock et al., 
1998; Robertson et al., 2001), increased levels of extracellular glutamate could cause 
over-stimulation of glutamate receptors that may result in secondary events, leading to 
neuronal cell death (Floyd, Gorin, & Lyeth, 2005; Yi & Hazell, 2006). In fact, glutamate 
as the most abundant excitatory neurotransmitter in the brain could cause prolonged 
depolarization and subsequent ionic imbalance, ATP depletion and increases in 
intracellular free calcium levels that together culminate in cerebral edema, raised 
intracranial pressure (ICP), vascular compression and brain herniation (DeWitt & Prough, 
2003; Obrenovitch & Urenjak, 1997). Following TBI, CNTF-activated astrocytes aid in 
buffering the effects of glutamate in the CNS by enhanced glutamate uptake (Beurrier et 
al., 2010). However, in individuals with the CNTF A allele, a non- functional aberrant 
CNTF protein is produced. Hence, it is likely that individuals with the CNTF A allele are 
at higher risk of excitotoxic damage to their neurons after TBI, contributing to 
unfavorable post-TBI recovery. 
In contrast to other studies we did not find any association between SNPs of the 
BDNF gene and outcome after TBI. Krueger et al. (2011) evaluated the effect of SNPs in 
the BDNF gene on executive function following TBI, and showed that G allele (valine) 
carriers had impaired executive function compared to the A allele (methionine) carriers 
(Krueger et al., 2011). The authors speculated that the A allele may favorably protect 
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neurons from apoptosis after injury through reduction of proBDNF secretion. Although 
BDNF helps to promote cell survival, its premature form, proBDNF, (Chao, 2003) tends 
to trigger apoptosis (R. Lee, Kermani, Teng, & Hempstead, 2001; Teng et al., 2005). 
Since, the A allele is associated with reduced secretion of proBDNF (Chiaruttini et al., 
2009), it may favorably protect neurons from apoptosis after injury and eventually prevent 
declines in executive function following TBI.  
There are several limitations in this study that should be noted in interpreting the 
results. Outcome after TBI is a complex interaction of the profile and type of brain injury, 
effects of injury to other areas, post-injury treatment and various psychosocial factors. 
Thus the contribution of a single polymorphism to outcome is probably quite modest. 
Another weakness in this study was the small number of females so this study did not 
have enough power to confirm that role of gender in TBI outcome. Since this is the first 
study in Malaysian population and the effects of CNTF A allele over a longer period are 
less clear, further and larger cohort studies are needed to explain why the CNTF A allele 
is associated with unfavorable outcome after TBI. 
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5.6 Conclusion 
 
Our findings showed that presence of CNTF A allele is associated with poor 
outcome at 6 month after TBI. We also found that GCS paired with status of CNTF A 
allele are a better predictor for unfavorable outcome at 6 months after TBI compared with 
GCS alone.  There is no association between alleles of BDNF gene and GDNF gene, 
respectively, with outcome after TBI.   
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CHAPTER 6 
SERUM BIOMARKERS ASSOCIATED WITH TRAUMATIC BRAIN INJURY 
 
6.1 Introduction 
 
Serum biomarkers have assisted physicians to identify and assess injuries to 
various organs e.g. “troponin and creatine phosphokinase isoenzyme MB for the heart, 
aspartate and alanine transaminases for the liver, lipases for pancreas, and blood urea 
nitrogen and creatinine for the kidney”. Similarly in TBI, several putative serum 
biomarkers have been used but they suffer from a lack of speciﬁcity in that they can be 
released into the serum by conditions not directly due to TBI. Moreover, serum 
biomarkers to determine the severity of TBI (mild, moderate and severe) have not been 
well studied. 
Conventional methods to study biomarkers for diseases/conditions had used 
ELISA and 2D gel-based mass spectrometry. In the last decade, mass spectrometry-based 
proteomics using iTRAQ technology for quantification has emerged as a new method for 
large-scale analysis of proteins in many types of diseases (Schulze & Usadel, 2010). As 
far as we are aware, so far there is only one study that used iTRAQ-based mass 
spectrometry to identify serum biomarkers in TBI (Hergenroeder et al., 2008). In this 
study, pooled sera of 11 cases of TBI were compared with sex and age matched normal 
controls and 15 candidate biomarkers were found to be increased; an additional 16 
biomarkers were found to be decreased in severe TBI. However, the association of these 
proteins with mild and moderate TBI were not investigated.  
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The objectives of this study were to identify serum proteins which may be 
increased or decreased after TBI alone by iTRAQ-based mass spectrometry, and to 
evaluate if these serum proteins were able to distinguish mild, moderate and severe TBI. 
We hypothesize that changes in multiple serum proteins may provide the speciﬁcity and 
sensitivity required to diagnose TBI in the setting of polytrauma, and may aid in the 
timely diagnosis of TBI in a minimally invasive manner.  
 
6.2 Literature Review 
 
The GCS provides a prognostic scale for TBI (Teasdale & Jennett, 1974, 1976).  
Due to its simplicity, reproducibility and prognostic ability (albeit limited) it has become 
a standard component of the initial examination of head injury patients. However, given 
the increased use of intubation, ventilation and sedation of patients with impaired 
consciousness (Marion & Carlier, 1994), the utility of GCS becomes limited since the 
patients are often under the influence of sedative medication by the time they arrive at the 
trauma unit or even before arrival at the hospital. In these cases, assessing GCS at this 
time will not be indicative of the actual conscious state. In a study of 1005 patients with 
TBI in European centers, assessment of each of the three components of the GCS (eye 
opening, motor and verbal response) was possible only in 61% of patients before hospital 
arrival, in 77% on arrival at the first hospital, in 56% on arrival in the neurosurgical unit, 
and in 49% of post-resuscitation patients (Murray et al., 1993). In addition, factors like 
drug use, alcohol intoxication, shock or low blood oxygen also can alter a patient’s level 
of consciousness which could eventually lead to an inaccurate GCS score. Problems also 
arise when the periorbital region is swollen, either following periorbital edema, direct 
ocular trauma, facial injury, craniotomy, cranial nerve VII injury or neuromuscular 
blockade. Mild TBI may be present in patients who appear normal with full GCS scores, 
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and a neuroimaging investigations such as the CT scan or brain MRI may or may not 
show evidence of any damage.  
Hence, a good serum biomarker for TBI could complement the clinical assessment 
of the conscious state of patients. It may perhaps be the sole measure of the severity of 
TBI in patients who have altered conscious states such as in patients with sedative drugs 
or hypotension or who are under the influence of alcohol. The application of serum 
protein markers could potentially lead to expeditious grading in the case of intubated, 
sedated and unconscious patients even before the application of neuroimaging techniques. 
To date, the most frequently studied TBI-related serum markers, and some of their 
characteristics are summarized in Table 6.1. (Full details are found in chapter 2, page 25 
to page 34). As indicated, most of them suffer from relative disadvantages as a serum 
biomarker for TBI.   
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Table 6.1: Most frequently examined TBI related serum markers and their relative 
disadvantages 
SERUM MARKER DISADVANTAGES REFERENCES 
S100B  Elevated after bone fractures, thoracic 
contusions without fractures, burns 
and even after minor bruises 
 Elevated in local ischemia and 
reperfusion of the liver, gut, and 
kidney 
 
(Anderson et al., 
2001; Pelinka, 
Harada, et al., 2004) 
 
Glial Fibrillary Acidic 
Protein 
 
Not sensitive enough for mild TBI  
 
(Vos et al., 2004) 
 
Neuron Specific 
Enolase 
 
Elevated in neuroendocrine bladder tumors 
small cell lung cancer, neuroblastoma and 
stroke. 
 
(Schoerkhuber et al., 
1999) 
Myelin Basic Protein Released into the bloodstream under the 
circumstances of demyelinating disease   
 
(Ingebrigtsen & 
Romner, 2002) 
 
Creatine Kinase Brain 
Isoenzyme 
 
 Has short half-life and rapidly 
eliminated from circulation 
 Blood brain barrier disruption is 
necessary for it to be present in serum.   
 Elevated during adenocarcinomas of 
the prostate, ovary, colon, breast, 
small cell anaplastic carcinoma of the 
lungs and other adenocarcinomas of 
the gastrointestinal tract making it not 
specific for TBI. 
 
(Schwartz et al., 
1989) 
Cleaved tau Poor diagnostic value for mild TBI 
 
(Zemlan et al., 2002) 
 
C- Reactive Protein & 
Serum Amyloid A 
 
General injury markers (Hergenroeder et al., 
2008) 
 
Interleukin 6 General marker for multi-organ failure 
 
(Chiaretti et al., 
2008; Winter, 
Pringle, Clough, & 
Church, 2004) 
 
Interleukin 8 General marker of inflammation 
 
(Buttram et al., 2007) 
 
Interleukin 10 General anti-inflammatory marker 
 
(Bell et al., 1997; 
Csuka et al., 1999) 
 
Interleukin 12p70 General marker of inflammation 
 
(Buttram et al., 2007) 
 
Tumor Necrosis 
Factor α 
General marker of inflammation 
 
(Crespo et al., 2007) 
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6.3 Methods 
 
6.3.1 Sample Collection 
 
For this study we used another cohort of TBI patients which is separate from the 
original cohort of 205 patients. Blood samples from 10 patients per group were collected 
from mild, moderate and severe TBI patient groups, respectively after obtaining consent. 
From each patient 10 mls of blood were drawn from the patient within 24 hours of 
admission to the Neuro Intensive Care Unit, University of Malaya Medical Centre. In this 
way, Each TBI group comprised samples from 5 males and 5 females. Their ages and 
nature of accidents summarized in Table 6.2, were generally representative of the cases 
in our original cohort of 205 patients. Age and sex-matched control samples were also 
obtained from 10 healthy individuals. 
Patients who had blood transfusions, and who had co-morbidities such as extra-
CNS traumatic injuries, polytrauma (e.g. fractures, abdominal and chest injuries), and 
other major systemic diseases that might interfere with serum protein marker discovery, 
were excluded from the study. The bottles were allowed to stand upright at room 
temperature for 1 hour for the clot to form. Upon centrifuging (2500 RPM, 4˚C) the serum 
separated and stored at -80 ˚C for subsequent analysis. Sera from each TBI group were 
then pooled for analysis with mass spectrometry. 
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Table 6.2: Characteristics of TBI groups for mass spectrometry 
 Severity of TBI 
 Mild 
(n=10) 
Moderate 
(n=10) 
Severe 
(n=10) 
    
    
Nature of accident    
MVA    
Motorcycle 3 5 7 
Car 2 1 - 
Other Vehicles 1 1 - 
Pedestrian - - 2 
Fall 3 1 - 
Fall from a height 1 - 1 
Assault - 2 - 
    
Gender    
Male (n=15) 5 5 5 
Female (n=15) 5 5 5 
    
Age    
16-30 (n=12) 4 4 4 
31-45 (n=10) 4 4 4 
>45 (n=8) 2 2 2 
    
 
Abbreviation: Motor Vehicle Accident (MVA); Footnote: For the subheading MVA, 
patient was using the vehicle when met with an accident. 
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6.3.2 iTRAQ Reagent- labeling 
 
Four iTRAQ (Isobaric tag for relative and absolute quantitation; AB SCIEX, USA) 
reagents (114, 115, 116 and 117) were utilized to label the primary amines of peptides in 
each of the 4 groups (mild, moderate, severe TBI and normal control groups), 
respectively. Each iTRAQ molecule consists of a reporter group linked to a peptide 
reactive group (Figure 6.1). The peptide reactive group binds to the primary amines of 
the peptide of interest to facilitate its quantification via measurement of reporter signal 
intensities by the “5800 MALDI TOF/ TOF mass spectrometer” (Applied Biosystems, 
USA). Duplicate sets from each of the four serum pools (mild TBI, moderate TBI, severe 
TBI, and normal control groups) were immunodepleted of the top 14 high-abundance 
proteins using the “Agilent MARS14 column” (Agilent, USA). Immunodepleted sera 
were “reduced”, “alkylated”, “trypsin digested” and “labelled with iTRAQ® reagent” 
according to the manufacturer’s protocol (AB SCIEX, USA). 
 
  
 
Figure 6.1: Structure of iTRAQ reagent- modified from Ross et al. (2004)  
iTRAQ reagent consist a reporter group with mass=114, 115, 116, or 117 and a peptide 
reactive group that is reactive and linked to the primary amines of the peptide of interest. 
  
Primary 
Amines of the 
peptide of 
interest 
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6.3.3 First Dimension Ion Exchange Chromatography 
 
The first dimension ion exchange chromatography was utilized to separate serum proteins 
according to their net charge. To achieve this, iTRAQ labeled peptides from the pooled 
sera were desalted on a “Strata-X 33 μm polymeric reversed phase column” 
(Phenomenex) and dissolved in a buffer containing 10 mM potassium hydrogen 
phosphate, pH 3 in 10% acetonitrile, before separation by “strong cation exchange liquid 
chromatography” (SCX) on an “Agilent 1100 HPLC system” (Agilent Technologies, 
USA) using a “PolySulfoethyl column” (4.6 x 100 mm, 5μm, 300 Å, Nest Group, USA). 
Peptides were eluted with a linear gradient of 0-400 mM KCl. A total of 8 fractions were 
collected, desalted on a “Strata-X 33 μM polymeric reversed phase column”.  
 
6.3.4 Second Dimension Reverse Phase nano- Liquid Chromatography 
 
Eluted fractions were subjected to the second dimension reverse phase nano- liquid 
chromatography that uses a hydrophobic stationary phase to separate the proteins by size. 
The fractions were loaded onto a “C18 pre-column” and then separated on a “C18 
PepMap100, 3 μm column” (Dionex, USA) using the “Ultimate 3000 nano HPLC 
system” (Dionex, USA). Peptides were resolved with a gradient of 10%- 40% acetonitrile 
(0.1% trifluoroacetic acid) and fractions were spotted every 30 seconds to “AnchorChip 
MALDI plates” using “ProBot robotic spotter” (LC Packings) 
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6.3.5 Matrix-Assisted Laser Desorption Ionization- Mass Spectrometry (MALDI-
MS/MS) 
 
The MALDI is a soft ionization technique in which a peptide sample is vaporized from a 
solid phase directly into a gas phase, ionized and accelerated to separate the ions 
according to their masses. Spotted chips containing peptide fractions were analyzed in a 
“5800 MALDI TOF/ TOF mass spectrometer” (Applied Biosystems, USA) operated in 
reflector positive mode. Mass spectrometry (MS) data were acquired over a mass range 
of 800−4000 m/z, and for each spectrum, a total of 400 shots were accumulated. A job-
wide interpretation method selected the 20 most intense precursor ions above a signal/ 
noise ratio of 20 from each spectrum for MS/MS acquisition but only in the spot where 
their intensity was at its peak. MS/ MS spectra were acquired with 4000 laser shots per 
selected ion with a mass range of 60 to the precursor ion −20. 
 
6.3.6 Data Analysis 
 
Protein identification was performed using the “ProteinPilot 4.0 Software” 
(Applied Biosystems, USA). MS/MS spectra were searched against the “Swiss-Prot” 
human genomic database using search parameters as follows: “Cys alkylation, MMTS; 
Digestion, trypsin; Instrument, 5800; Special factors, none; Species, none; iTRAQ 4plex 
(peptide labeled) modification; Quantitate tab, checked; Detected protein threshold 
(unused ProtScore), 1.3, which corresponds to proteins identified with >95% confidence”.  
For quantitation analysis, the duplicates from each of the 4 pools serum pools 
were analyzed separately. Average protein ratios and p-values to indicate significant 
increase or decrease were calculated by the software. To be considered increased or 
decreased, proteins were required to have an unused protein score greater than 1.3, 
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corresponding to a confidence interval of 95%, and to have significantly different protein 
ratios in both duplicates (≥1.6 is increased, <0.625 is decreased), also at a confidence 
level of 95% (p < 0.05). The p values represented the variation in the reported iTRAQ 
ratios for all the peptides of the associated protein and do not relate to either biological 
variation or technical reproducibility. The false discovery rate was less than 1%, 
calculated using a database containing reversed sequences. In order to categorize the 
identified proteins, the results were analyzed using the software program IPA (Ingenuity 
Databases) and the UniProt Database release 2011_6 (http://www.uniprot.org/). 
 
Figure 6.2 summarizes the workflow to prepare samples for mass spectrometry. 
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Figure 6.2: iTRAQ workflow- modified from (Ross et al., 2004) 
Pooled samples from control, mild, moderate and severe TBI groups were digested and 
iTRAQ labelled for mass spectrometry. Combined labelled digests were 
chromatographically separated by charge and size, and analyzed by the mass 
spectrometer. Peptide sequence identification was derived from the spectra chart that 
showed various peptide sequences as vertical peaks. Quantification of the protein was 
obtained from the iTRAQ reporter ion signal intensities.   
 
  
Control Mild Moderate Severe 
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6.3.7 Validation with ELISA 
 
Proteins which were identified to be increased or decreased by iTraq were confirmed and 
validated by commercially-available ELISA in accordance with the manufacturers’ 
instruction (ABCAM, United Kingdom). ELISA was performed on entirely new groups 
of normal controls, mild, moderate and severe TBI patient samples (n=10 for each group), 
which were collected separately from those used for mass spectrometry. These samples 
were also age and sex matched to patients in the mass spectrometry study. In addition to 
normal controls (n=10), blood samples were also collected from another group of 10 
patients with femoral fractures as additional controls. Data were expressed as mean ± 
standard deviation and statistical analysis was performed with SPSS 13.0 software (SPSS, 
Chicago, IL). p < 0.05 was considered statistically significant increase/decrease. 
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6.4 Results 
 
The spectra from mass spectrometry analysis identified a total of 83 proteins 
(Appendix H) with >95% confidence in each of the 3 TBI group pooled sera samples. 
From this list, we identified 12 proteins that in general have a consistent and 
proportionally/gradually increasing or decreasing serum levels in the 3 TBI groups. Using 
these protein names as keywords, we extensively searched existing published literature 
available in Pubmed, EBSCO and Web of Science databases for links to neurological 
diseases/conditions. In this way, 11 proteins that have some relationship to brain 
pathology were shortlisted; 1 protein (“Ceruloplasmin”) was excluded for lack of any 
such relationship. The spectra of these 11 proteins of particular interest are shown in 
panels A of Figure 6.3 to Figure 6.13. These proteins include: 
 
1. “Serum Amyloid-A” (Figure 6.3) 
2. “C- Reactive Protein” (Figure 6.4) 
3. “Leucine- Rich alpha-2 Glycoprotein-1” (Figure 6.5) 
4. “Lipopolysaccharide Binding Protein” (Figure 6.6) 
5. “Fibronectin” (Figure 6.7) 
6. “Vitronectin” (Figure 6.8) 
7. “Alpha-1 antichymotrypsin” (Figure 6.9) 
8. “Apolipoprotein E” (Figure 6.10)  
9. “Zinc Alpha-2 glycoprotein” (Figure 6.11)  
10. “Gelsolin” (Figure 6.12) 
11. “Kininogen” (Figure 6.13) 
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In the spectra, various peptide sequences of a particular protein, shown as vertical 
peaks, enable the positive identification of the protein. For an example, panel A in Figure 
6.3 shows the peptide sequence SFFSFLGEAFDGAR as denoted in the “Swiss-Prot” 
protein database, thus identifying the protein as “Serum Amyloid-A”.   
Panel B in Figure 6.3 to Figure 6.13 show the relative abundance of proteins in 
each of the normal control, mild, moderate and severe TBI groups. For an example, in 
panel B, Figure 6.3, the 4 peaks indicate the relative abundance of “Serum Amyloid-A” 
in all 4 groups, the highest being in the severe TBI group. Conversely, in panel B, Figure 
6.12, the 4 peaks indicate that “Gelsolin” in the 4 groups, were almost similar in relative 
abundance.  
Protein levels were only considered to be increased in sera from TBI subjects if 
the iTRAQ ratio of the relative abundance of the protein in TBI sera to normal control 
sera was ≥ 1.6. If the iTRAQ ratio of TBI/control was <0.625, then the protein was 
considered to be decreased. These cut-off ratios are equivalent to a confidence interval of 
95% (p < 0.05). 
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Figure 6.3: MS data acquired for “Serum Amyloid-A”. 
Panel A shows the multiple peaks of the protein spectrum of “Serum Amyloid-A” as 
identified by the “Protein Pilot 4.0 Software” using the peptide sequence 
SFFSFLGEAFDGAR in the “Swiss-Prot” protein database. These peaks were derived 
from the sera pools of normal control, mild, moderate and severe TBI groups. The green 
box (bottom left of panel A) shows iTRAQ signals from each of the 4 groups and are 
reproduced in Panel B as an enlarged image. The 4 peaks in Panel B indicate the levels 
of “Serum Amyloid-A” protein in these groups. Severe TBI (ratio over control= 47.9) had 
the highest level of the protein, followed by moderate (ratio over control= 35.3) and mild 
TBI (ratio over control= 29.4). A ratio of ≥1.6 is considered as a significant increase.  
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Figure 6.4: MS data acquired for “C-reactive protein”. 
Panel A shows the multiple peaks of the protein spectrum of “C-reactive protein” as 
identified by the “Protein Pilot 4.0 Software” using the peptide sequence 
ALKYEVQGEVFTKPQLWP in the “Swiss-Prot” protein database. These peaks were 
derived from the sera pools of normal control, mild, moderate and severe TBI groups. 
The green box (bottom left of panel A) shows iTRAQ signals from each of the 4 groups 
and are reproduced in Panel B as an enlarged image. The 4 peaks in Panel B indicate the 
levels of “C-reactive protein” protein in these groups. Severe TBI (ratio over control= 
32.0) had the highest level of the protein, followed by moderate (ratio over control= 20.0) 
and mild TBI (ratio over control= 16.7). A ratio of ≥1.6 is considered as a significant 
increase. 
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Figure 6.5: MS data acquired for “Leucine-rich alpha-2 glycoprotein-1”. 
Panel A shows the multiple peaks of the protein spectrum of “Leucine-rich alpha-2 
glycoprotein-1” as identified by the “Protein Pilot 4.0 Software” using the peptide 
sequence TLDLGENQLETLPPDLLR in the “Swiss-Prot” protein database. These peaks 
were derived from the sera pools of normal control, mild, moderate and severe TBI 
groups. The green box (bottom left of panel A) shows iTRAQ signals from each of the 4 
groups and are reproduced in Panel B as an enlarged image. The 4 peaks in Panel B 
indicate the levels of “Leucine-rich alpha-2 glycoprotein-1” protein in these groups. 
Severe TBI (ratio over control= 37.0) had the highest level of the protein, followed by 
moderate (ratio over control= 23.8) and mild TBI (ratio over control= 21.3). A ratio of 
≥1.6 is considered as a significant increase.  
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Figure 6.6: MS data acquired for “Lipopolysaccharide binding protein”. 
Panel A shows the multiple peaks of the protein spectrum of “Lipopolysaccharide-
binding protein” as identified by the “Protein Pilot 4.0 Software” using the peptide 
sequence SFRPFVPR in the “Swiss-Prot” protein database. These peaks were derived 
from the sera pools of normal control, mild, moderate and severe TBI groups. The green 
box (bottom left of panel A) shows iTRAQ signals from each of the 4 groups and are 
reproduced in Panel B as an enlarged image. The 4 peaks in Panel B indicate the levels 
of “Lipopolysaccharide-binding protein” protein in these groups. Severe TBI (ratio over 
control= 7.3) had the highest level of the protein, followed by moderate (ratio over 
control= 6.9) and mild TBI (ratio over control= 5.3). A ratio of ≥1.6 is considered as a 
significant increase. 
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Figure 6.7: MS data acquired for “Fibronectin”. 
Panel A shows the multiple peaks of the protein spectrum of “Fibronectin” as identified 
by the “Protein Pilot 4.0 Software” using the peptide sequence MSESGFK in the “Swiss-
Prot” protein database. These peaks were derived from the sera pools of normal control, 
mild, moderate and severe TBI groups. The green box (bottom left of panel A) shows 
iTRAQ signals from each of the 4 groups and are reproduced in Panel B as an enlarged 
image. The 4 peaks in Panel B indicate the levels of “Fibronectin” protein in these groups. 
Severe TBI (ratio over control= 5.2) had the highest level of the protein, followed by 
moderate (ratio over control= 2.6) and mild TBI (ratio over control= 2.2). A ratio of ≥1.6 
is considered as a significant increase. 
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Figure 6.8: MS data acquired for “Vitronectin”. 
Panel A shows the multiple peaks of the protein spectrum of “Vitronectin” as identified 
by the “Protein Pilot 4.0 Software” using the peptide sequence DVWGIEGPIDAAFTR 
in the “Swiss-Prot” protein database. These peaks were derived from the sera pools of 
normal control, mild, moderate and severe TBI groups. The green box (bottom left of 
panel A) shows iTRAQ signals from each of the 4 groups and are reproduced in Panel B 
as an enlarged image. The 4 peaks in Panel B indicate the levels of “Vitronectin” protein 
in these groups. Mild, moderate and severe TBI had equal levels of protein increase (ratio 
over control= 1.6). A ratio of ≥1.6 is considered as a significant increase. 
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Figure 6.9: MS data acquired for “Alpha-1 antichymotrypsin”. 
Panel A shows the multiple peaks of the protein spectrum of “Alpha-1 antichymotrypsin” 
as identified by the “Protein Pilot 4.0 Software” using the peptide sequence 
ITLLSALVETR in the “Swiss-Prot” protein database. These peaks were derived from the 
sera pools of normal control, mild, moderate and severe TBI groups. The green box 
(bottom left of panel A) shows iTRAQ signals from each of the 4 groups and are 
reproduced in Panel B as an enlarged image. The 4 peaks in Panel B indicate the levels 
of “Alpha-1 antichymotrypsin” protein in these groups. Severe TBI (ratio over control= 
19.0) had the highest level of the protein, followed by moderate (ratio over control= 16.0) 
and mild TBI (ratio over control= 15.0). A ratio of ≥1.6 is considered as a significant 
increase. 
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Figure 6.10: MS data acquired for “Apolipoprotein E”. 
Panel A shows the multiple peaks of the protein spectrum of “Apolipoprotein E” as 
identified by the “Protein Pilot 4.0 Software” using the peptide sequence 
AKLEEQAQQIR in the “Swiss-Prot” protein database. These peaks were derived from 
the sera pools of normal control, mild, moderate and severe TBI groups. The green box 
(bottom left of panel A) shows iTRAQ signals from each of the 4 groups and are 
reproduced in Panel B as an enlarged image. The 4 peaks in Panel B indicate the levels 
of “Apolipoprotein E” protein in these groups. The protein was only increased in severe 
TBI (ratio over control= 2.3). A ratio of ≥1.6 is considered as a significant increase. The 
protein levels were not changed significantly in moderate and mild TBI (ratio over control 
<1.6).  
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Figure 6.11:  MS data acquired for “Zinc alpha-2 glycoprotein”. 
Panel A shows the multiple peaks of the protein spectrum of “Zinc-alpha-2 glycoprotein” 
as identified by the “Protein Pilot 4.0 Software” using the peptide sequence 
AKAYLEEECPATLR in the “Swiss-Prot” protein database. These peaks were derived 
from the sera pools of normal control, mild, moderate and severe TBI groups. The green 
box (bottom left of panel A) shows iTRAQ signals from each of the 4 groups and are 
reproduced in Panel B as an enlarged image. The 4 peaks in Panel B indicate the levels 
of “Zinc-alpha-2 glycoprotein” protein in these groups. The protein was only increased 
in severe TBI (ratio over control= 3.2). A ratio of ≥1.6 is considered as a significant 
increase. The protein levels were not changed significantly in moderate and mild TBI 
(ratio over control <1.6).  
  
A 
 
 
 
 
 
 
B 
Mass (m/z) 
Mass (m/z) 
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e 
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e 
Severe 
 
Control 
 
Moderate 
 
 
Mild 
 
113 
 
 
 
 
Figure 6.12: MS data acquired for “Gelsolin”. 
Panel A shows the multiple peaks of the protein spectrum of “Gelsolin” as identified by 
the “Protein Pilot 4.0 Software” using the peptide sequence VPEARPNSMVVEHPEFLK 
in the “Swiss-Prot” protein database. These peaks were derived from the sera pools of 
normal control, mild, moderate and severe TBI groups. The green box (bottom left of 
panel A) shows iTRAQ signals from each of the 4 groups and are reproduced in Panel B 
as an enlarged image. The 4 peaks in Panel B indicate the levels of “Gelsolin” protein in 
these groups. Severe and moderate TBI had the highest levels of the protein decrease 
(ratio over control= 0.3), followed by mild TBI (ratio over control= 0.4). A ratio of <0.625 
is considered as a significant decrease.  
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Figure 6.13: MS data acquired for “Kininogen”. 
Panel A shows the multiple peaks of the protein spectrum of “Kininogen” as identified 
by the “Protein Pilot 4.0 Software” using the peptide sequence YFIDFVAR in the “Swiss-
Prot” protein database. These peaks were derived from the sera pools of normal control, 
mild, moderate and severe TBI groups. The green box (bottom left of panel A) shows 
iTRAQ signals from each of the 4 groups and are reproduced in Panel B as an enlarged 
image. The 4 peaks in Panel B indicate the levels of “Kininogen” protein in these groups. 
The protein was only decreased in severe and moderate TBI (ratio over control= 0.4). A 
ratio of <0.625 is considered as a significant decrease. The protein levels was not changed 
in mild TBI (ratio over control >0.625).  
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Based on this criteria, 7 of these 11 biomarkers were increased in all the grades of 
TBI (Table 6.3). Among these 7 markers, except for “Alpha-1 antichymotrypsin”, 4 of 
these markers (“Leucine-Rich alpha-2 Glycoprotein-1”, “Lipopolysaccharide Binding 
Protein”, “Fibronectin” and “Vitronectin”) appear to be novel biomarkers for TBI. Two 
markers, “Serum Amyloid-A” and “C-reactive Protein”, are known general markers of 
inflammation. The serum biomarker with the highest ratio of increase was “Serum 
Amyloid-A” (severe TBI/control ratio = 47.9; moderate TBI/control ratio = 35.3 and mild 
TBI/control ratio = 29.4), and the lowest ratio of increase was “Vitronectin” (with the 
same ratio of 1.6 for severe, moderate and mild TBI) (Table 6.3). Moreover, except for 
“Vitronectin”, all the other proteins viz., “Serum Amyloid-A”, “C-reactive Protein”, 
“Leucine-Rich alpha-2 Glycoprotein-1”, “Lipopolysaccharide Binding Protein”, 
“Fibronectin”, and “Alpha-1 antichymotrypsin”, showed the most definite gradual 
increase of proteins from mild, moderate to severe TBI groups (Table 6.3). Two 
biomarkers, “Apolipoprotein E” and “Zinc alpha-2 glycoprotein” were only increased in 
severe TBI (Table 6.3). Most of these increased serum biomarkers were secreted proteins 
except “Fibronectin” and “Apolipoprotein E”. “Fibronectin” is an extracellular matrix 
structural constituent, whereas “Apolipoprotein E” is a constituent of lipid-protein 
complexes. 
On the other hand, “Gelsolin” was more or less equally decreased in all grades of 
TBI compared to the controls, whereas “Kininogen” was equally decreased in moderate 
and severe TBI (Table 6.3). Only “Kininogen” is apparently novel for TBI. “Gelsolin” is 
a cytoplasmic component, a structural constituent of cytoskeleton as well as a secretory 
protein. “Kininogen” is a secretory protein.  
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Table 6.3: Serum protein changes in mild, moderate and severe TBI  
Protein name 
(Accession Number) 
Ratio * 
Biological Process 
Subcellular 
Location 
Molecular Function 
Mild/Control 
Moderate/
Control 
Severe/ 
Control 
       
INCREASED       
       
Serum Amyloid-A 
(P0DJI8) 
29.4 35.3 47.9 
Major acute phase 
reactant 
Secreted 
G-protein coupled receptor 
binding 
       
C-reactive Protein 
(P02741) 
16.7 20.0 32.0 Acute phase response Secreted 
Cholesterol binding, choline 
binding, low-density 
lipoprotein particle binding, 
metal ion binding 
       
Leucine-Rich alpha-2-
Glycoprotein-1 
(P02750) 
21.3 23.8 37.0 Unclassified Secreted Unclassified 
       
Lipopolysaccharide-
Binding Protein 
(P18428) 
5.3 6.9 7.3 
Lipid transport, 
transport 
Secreted 
Lipopolysaccharide binding, 
lipoteichoic acid binding, 
receptor binding 
       
Fibronectin  
(P02751) 
2.2 2.6 5.2 
Acute phase, 
angiogenesis, Cell 
adhesion, Cell shape 
Extracellular matrix, 
Secreted 
Collagen binding, 
extracellular matrix structural 
constituent, heparin binding, 
peptidase activator activity 
       
Vitronectin  
(P04004) 
1.6 1.6 1.6 Cell adhesion Secreted 
Extracellular matrix binding, 
heparin binding, 
polysaccharide binding, 
scavenger receptor activity 
       
Alpha-1 
antichymotrypsin 
(P01011) 
15.0 16.0 19.0 Acute phase response Secreted 
DNA binding, serine-type 
endopeptidase inhibitor 
activity 
       
* The protein level is considered increased if the ratio is ≥1.6 and it is considered decreased if the ratio <0.625
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Table 6.3, Continued: Serum protein changes in mild, moderate and severe TBI  
Protein name 
Ratio * 
Biological Process 
Subcellular 
Location 
Molecular Function 
Mild/Control 
Moderate/
Control 
Severe/ 
Control 
       
Apolipoprotein E 
(P02649) 
Unchanged Unchanged 2.3 
Cholesterol 
metabolism, Lipid 
metabolism, Lipid 
transport, Steroid 
metabolism, Sterol 
metabolism, 
Transport 
Chylomicron, HDL, 
Secreted, VLDL 
Antioxidant activity, 
cholesterol transporter 
activity, heparin binding, 
hydroxyapatite binding, lipid 
transporter activity, 
lipoprotein particle binding, 
low-density lipoprotein 
particle receptor binding, 
metal chelating activity, 
phosphatidylcholine-sterol O-
acyltransferase activator 
activity, phospholipid binding, 
very-low-density lipoprotein 
particle receptor binding 
       
Zinc alpha-2-
glycoprotein  
(P25311) 
Unchanged Unchanged 3.2 Lipid degradation Secreted 
Antigen binding, peptide 
antigen binding, protein 
transmembrane transporter 
activity, ribonuclease activity 
       
DECREASED       
       
Gelsolin 
(P06396) 
0.4 0.3 0.3 
Cilium biogenesis or 
degradation 
Amyloid, Cytoplasm, 
Cytoskeleton, 
Secreted 
Calcium ion binding 
       
Kininogen  
(P01042) 
 
Unchanged 0.4 0.4 
Blood coagulation 
Hemostasis 
Inflammatory 
response 
Secreted 
Cysteine-type endopeptidase 
inhibitor activity, heparin 
binding, zinc ion binding 
       
* The protein level is considered increased if the ratio is ≥1.6 and it is considered decreased if the ratio <0.625
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We were able to validate by ELISA in a separate cohort of TBI patients all the 11 
serum protein biomarkers that were found to be increased/decreased by mass 
spectrometry. The mean concentrations of these biomarkers and the P values compared 
to normal controls and femoral fracture controls are shown in Table 6.4. Similar to mass 
spectrometry results, the ELISA showed that the serum level for “Serum Amyloid-A”, 
“C-reactive Protein”, “Leucine-Rich alpha-2 Glycoprotein-1”, “Lipopolysaccharide 
Binding Protein”, “Fibronectin”, “Vitronectin” and “Alpha-1 antichymotrypsin” were 
significantly increased (t-test, P value < 0.05) in all grades of TBI. As expected, the 
ELISA results also showed that the general inflammatory markers, “Serum Amyloid-A” 
and “C-reactive protein” levels, were significantly increased in femoral fracture controls 
(t-test, P value < 0.05), and thus, these markers are nonspecific for TBI. On the other 
hand, “Leucine-Rich alpha-2 Glycoprotein-1”, “Lipopolysaccharide Binding Protein”, 
“Fibronectin”, “Vitronectin” and “Alpha-1 antichymotrypsin”  were not increased in the 
femoral fracture controls (t-test, P value > 0.05), suggesting that these biomarkers are 
specific for TBI (Table 6.4).  
“Apolipoprotein E” and “Zinc Alpha-2 glycoprotein” were also confirmed to be 
only significantly increased in severe TBI compared to normal control samples (t-test, P 
value < 0.05). These 2 markers were not found to be increased in the femoral fracture 
controls (t-test, P value > 0.05) (Table 6.4). Furthermore, the ELISA results confirmed 
that serum level of “Gelsolin” was significantly decreased in all grades of TBI and 
“Kininogen” was significantly decreased only in moderate and severe TBI (t-test, P Value 
< 0.05). These markers were unchanged in the femoral fracture controls (t-test, P value > 
0.05), suggesting that these biomarkers were specific to TBI.  
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Table 6.4: Validation of Identified Biomarkers by ELISA 
Protein Normal Control Mild Moderate Severe Femoral Fracture Control 
 Mean Con. (mg/ml) Mean Con. (mg/ml) P value Mean Con. (mg/ml) P value Mean Con. (mg/ml) P value Mean Con. (mg/ml) P value 
“Serum Amyloid-A” 0.02 ± 0.0032 0.61 ± 0.0012 0.01 0.71 ± 0.0023 0.01 0.96 ± 0.0046 0.01 0.47 ± 0.0071 0.04 
“C-reactive Protein” 0.009 ± 0.0001 0.147 ± 0.0001 0.01 0.182 ± 0.0005 0.01 0.312 ± 0.0002 0.01 0.11 ± 0.0061 0.04 
“Leucine-Rich alpha-2 Glycoprotein-1” 0.05 ± 0.002 1.08 ± 0.001 0.01 1.17 ± 0.002 0.01 19.2 ± 0.007 0.01 0.05 ± 0.007 P > 0.05 
“Lipopolysaccharide Binding Protein” 0.0181 ± 0.0002 0.0962 ± 0.0001 0.04 0.1324 ± 0.0006 0.03 0.142 ± 0.0002 0.03 0.0211 ± 0.0011 P > 0.05 
“Fibronectin”  0.00216 ± 0.00003 0.00487 ± 0.00002 0.04 0.00571 ± 0.00002 0.04 0.01254 ± 0.00007 0.03 0.00201 ± 0.00022 P > 0.05 
“Vitronectin” 3.0 ± 0.2 4.6 ± 0.12 0.04 4.7 ± 0.18 0.04 4.7 ± 0.27 0.04 2.9 ± 0.4 P > 0.05 
“Alpha-1 antichymotrypsin” 0.48 ± 0.01 7.12 ± 0.02 0.01 7.68 ± 0.02 0.01 9.23 ± 0.06 0.01 0.52 ± 0.02 P > 0.05 
“Apolipoprotein E” 0.07 ± 0.003 0.075 ± 0.001 > 0.05 0.078 ± 0.003 > 0.05 0.22 ± 0.005 0.04 0.08 ± 0.007 P > 0.05 
“Zinc Alpha-2 glycoprotein” 0.6 ± 0.02 0.62 ± 0.009 > 0.05 0.64 ± 0.007 > 0.05 1.97 ± 0.002 0.04 0.6 ± 0.08 P > 0.05 
“Gelsolin” 200 ± 12.1 87 ± 4.2 0.03 54 ± 3.7 0.02 52 ± 2.2 0.02 218 ± 12.0 P > 0.05 
“Kininogen” 0.055 ± 0.0008 0.055 ± 0.0003 > 0.05 0.029 ± 0.0001 0.02 0.030 ± 0.0006 0.02 0.061 ± 0.0019 P > 0.05 
 
Abbreviation: Concentration (Con), milligram/milliliter (mg/mL); Footnote: (1) Independent t-test were used to compare the concentration of protein from each TBI groups and femoral fracture group with control group; (2) A 
P-value <0.05 was considered as significant increase or decrease of the protein. 
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6.5 Discussion 
 
Polytrauma patients are managed by a multidisciplinary trauma team led by the 
emergency department consultant based on the 'golden hour in shock' principle. Usually 
a rapid primary survey will be performed to immediately identify and manage life-
threatening injuries, followed by a detailed head-to-toe secondary survey in the 
resuscitation room. Often a tertiary trauma survey will be performed to identify injuries 
missed after the primary and secondary surveys (Enderson et al., 1990). Accurate 
interpretation of the clinical signs and mechanisms of injury is key to avoid missing 
potential life-threatening injuries.  
Despite these efforts, it is recognized that many injuries may still escape detection 
in the hospital (Enderson & Maull, 1991). Confused unconscious patients or patients 
under the influence of drugs and/or alcohol, often have difficulty giving an accurate 
clinical history, leading to missed diagnosis of TBI (Mahoney, Biffl, Harrington, & 
Cioffi, 2003). This situation is aggravated in mild TBI as symptoms are more subtle, and 
current technologies are unable to reliably detect neural damage in mild TBI (Borg et al., 
2004). The timely diagnosis of TBI is important for acute management, counseling of 
family members, and provision of rehabilitation services.  
The present study used the iTRAQ-based mass spectrometer technology to 
identify changes, if any, in the levels of serum protein markers that may be specific for 
TBI. These markers may be able to diagnose and grade mild, moderate or severe TBI. We 
found 7 biomarkers (“Serum Amyloid-A”, “C-reactive Protein”, “Leucine-Rich alpha-2 
Glycoprotein-1”, “Lipopolysaccharide Binding Protein”, “Fibronectin”, “Vitronectin” 
and “Alpha-1 antichymotrypsin”) to be increased in all grades of TBI (Table 6.3). In 
addition, except perhaps for “Vitronectin”, these proteins show a definite and gradual 
increase from mild, moderate to severe TBI groups. 
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 Two of these proteins (“Serum Amyloid-A” and “C-reactive Protein”) are 
markers for general injury and inflammation. Five biomarkers (“Leucine-Rich alpha-2 
Glycoprotein-1”, “Lipopolysaccharide Binding Protein”, “Fibronectin”, “Vitronectin” 
and “Alpha-1 antichymotrypsin”) appear to be specific for TBI. Except for “Alpha-1 
antichymotrypsin”, 4 of these appear to be novel biomarkers for TBI.  
“Apolipoprotein E” and “Zinc Alpha-2 glycoprotein” were found to be increased 
only in severe TBI, but had been previously reported to be increased in TBI. “Gelsolin”, 
was found to be decreased in all grades of TBI, whereas, “Kininogen” was decreased in 
moderate and severe TBI. Only “Kininogen” appears to be novel for TBI.  
Validation with ELISA with an entirely different cohort of patients (normal 
control, femoral fracture control, mild, moderate, severe TBI groups) further confirmed 
that the serum level for “Serum Amyloid-A”, “C-reactive Protein”, “Leucine-Rich alpha-
2 Glycoprotein-1”, “Lipopolysaccharide Binding Protein”, “Fibronectin”, “Vitronectin” 
and “Alpha-1 antichymotrypsin” were increased in all grades of TBI. As expected, 
“Serum Amyloid-A” and “C-reactive protein” were confirmed as general inflammatory 
markers, as these proteins were also increased in the femoral fracture controls. Similarly, 
“Apolipoprotein E” and “Zinc Alpha-2 glycoprotein” were confirmed by ELISA to be 
increased only in severe TBI, and serum level to be decreased for “Gelsolin” in all TBI 
grades and “Kininogen” in moderate/severe TBI.  
If further validated in larger cohort studies, some or all of these protein biomarkers 
may aid in the detection of TBI, including mild TBI, especially in patients with 
polytrauma. Based on our findings, it may be possible that a serum sample taken at 24 
hours of the trauma or even before 24 hours, could supplement the diagnosis of TBI using 
a panel of the 5 specific biomarkers that are increased and 1 specific biomarker that is 
decreased in all grades of TBI (Table 6.5). With the addition of “Kininogen”, 
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“Apolipoprotein E” and “Zinc Alpha-2 glycoprotein” it may be possible to grade TBI as 
mild, moderate and severe (Table 6.5).  
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Table 6.5: Panel of specific biomarkers for diagnosis and grading of TBI 
 
 
Specific TBI Biomarkers 
 
  
 “Leucine-Rich alpha-2 Glycoprotein-1” 
“Lipopolysaccharide Binding Protein” 
“Fibronectin” 
“Vitronectin” 
“Alpha-1 antichymotrypsin” 
“Gelsolin” “Kininogen” “Apolipoprotein E”  
“Zinc Alpha-2 glycoprotein” 
     
     
Mild TBI ↑ ↓ ↔ ↔ 
     
Moderate TBI ↑ ↓ ↓ ↔ 
     
Severe TBI ↑ ↓ ↓ ↑ 
     
 
Symbols: ↑ (increased level in the serum), ↓ (decreased level in serum) and ↔ (unchanged level in the serum) 
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“Serum Amyloid-A”, as a general injury/inflammatory protein marker, has been 
previously reported to show dramatic increases of up to a mean plasma level of 0.764 g/l 
after TBI (Saile et al., 1990).  However, in large groups of patients with a variety of 
disorders, rapid production and exceptionally wide dynamic range of the “Serum 
Amyloid-A” response has been observed thus making it a rather non-specific marker for 
TBI (Lowe, 2001; Malle & De Beer, 1996). “C-reactive protein” has been reported to be 
rapidly elevated after brain trauma and are robust indicators of injury at very acute time 
points (Hergenroeder et al., 2008; Lin, Howng, Hu, & Huang, 1992). However, “C-
reactive protein” is also elevated in infections or trauma unrelated to TBI (Hergenroeder 
et al., 2008). Moreover, “C-reactive protein” levels were increased corresponding to the 
degree of intra-operative surgical insult (Al-Jabi & El-Shawarby, 2010). Similar to these 
studies we found that, “Serum Amyloid-A” and “C-reactive protein” were gradually 
increased in all grades of TBI, as well as significantly increased in femoral fracture 
controls compared to normal controls. Hence, these proteins are not specific markers for 
TBI and are unsuitable to be used in the setting of polytrauma.  
“Leucine-Rich alpha-2 Glycoprotein-1” is a highly conserved member of the 
leucine-rich repeat family of proteins involved in protein-protein interaction, signaling 
and cell adhesion. It is distributed throughout the entire brain, with an especially high 
expression in the deep cerebral cortex. The expression was observed in resident 
astrocytes, as well as in the capillary onto which astrocytic processes grow and adhere 
(Nakajima et al., 2012). “Leucine-Rich alpha-2 Glycoprotein-1” was found to be a marker 
of interest for idiopathic normal pressure hydrocephalus as it levels in cerebrospinal fluid 
(together with tau protein and positive cerebrospinal fluid Tap Test) can reliably predict 
shunting outcome in idiopathic normal pressure hydrocephalus patients (Nakajima, Arai, 
& Miyajima, 2010; Nakajima et al., 2012; Nakajima et al., 2011). We found this 
apparently novel TBI biomarker to be significantly increased gradually in all grades of 
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TBI. The significance of raised “Leucine-Rich alpha-2 Glycoprotein-1” after TBI is 
uncertain and requires further research to elucidate its role in brain injury.  
“Lipopolysaccharide Binding Protein” is a glycosylated 60 kDa serum protein that 
is primarily produced in the liver (Ramadori, Meyer zum Buschenfelde, Tobias, 
Mathison, & Ulevitch, 1990). It has been recognized as a marker of overall inflammation 
in systemic inflammatory response syndrome, a subset of cytokine storm, in which there 
is abnormal regulation of various cytokines arising from an infectious or a noninfectious 
insult (Davies & Hagen, 1997). It has been shown that “Lipopolysaccharide Binding 
Protein” concentrations in non-TBI trauma patients on admission were significantly 
greater in non- survivors than in survivors. The same study also showed that among the 
survivors, older patients (age ≥65 years) had higher levels of “Lipopolysaccharide 
Binding Protein” than younger patients on admission (Cunningham et al., 2006). The 
authors further speculate that, the mean “Lipopolysaccharide Binding Protein” 
concentrations on admission and at 24 hour after admission were similar to the 
concentrations previously reported in septic patients (Sakr, Burgett, Nacul, Reinhart, & 
Brunkhorst, 2008). However, none of the trauma patients in their study had infection at 
the time of hospital admission. The finding that plasma “Lipopolysaccharide Binding 
Protein” concentrations are increased to the same degree as in patients with severe sepsis 
and septic shock is interesting, but the underlying differences in the mechanisms are not 
known. “Lipopolysaccharide Binding Protein” was increased gradually in all the grades 
of TBI in our study but its role in TBI is not known.  
“Fibronectin”, a high-molecular weight glycoprotein of the extracellular matrix, 
plays a major role in cell adhesion, growth, migration and differentiation. As it binds 
extracellular matrix components such as collagen, fibrin, and heparan sulfate 
proteoglycans, it is important for processes such as wound healing and embryonic 
development. Egan et al. (1991) detected “fibronectin” in neutropils and non-neuronal 
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cells adjacent to wounds in rat cerebral cortex (R. A. Egan & K Vijayan, 1991). Both 
expression of “fibronectin” and increased mRNA was found after TBI in the rat model 
(Chen et al., 2001). Plasma “fibronectin” deficient mouse showed increased neuronal 
apoptosis and larger areas of infarction following transient focal cerebral ischemia (Sakai 
et al., 2001). These mice also showed worse performances on motor and cognitive tasks 
and had significantly less phagocytic cells in the injured cortex compared to mice with 
normal plasma “fibronectin” levels. Tate et al. (2002) further showed that intravenous 
injections of “fibronectin” prior to the injury restored the neural deficits seen in the 
plasma “fibronectin” deficient mice demonstrating that plasma “fibronectin” may be 
neuroprotective (Tate et al., 2002). The increased “fibronectin” found in our study may 
inhibit neuronal apoptosis. However, further studies are required to better understand the 
mechanisms of neuroprotection, if any. 
“Vitronectin” is a 75 kDa glycoprotein that consists of 459 amino acid residues 
involved with cell adhesion and spread. It is found in serum and the extracellular matrix. 
In primary rat neuron cultures which were treated with lipoteichoic acid (used to 
induce/mimic secondary TBI inflammatory reaction), blocking microglial “vitronectin” 
receptors efficiently prevented neuronal death caused by microglial phagocytosis (Neher 
et al., 2011). Another study found that TNF-α induced microglial phagocytosis of neurons 
can be blocked by inhibiting microglial “vitronectin” receptors (Neniskyte, Vilalta, & 
Brown, 2014). This has raised the concern that “vitronectin” may have neurotoxic effect 
on neurons by increasing microglial activity. “Vitronectin” itself has been 
immunolocalized to senile plaques and neurofibrillary tangles in Alzheimer entorhinal 
cortex, and the senile plaques had microglial cores that were strongly positive for the 
“vitronectin” receptor. The high levels of “vitronectin” receptor on reactive microglia in 
areas containing extracellular “vitronectin” suggest the possibility that “vitronectin” is 
serving an opsonizing function for microglial phagocytosis (Akiyama, Kawamata, 
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Dedhar, & McGeer, 1991). It is possible that increased “Vitronectin” in TBI, may enhance 
phagocytic action against neurons that may have a deleterious effect on post-TBI 
recovery. Further studies are required to understand the mechanisms involving 
“Vitronectin” in TBI. 
“Alpha-1 antichymotrypsin” is an alpha globulin glycoprotein and a member of 
the serpin superfamily. It inhibits the activity of proteases, e.g. cathepsin G of neutrophils, 
and chymases of mast cells, by cleaving them into a different shape or conformation. 
“Alpha-1 antichymotrypsin” was found to be expressed by reactive astrocytes around 
cerebral wound margins between 18 hours to 13 days after neural lesions in mouse and 
are believed to assist in early wound repair (Abraham, 1992; Abraham, Kanemaru, & 
Mucke, 1993). “Alpha-1 antichymotrypsin” has also been identified as a major 
constituent of the neurofibrillary plaques associated with Alzheimer's disease, and in vitro 
studies have shown that it enhances the rate of amyloid-fibril formation (Padmanabhan, 
Levy, Dickson, & Potter, 2006). Furthermore, a study of biomarkers in severe TBI using 
similar iTRAQ-based mass spectrometry also found “Alpha-1 antichymotrypsin” to be 
increased. However, this study did not investigate the level of this biomarker in mild and 
moderate TBI (Hergenroeder et al., 2008). The significance of this biomarker in TBI 
requires further research to elucidate its role in TBI.  
“Apolipoprotein E” is a 299 amino acid protein with a relative molecular mass of 
34 KDa. It is the major apolipoprotein in human cerebrospinal fluid and is synthesized by 
astrocytes (Mahley, 1988; Mahley et al., 1984). It exist as small spherical, discoidal 
lipoproteins, often packed together with cholesterol and phospholipid to form lipid-
protein complexes. These complexes bind to “Apolipoprotein E” receptors on the surfaces 
of nerve cells and are internalised into the cell. In our study, serum “Apolipoprotein E” 
was found to be significantly increased only in severe TBI.  Interestingly, as long as two 
decades ago, “Apolipoprotein E” had been proposed as a marker of severe TBI, its levels 
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reaching three times the normal value 10 days after severe TBI (Kabbaj et al., 1989). It 
has been suggested that “Apolipoprotein E” may play a role in neuronal homeostasis 
(Laws et al., 2003), particularly, the mobilization of cholesterol in the CNS where it is 
required for neuronal plasticity (Moestrup et al., 1992; Rebeck et al., 1993). 
“Apolipoprotein E” is also postulated to be involved with neuronal repair by mediating 
the recycle of damaged cell membranes (Laws et al., 2003). 
“Zinc Alpha-2 glycoprotein” is a 40-kDa single-chain polypeptide (Burgi & 
Schmid, 1961) is involved preferentially in depletion of fatty acids from adipose tissues, 
thus subsequently named as a lipid-mobilizing factor (Bao et al., 2005). In the 
cerebrospinal fluid, an increased level of “Zinc Alpha-2 glycoprotein” had been 
previously proposed as a marker for Parkinson’s Disease (Yin, Lee, Cho, & Suk, 2009; 
Zhao, Xiao, Pu, & Zhong, 2010) but the underlying mechanism for the increase is 
unknown.  Similar to our findings, “Zinc Alpha-2 glycoprotein” was also found to be 
increased in severe TBI patients using the same iTRAQ- based mass spectrometry 
approach (Hergenroeder et al., 2008). The significance of its elevation in severe TBI but 
not in mild or moderate TBI needs further investigation. 
“Gelsolin” is an 82-kD actin-binding protein that regulates the assembly and 
disassembly of actin filaments. This biomarker was found to be reduced after TBI in the 
current study. Other studies also showed that plasma “gelsolin” level in TBI patients 
decreased after TBI compared to healthy controls (Jin, Li, Qiu, Ling, & Bai, 2012; Xu, 
Liu, Dong, Yang, & Fan, 2012). Xu et al., (2012) further reported that “gelsolin” level 
decreased during the 6-hour period immediately after TBI, was at the nadir in 24 hours, 
increased gradually thereafter, and was substantially lower than that in healthy controls 
during the 7-day period (Xu et al., 2012). Similar iTRAQ-based mass spectrometry also 
showed that “gelsolin” levels were decreased in severe TBI (Hergenroeder et al., 2008). 
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However, the role of “gelsolin” in TBI and why there is a decrease in its levels remains 
uncertain and requires further research. 
Kininogen is a 299 amino acid protein, which upon cleavage by human plasma 
kallikrein, or factor XIIa it releases and activates kinin (Colman & Muller-Esterl, 1988) 
in the CNS. Kinins are pro- inflammatory mediators involved in pain, edema, brain blood 
barrier disruption and are associated with neurodegenerative disorders (Guevara-Lora, 
2012). In our study, “kininogen” was found to be decreased only in moderate and severe 
TBI suggesting that it may be able to differentiate moderate/severe TBI from mild TBI. 
We speculate that its decrease in moderate and severe TBI may be a mechanism that could 
help to protect neurons. “Kininogen” has never been studied in human serum as a marker 
for TBI. However, in a study by Ellis et al., injury in the right cerebral cortex of rats 
showed the “kininogen” content in the right hemisphere was significantly elevated within 
one hour after injury and continued to rise until 15 hours after injury. The reason for the 
contrast between increased “Kininogen” level in cerebral cortex of rat and decreased 
“Kininogen” in human serum is uncertain and requires further research to elucidate the 
role of this protein in brain injury. 
Except for “Serum Amyloid-A” and “C-reactive Protein”, our study did not 
confirm the usefulness of other putative serum biomarkers that were previously shown to 
be raised in TBI, including Interleukin 6, Interleukin 8, Interleukin 10, Interleukin 12p70, 
Tumor Necrosis Factor α, Glial Fibrillary Acidic Protein, Creatine Kinase Brain 
Isoenzyme and Cleaved tau (Table 6.1). In fact, these proteins were not detected in our 
study samples so they were not studied further. Similar to the findings in our study, these 
serum biomarkers were also not detected in severe TBI using the iTRAQ-based mass 
spectrometry approach (Hergenroeder et al., 2008). We are not sure why these proteins 
were not detected by iTRAQ-based mass spectrometry. One possible reason may be that 
generally mass spectrometry is unable to identify all the proteins in very complex 
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samples, such as pooled sera (Bantscheff, Lemeer, Savitski, & Kuster, 2012; Schulze & 
Usadel, 2010). In mass spectrometry, the presence of 4 to 5 peptides are usually adequate 
to accurately identify a known protein. However, as the number of proteins contained 
within a sample increases, the required number of peptides sequences to positively 
identify a specific protein also increases. It is possible that these proteins could not be 
identified in our samples because of this. However, it cannot be over emphasized that all 
the proteins of interests detected by iTRAQ-based mass spectrometry were confirmed by 
ELISA. 
Using a targeted ELISA method, “Interleukin 6” (Chiaretti et al., 2008; Winter et 
al., 2004), “Interleukin 8” (Buttram et al., 2007), “Interleukin 10” (Bell et al., 1997; Csuka 
et al., 1999), “Interleukin 12p70” (Buttram et al., 2007), “Tumor Necrosis Factor α” 
(Crespo et al., 2007),  Glial Fibrillary Acidic Protein (Missler et al., 1999; Nylen et al., 
2006; Pelinka, Kroepfl, et al., 2004; Vos et al., 2004), Creatine Kinase Brain Isoenzyme 
(Carr, Masullo, Brown, & Lewis, 2009; Schwartz et al., 1989; Skogseid et al., 1992) and 
Cleaved tau (Guzel, Karasalihoglu, Aylanc, Temizoz, & Hicdonmez, 2010; Kavalci et al., 
2007; Liliang et al., 2010) had been reported in literature as possible TBI markers. 
Unfortunately, Interleukin 6, Interleukin 8, Interleukin 10, Interleukin 12p70 and Tumor 
Necrosis Factor α, being cytokines may also be increased in other systemic 
injuries/conditions such as infection, extracranial trauma or organ failures (Chiaretti et 
al., 2008; Chiaretti et al., 2005; Csuka et al., 1999; Hergenroeder et al., 2008; Winter et 
al., 2004). Among the 3 brain-speciﬁc proteins, viz., “Glial Fibrillary Acidic Protein”, 
“Creatine Kinase Brain Isoenzyme” and “Cleaved tau”, “Glial Fibrillary Acidic Protein” 
was suggested to be the most promising marker for TBI (Missler et al., 1999; Vos et al., 
2004). However, its increase in serum of patients with mild TBI is inconsistent, and might 
be below the detectable limit (Zemlan et al., 2002).  
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The serum protein markers identified in this study should be confirmed as specific 
and/or sensitive for the detection and grading of TBI by validating its usefulness in larger 
cohorts of TBI patients. Moreover, the alterations of protein levels need to be evaluated 
in other disease control groups such as infections, autoimmune diseases and cancers. As 
protein levels changes over time and also may be altered by treatment, studies on how 
these parameters impact on the protein levels may be important. Studies of autopsy brain 
tissues may also be needed further understand the role of these proteins in TBI.  
Neurotoxic or neuroprotective effects, if any, of these protein markers need to be 
established by developing cell/tissue culture or animal models. 
 
6.6 Conclusion 
 
Alterations in levels of serum proteins within 24 hours in patients with mild, moderate 
and severe TBI may be useful as an adjunct to detect and even grade TBI, especially in 
the polytrauma setting. These biomarkers allow a quantitative diagnostic, even for 
patients who cannot be evaluated by GCS due to intubation, ventilation and/or sedation. 
For this purpose, we propose a panel of serum proteins that includes “Leucine rich alpha-
2 glycoprotein-1”, “Lipopolysaccharide binding protein”, “Fibronectin”, “Vitronectin” 
and “Alpha-1 antichymotrypsin” and “gelsolin” to diagnose TBI. In addition to these 
biomarkers, “Kininogen”, “Apolipoprotein E” and “Zinc Alpha-2 glycoprotein” may 
further able to grade TBI into mild, moderate and severe. Especially in mild TBI, as the 
patients’ GCS scores are normal, and neuroimaging investigations such as the CT scan or 
brain MRI may not show evidence of injury.  
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CHAPTER 7 
CONCLUSION AND RECOMMENDATION 
 
We have found that possession of either the APOE ε4 allele or COMT AA 
genotype or CNTF A allele was independently associated with poor outcome at 6 months 
after TBI. Combined with the GCS these parameters were even better predictors for 
unfavorable outcome at 6 month compared with GCS alone.  All these 3 SNPs should be 
further investigated and confirmed as prognostic indicators in larger cohort studies. We 
did not find any association between SNPs in the APOE promoter region, DRD2 gene, 
DRD3 gene, BDNF gene and GDNF gene with outcome after TBI.  
It is important to note that the contribution of SNPs to outcome may be modest as 
outcome after TBI is a complex interaction of the type of brain injury, effects of injury to 
other areas, post-injury treatment and various psychosocial factors. Genome Wide 
Association Studies (GWAS) are particularly useful in identifying groups of genetic 
variants or regions of interest within a specific gene that can be further analyzed to better 
characterize pathophysiologic pathways. These studies are exploratory in nature and 
require screening of millions of SNPs for an association with an outcome of interest. A 
major limitation for GWAS is the large number (> 100,000 cases) of samples required to 
attain robust statistical significance. Hence, a multi-center study with much larger sample 
size is needed to confirm our results. In this study we only utilized GOS to measure the 
functional outcome after TBI but other parameters such as neurocognitive and 
neuropsychological outcomes may also be studied.  
Altogether we found 9 serum protein biomarkers viz., “Serum Amyloid-A”, “C- 
reactive Protein”, “Leucine-Rich alpha-2 Glycoprotein-1”, “Lipopolysaccharide Binding 
Protein”, “Fibronectin”, “Vitronectin” and “Alpha-1 antichymotrypsin”,  to be increased in 
mild, moderate and severe TBI, while a further 2 “Apolipoprotein E” and “Zinc Alpha-2 
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glycoprotein” were only increased in severe TBI. However, “Serum Amyloid-A” and “C- 
reactive Protein” are considered as general injury and inflammatory markers whereas the 
other 7 may be more specific.  Some of the specific protein markers that were increased in 
mild/moderate/severe TBI may aid in the detection of mild TBI, which is often missed in the 
initial diagnostic assessment. Decreased levels of “Gelsolin” in mild/moderate/severe TBI 
and “Kininogen” in moderate/severe TBI may be specific to TBI. Our findings suggest that a 
24 hour post-trauma serum protein profile of some or all of these biomarkers may be of the 
trauma useful as an adjunct to confirm and/or help grade TBI to complement the traditional 
use of the GCS score. 
Further investigations are needed to assess the specificity and sensitivity of the 
proposed markers in larger cohorts, in particular the proteins that appear to be novel to 
TBI (“Leucine- Rich alpha-2 Glycoprotein-1”, “Lipopolysaccharide Binding Protein”, 
“Fibronectin”, “Vitronectin” and “Kininogen”). Most importantly, changes in the serum 
levels of these markers over time need also to be established. Changes in response to 
treatment, if any, may help elucidate the role of these markers on outcome after TBI. 
Histopathological studies in autopsy brain tissue may be useful to map the distribution of 
these proteins in the CNS. Finally, neurotoxic or neuroprotective effect of these protein 
markers need to be established by developing cell culture model, tissue culture model or 
animal model. 
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II. APPENDICES 
 
APPENDIX A: REAGENTS PREPARATION FOR DNA EXTRACTION AND 
GEL ELECTROPHORESIS 
 
1. 20X Standard Saline Citrate buffer 
 Materials: 
175.3g of NaCl  
88.2g of sodium citrate  
 Method: 
The chemicals dissolved in 800 mL of ultrapure H2O. The pH was adjusted to 
7.0 with a few drops of 1M HCl. The final volume adjusted to 1L with 
additional ultrapure H2O. The reagent sterilized by autoclaving. 
  
2. 1X Standard Saline Citrate buffer 
 Materials: 
20X SSC Buffer 
 Method: 
Dissolve 25 mL of 20X Standard Saline Citrate buffer in 475 mL of ultrapure 
H2O to prepare 500 mL of 1X Standard Saline Citrate buffer. The reagent 
sterilized by autoclaving. 
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3. Proteinase K 
 Materials: 
20 mg of Proteinase K 
 Method: 
Dissolve 20 mg of Proteinase K in 1 mL of ultrapure H2O. Do not autoclave 
as this will denature the enzyme. Aliquots were stored at -20ºC. 
  
4. 10% Sodium Dodecyl Sulphate Buffer 
 Materials: 
10 g Sodium Dodecyl Sulphate 
 Method: 
Dissolve 10 g Sodium Dodecyl Sulphate in 100 mL ultrapure H2O. Do not 
autoclave.   
  
5. 2M Nacl 
 Materials:  
117 g NaCl 
 Method: 
Dissolve 117 g of NaCl in 1 L of ultrapure H2O. The reagent sterilized by 
autoclaving. 
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6. 10:1 Tris-EDTA buffer 
 Materials: 
10 mL 1 M Tris-HCl, pH 7.6 
2 ml 0.5 M EDTA 
 Method: 
Dissolve the solution in ultrapure H2O to 1L. The reagent sterilized by 
autoclaving. 
  
7. 1 M Tris- HCl 
 Materials: 
121.1 g Tris base 
 Method:  
121.1 g of Tris base dissolved in 800 ml of ultrapure H2O. The pH adjusted 
to 7.6 with concentrated HCl and ultrapure H2O added to 1 L. The reagent 
sterilized by autoclaving. 
  
8. 0.5 M EDTA 
 Materials: 
186.1 g Na2EDTA  
ddH2O to 500 millilitre (ml)  
Total volume 1000 millilitre (ml)  
Note:  
 Method:  
Na2EDTA dissolved in 400 mL ultrapure H2O and pH adjusted to 8.0 with 10 
N NaOH. Final volume adjusted to 1 L with ultrapure H2O. The reagent 
sterilized by autoclaving. 
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9. 50X Tris-acetate-EDTA buffer (TAE) 
 Materials: 
240 g Tris base 
57.1 mL Glacial acetic acid  
100 mL 0.5 M EDTA  
 Method: 
The materials were dissolved to 1L of ultrapure H2O. The reagent sterilized 
by autoclaving. 
  
10. 1.5% Agarose Gel 
 Materials: 
0.45 g Agarose Powder 
30 ml of TAE buffer 
1 µl of Ethidium Bromide Solution 
 Method: 
0.45g of Agarose powder dissolved in 3o mL of TAE buffer by heating for 1 
min in microwove oven. The solution let to cooldown and 1 ul of Ethidium 
Bromide solution were added. The mixture poured on gel casting tray with 
gel comb. 
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APPENDIX B: COMPLETE PROTOCOL FOR DNA EXTRACTION FROM 
FROZEN BLOOD SAMPLES 
1. Blood samples typically were obtained as 1 mL of whole blood stored in EDTA 
vacutainer tubes frozen at -80˚C. 
2. Frozen samples were thawed, and to each 1 mL sample, 0.8 mL 1X SSC buffer 
added, and mixed. The mixture centrifuged for 20 minute at 13,000 rpm in a 
microcentrifuge. 
3. 1 mL of the supernatant removed and discarded into disinfectant. 
4. 1 mL of 1X SSC buffer added, vortexed, centrifuged as above and all of the 
supernatant removed. The washing step repeated until the pellet appears white. 
5. 375 µl of 0.2M NaCL were added to each pellet and vortexed briefly. Then add 
25 µl of 10% SDS and 5 µl of proteinase K (20mg/ml H2O) were added, vortexed 
briefly and incubated for 1 hour at 55˚C. 
6. 200 µl phenol/chloroform/isoamyl alcohol were added and mixed gently for 30 
seconds. The sample centrifuged for 10 minutes at 13,000 rpm in a 
microcentrifuge tube. 
7. The aqueous layer were carefully removed to a new 1.5 mL microcentrifuge tube. 
8. 1 mL of cold 100% ethanol added, mixed, and incubated for 15 minutes at -20˚C. 
9. The mixture centrifuged for 2 minutes at 12,000 rpm in a microcentrifuge. The 
supernatant decanted and drained. 
10. 180 ul 10:1 TE buffer were added, vortexed, and incubated at 55˚C for 10 minutes. 
11. 20 µl 2M NaCl added and mixed.  
12. 500 µl of cold 100% ethanol were added, mixed, and centrifuged for 1 minute at 
12,000 rpm in a microcentrifuge. 
13. The supernatant decanted and the pellet rinsed with 1 mL of 80% ethanol. Mixture 
centrifuged for 1 minute at 12,000 rpm in a microcentrifuge. 
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14. The supernatant decanted and the pellet dried in a clean drying oven overnite at 
37˚C (or until dry). 
15. The pellet resuspended by adding 200 µl of 10:1 TE buffer.  
16. The mixture incubated overnight at 55˚C, vortexing periodically to dissolve the 
genomic DNA.  
17. The samples store at -20˚C. 
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APPENDIX C: REGION OF APOE GENE AND PRIMERS 
 
APOE  
Sense Primer 5’-CTG GAG GAA CAA CTG ACC 
CCG GTG- 3’ 
Anti- Sense Primer 5’-CAG GCG CTC GCG GAT GGC 
GCT GAG-3’ 
 
Region of APOE gene covered 
5’-ctggaggaacaactgaccccggtggcggaggagacgcgggcacggctgtccaaggagctgcaggcggcgca 
ggcccggctgggcgcggacatggaggacgtgt/cgc112ggccgcctggtgcagtaccgcggcgaggtgcaggccat
gctcggccagagcaccgaggagctgcgggtgcgcctcgcctcccacctgcgcaagctgcgtaagcggctcctccgc 
gatgccgatgacctgcagaagc/tgc158ctggcagtgtaccaggccggggcccgcgagggcgccgagcgcggcctca
gcgccatccgcgagcgcctg - 3’ 
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APPENDIX D: REGION OF APOE PROMOTER AND PRIMERS 
 
APOE promoter  
Sense Primer 5’-GGG GCT CCC CTG TGC TCA AG- 3’ 
Anti- Sense Primer 5’- TGT TCT CCC CCT GCC CCA GG- 3’ 
 
Region of APOE promoter covered 
5’-
ggggctcccctgtgctcaaggtcacaaccaaagaggaagctgtgattaaaacccaggtcccatttgcaaagcctcgactttt
agcaggtgcatcatactgttcccacccctcccatcccacttctgtccagccgcctagccccactttcttttttttctttttttgagac
agtctccctcttgctgaggctggagtgcagtggcgagatctcggctcactgtaacctccgcctcccgggttcaagcgattct
cctgcctcagcctcccaagtagctaggattacaggcgcccgccaccacgcctggctaacttttgtatttttagtagagatggg
gtttcaccatgttggccaggctggtctcaaa/t
-491
ctcctgaccttaagtgattcgcccactgtggcctcccaaagtgctg 
ggattacaggcgtgagct/c
-427
accgcccccagcccctcccatcccacttctgtccagccccctagccctactttctttct 
gggatccaggagtccagatccccagccccctctccagattacattcatccaggcacaggaaaggacagggtcaggaaag
gaggactctgggcggcagcctccacattccccttccacgcttggcccccagaatggaggagggtgtctgt/g
-219
attact 
gggcgaggtgtcctcccttcctggggactgtggggggtggtcaaaagacctctatgccccacctccttcctccctctg 
ccctgctgtgcctggggcagggggagaaca- 3’ 
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APPENDIX E: LIST OF PROBES 
 
SNP ASSAY PROBES (VIC/FAM) 
rs4680 C__25746809_50 CCAGCGGATGGTGGATTTCGCTGGC[A/G]TGAAGGACAAGGTGTGCATGCCTGA 
rs1800497 C__7486676_10 CACAGCCATCCTCAAAGTGCTGGTC[T/C]AGGCAGGCGCCCAGCTGGACGTCCA 
rs6280 C__949770_10 GCCCCACAGGTGTAGTTCAGGTGGC[T/C]ACTCAGCTGGCTCAGAGATGCCATA 
rs6265 C__11592758_10 TCCTCATCCAACAGCTCTTCTATCA[G/A]GTGTTCGAAAGTGTCAGCCAATGAT 
rs36119840 C__648651_20 TCTGGGTTGGCAGCTGCAGCCTGCC[G/A]ATTCCGCTCTCTTCTAGGAAGCACT 
rs1800169 C__7511603_10 AGATGTGGTGTTTTCCTGTATCCTC[G/A]GCCAGGTGAAGCATCAGGGCCTGAA 
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APPENDIX F: EVALUATION FORM FOR DISABILITY RATING SCALE 
 
DISABILITY RATING SCALE 
Patient Name:  
Date of Rating:  
Name of Person Completing Form:  
 
 
A EYE OPENING 
 (0) Spontaneous 0-SPONTANEOUS: eyes open with sleep/wake 
rhythms indicating active arousal mechanisms, does 
not assume awareness. 
1-TO SPEECH AND/OR SENSORY STIMULATION: 
a response to any verbal approach, whether spoken 
or shouted, not necessarily the command to open the 
eyes. Also, response to touch, mild pressure. 
2-TO PAIN: tested by a painful stimulus. 
3-NONE: no eye opening even to painful stimulation. 
 (1) To Speech 
 (2) To Pain 
 (3) None 
   
B. COMMUNICATION ABILITY 
 (0) Oriented 0-ORIENTED: implies awareness of self and the 
environment. Patient able to tell you a) who he is; b) 
where he is; c) why he is there; d) year; e) season; f) 
month; g) day; h) time of day. 
1-CONFUSED: attention can be held and patient 
responds to questions but responses are delayed 
and/or indicate varying degrees of disorientation and 
confusion. 
2-INAPPROPRIATE: intelligible articulation but 
speech is used only in an exclamatory or random way 
(such as shouting and swearing); no sustained 
communication exchange is possible. 
3-INCOMPREHENSIBLE: moaning, groaning or 
sounds without recognizable words, no consistent 
communication signs. 
4-NONE: no sounds or communications signs from 
patient. 
 (1) Confused 
 (2) Inappropriate 
 (3) Incomprehensible 
 (4) None 
   
C. MOTOR RESPONSE 
 (0) Obeying 0-OBEYING: obeying command to move finger on 
best side. If no response or not suitable try another 
command such as “move lips,” “blink eyes,” etc.  Do 
not include grasp or other reflex responses.  
1-LOCALIZING: a painful stimulus at more than one 
site causes limb to move (even slightly) in an attempt 
to remove it.  It is a deliberate motor act to move away 
from or remove the source of noxious stimulation.  If 
there is doubt as to whether withdrawal or localization 
has occurred after 3 or 4 painful stimulations, rate as 
localization.  
2-WITHDRAWING: any generalized movement away 
from a noxious stimulus that is more than a simple 
reflex response  
3-FLEXING: painful stimulation results in either 
flexion at the elbow, rapid withdrawal with abduction 
of the shoulder or a slow withdrawal with adduction of 
the shoulder.  If there is confusion between flexing 
and withdrawing, then use pinprick on hands.  
4-EXTENDING: painful stimulation results in 
extension of the limb.  
5-NONE: no response can be elicited.  Usually 
associated with hypotonia. Exclude spinal transection 
as an explanation of lack of response; be satisfied 
that an adequate stimulus has been applied. 
 (1) Localizing 
 (2) Withdrawing 
 (3) Flexing 
 (4) Extending 
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D. FEEDING (COGNITIVE ABILITY ONLY) 
 (0.0) Complete Does the patient show awareness of how and when 
to perform this activity?  Ignore motor disabilities that 
interfere with carrying out this function.  (This is 
rated under Level of Functioning described below.)   
0-COMPLETE: continuously shows awareness that 
he knows how to feed and can convey unambiguous 
information that he knows when this activity should 
occur.  
1-PARTIAL: intermittently shows awareness that he 
knows how to feed and/or can intermittently convey 
reasonably clearly information that he knows when 
the activity should occur.  
2-MINIMAL: shows questionable or infrequent 
awareness that he knows in a primitive way how to 
feed and/or shows infrequently by certain signs, 
sounds, or activities that he is vaguely aware when 
the activity should occur.  
3-NONE: shows virtually no awareness at any time 
that he knows how to feed and cannot convey 
information by signs, sounds, or activity that he 
knows when the activity should occur. 
 (1.0) Partial 
 (2.0) Minimal 
 (3.0) None 
   
   
E. TOILETING (COGNITIVE ABILITY ONLY) 
 (0.0) Complete Does the patient show awareness of how and when 
to perform this activity?  Ignore motor disabilities that 
interfere with carrying out this function.  (This is 
rated under Level of Functioning described below.)  
Rate best response for toileting based on bowel and 
bladder behavior  
0-COMPLETE: continuously shows awareness that 
he knows how to toilet and can convey unambiguous 
information that he knows when this activity should 
occur.  
1-PARTIAL: intermittently shows awareness that he 
knows how to toilet and/or can intermittently convey 
reasonably clearly information that he knows when 
the activity should occur.  
2-MINIMAL: shows questionable or infrequent 
awareness that he knows in a primitive way how to 
toilet and/or shows infrequently by certain signs, 
sounds, or activities that he is vaguely aware when 
the activity should occur.  
3-NONE: shows virtually no awareness at any time 
that he knows how to toilet and cannot convey 
information by signs, sounds, or activity that he 
knows when the activity should occur. 
 (1.0) Partial 
 (2.0) Minimal 
 (3.0) None 
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F. GROOMING (COGNITIVE ABILITY ONLY) 
 (0.0) Complete Does the patient show awareness of how and when 
to perform this activity?  Ignore motor disabilities that 
interfere with carrying out this function.  (This is 
rated under Level of Functioning described below.)  
Grooming refers to bathing, washing, brushing of 
teeth, shaving, combing or brushing of hair and 
dressing.  
0-COMPLETE: continuously shows awareness that 
he knows how to groom self and can convey 
unambiguous information that he knows when this 
activity should occur.  
1-PARTIAL: intermittently shows awareness that he 
knows how to groom self and/or can intermittently 
convey reasonably clearly information that he knows 
when the activity should occur.  
2-MINIMAL: shows questionable or infrequent 
awareness that he knows in a primitive way how to 
groom self and/or shows infrequently by certain 
signs, sounds, or activities that he is vaguely aware 
when the activity should occur.  
3-NONE: shows virtually no awareness at any time 
that he knows how to groom self and cannot convey 
information by signs, sounds, or activity that he 
knows when the activity should occur. 
 (1.0) Partial 
 (2.0) Minimal 
 (3.0) None 
   
G.  LEVEL OF FUNCTIONING (PHYSICAL, MENTAL, EMOTIONAL OR SOCIAL FUNCTION) 
 (0.0) Completely Independent 0-COMPLETELY INDEPENDENT: able to live as he 
wishes, requiring no restriction due to physical, 
mental, emotional or social problems.  
1-INDEPENDENT IN SPECIAL ENVIRONMENT: 
capable of functioning independently when needed 
requirements are met (mechanical aids)  
2-MILDLY DEPENDENT: able to care for most of 
own needs but requires limited assistance due to 
physical, cognitive and/or emotional problems (e.g., 
needs non-resident helper).  
3-MODERATELY DEPENDENT: able to care for 
self partially but needs another person at all times. 
(person in home)  
4-MARKEDLY DEPENDENT: needs help with all 
major activities and the assistance of another person 
at all times.  
5-TOTALLY DEPENDENT: not able to assist in own 
care and requires 24-hour nursing care 
 (1.0) Independent in special environment 
 (2.0) Mildly Dependent-Limited   
        assistance (non-resid - helper) 
 (3.0) Moderately Dependent-moderate  
         assist (person in home) 
 (4.0) markedly Dependent-assist all  
        major activities, all times 
 (5.0) Totally Dependent-24 hour nursing  
         care 
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H. EMPLOYABILITY (AS A FULL TIME WORKER, HOMEMAKER OR STUDENT) 
 (0.0) Not Restricted 0-NOT RESTRICTED: can compete in the open 
market for a relatively wide range of jobs 
commensurate with existing skills; or can initiate, 
plan execute and assume responsibilities associated 
with homemaking; or can understand and carry out 
most age relevant school assignments.  
1-SELECTED JOBS, COMPETITIVE: can compete 
in a limited job market for a relatively narrow range 
of jobs because of limitations of the type described 
above and/or because of some physical limitations; 
or can initiate, plan, execute and assume many but 
not all responsibilities associated with homemaking; 
or can understand and carry out many but not all 
school assignments.  
2-SHELTERED WORKSHOP, NON-
COMPETITIVE: cannot compete successfully in a 
job market because of limitations described above 
and/or because of moderate or severe physical 
limitations; or cannot without major assistance 
initiate, plan, execute and assume responsibilities for 
homemaking; or cannot understand and carry out 
even relatively simple school assignments without 
assistance.  
3-NOT EMPLOYABLE: completely unemployable 
because of extreme psychosocial limitations of the 
type described above, or completely unable to 
initiate, plan, execute and assume any 
responsibilities associated with homemaking; or 
cannot understand or carry out any school 
assignments. 
 (1.0) Selected jobs, competitive 
 (2.0) Sheltered workshop, Non-  
         competitive 
 (3.0) Not Employable 
 
Notes: 
The psychosocial adaptability or “employability” item takes into account overall cognitive and physical ability to be an 
employee, homemaker or student. 
This determination should take into account considerations such as the following: 
1. Able to understand, remember and follow instructions. 
2. Can plan and carry out tasks at least at the level of an office clerk or in simple routine, repetitive industrial 
situation or can do school assignments. 
3. Ability to remain oriented, relevant and appropriate in work and other psychosocial situations. 
4. Ability to get to and from work or shopping centers using private or public transportation effectively. 
5. Ability to deal with number concepts. 
6. Ability to make purchases and handle simple money exchange problems. 
7. Ability to keep track of time and appointments. 
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APPENDIX G: iTRAQ REAGENT LABELLING PROTOCOL 
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APPENDIX H: LIST OF 83 PROTEINS IDENTIFIED BY iTRAQ 
 
 
Accession Name Molecular Function Subcellular location 
 
     
1 sp|P0C0L5|CO4B_HUMAN Complement C4-B Carbohydrate binding, endopeptidase inhibitor activity, complement 
binding 
Secreted 
2 sp|P04114|APOB_HUMAN Apolipoprotein B-100 Cholesterol transporter activity, lipase binding, low-density lipoprotein 
particle receptor binding, phospholipid binding, heparin binding 
Cytoplasm, secreted 
3 sp|P01023|A2MG_HUMAN Alpha-2-macroglobulin Calcium- dependent protein binding, growth factor binding, interleukin-8 
binding, receptor binding, serine-type endopeptidase inhibitor activity, 
tumor necrosis factor binding, enzyme binding, interleukin-1 binding, 
protease binding 
Secreted 
4 sp|P00751|CFAB_HUMAN Complement factor B Complement binding Secreted 
5 sp|P02452|CO1A1_HUMAN Collagen alpha-1(I) chain Extracellular matrix structural constituent, identical protein binding, 
platelet-derived growth factor binding, metal ion binding 
Secreted › extracellular 
space › extracellular 
matrix 
6 sp|Q14624|ITIH4_HUMAN Inter-alpha-trypsin inhibitor heavy chain H4 Endopeptidase inhibitor activity, serine-type endopeptidase inhibitor 
activity  
Secreted 
7 sp|P00450|CERU_HUMAN Ceruloplasmin  Chaperone binding, ferroxidase activity, copper ion binding Secreted 
8 sp|P02751|FINC_HUMAN Fibronectin Collagen binding, integrin binding, protease binding, heparin binding, 
peptidase activator activity 
Secreted › extracellular 
space › extracellular 
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9 sp|P06727|APOA4_HUMAN Apolipoprotein A-IV Antioxidant activity, copper ion binding, lipid transporter activity, 
phosphatidylcholine-sterol-O-acyltransferase activator activity, protein 
homodimerization activity, cholesterol transporter activity, lipid binding, 
phosphatidylcholine binding 
Secreted 
10 sp|P19823|ITIH2_HUMAN Inter-alpha-trypsin inhibitor heavy chain H2 Endopeptidase inhibitor activity, serine-type endopeptidase inhibitor 
activity 
Secreted 
11 sp|P02790|HEMO_HUMAN Hemopexin Heme transporter activity, metal ion binding Secreted 
12 sp|P08603|CFAH_HUMAN Complement factor H Heparan sulfate proteoglycan binding, heparin binding Secreted 
13 sp|P02750|A2GL_HUMAN Leucine-rich alpha-2-glycoprotein Brown fat cell differentiation, positive regulation of endothelial cell 
proliferation, positive regulation of transforming growth factor beta 
receptor signaling pathway, positive regulation of angiogenesis 
Secreted 
14 sp|P01011|AACT_HUMAN Alpha-1-antichymotrypsin DNA binding, serine-type endopeptidase inhibitor activity Secreted 
15 sp|P04217|A1BG_HUMAN Alpha-1B-glycoprotein Unknown Secreted 
16 sp|P19827|ITIH1_HUMAN Inter-alpha-trypsin inhibitor heavy chain H1 Calcium ion binding, serine-type endopeptidase inhibitor activity Secreted 
17 sp|P01042|KNG1_HUMAN Kininogen-1 Cysteine-type endopeptidase inhibitor activity, heparin Binding, zinc ion 
binding, receptor binding 
Secreted › extracellular 
space 
18 sp|P01008|ANT3_HUMAN Antithrombin-III Heparin binding, serine-type endopeptidase inhibitor activity, protease 
binding 
Secreted › extracellular 
space 
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19 sp|P02647|APOA1_HUMAN Apolipoprotein A-I Apolipoprotein A-I receptor binding, apolipoprotein receptor binding, beta-
amyloid binding, chemorepellent activity, cholesterol binding, cholesterol 
transporter activity, enzyme binding, high-density lipoprotein particle 
binding, high-density lipoprotein particle receptor binding, identical protein 
binding, lipase inhibitor activity, phosphatidylcholine-sterol O-
acyltransferase activator activity, phospholipid binding, phospholipid 
transporter activity 
Secreted 
20 sp|P02765|FETUA_HUMAN Alpha-2-HS-glycoprotein Cysteine-type endopeptidase inhibitor activity, kinase inhibitor activity Secreted 
21 sp|P06396|GELS_HUMAN Gelsolin Calcium ion binding Secreted, Cytoskeleton 
22 sp|P25311|ZA2G_HUMAN Zinc-alpha-2-glycoprotein Glycoprotein binding, protein transmembrane transporter activity, 
ribonuclease activity, peptide antigen binding 
Secreted 
23 sp|P08123|CO1A2_HUMAN Collagen alpha-2(I) chain Extracellular matrix structural constituent, identical protein binding, 
platelet-derived growth factor binding, metal ion binding, protein binding, 
bridging 
Secreted › extracellular 
space › extracellular 
matrix 
24 sp|P04196|HRG_HUMAN Histidine-rich glycoprotein Cysteine-type endopeptidase inhibitor activity, heme binding, heparan 
sulfate proteoglycan binding, heparin binding, metal ion binding, serine-
type endopeptidase inhibitor activity, zinc ion binding, immunoglobulin 
binding, receptor binding 
Secreted 
25 sp|P05155|IC1_HUMAN Plasma protease C1 inhibitor Serine-type endopeptidase inhibitor activity Secreted 
26 sp|P00734|THRB_HUMAN Prothrombin Calcium ion binding, receptor binding, thrombospondin receptor activity, 
growth factor activity, serine-type endopeptidase activity 
Secreted › extracellular 
space 
27 sp|P10909|CLUS_HUMAN Clusterin Misfolded protein binding, ubiquitin protein ligase binding Secreted, cytoplasmic or 
nuclear component 
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28 sp|P02749|APOH_HUMAN Beta-2-glycoprotein 1 Glycoprotein binding, identical protein binding, lipoprotein lipase activator 
activity, heparin binding, lipid binding, phospholipid binding 
Secreted 
29 sp|P04004|VTNC_HUMAN Vitronectin Extracellular matrix binding, integrin binding, scavenger receptor activity, 
heparin binding, polysaccharide binding 
Secreted › extracellular 
space 
30 sp|P36955|PEDF_HUMAN Pigment epithelium-derived factor Serine-type endopeptidase inhibitor activity Secreted, melanosome 
31 sp|P00747|PLMN_HUMAN Plasminogen Apolipoprotein binding, serine-type endopeptidase activity, protein domain 
specific binding, serine-type peptidase activity 
Secreted 
32 sp|P02774|VTDB_HUMAN Vitamin D-binding protein Actin binding, vitamin D binding, calcidiol binding, vitamin transporter 
activity 
Secreted 
33 sp|P51884|LUM_HUMAN Lumican Collagen binding, extracellular matrix structural constituent Secreted › extracellular 
space › extracellular 
matrix 
34 sp|P43652|AFAM_HUMAN Afamin Vitamin E binding Secreted 
35 sp|P02748|CO9_HUMAN Complement component C9 Complement activation, alternative pathway Secreted. Cell 
membrane; Multi-pass 
membrane protein 
36 sp|P02649|APOE_HUMAN Apolipoprotein E Antioxidant activity, cholesterol transporter activity, heparin binding, 
hydroxyapatite binding, lipid transporter activity, lipoprotein particle 
binding, low-density lipoprotein particle receptor binding, metal chelating 
activity, phosphatidylcholine-sterol O-acyltransferase activator activity, 
phospholipid binding, very-low-density lipoprotein particle receptor 
binding 
Secreted 
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37 sp|P09871|C1S_HUMAN Complement C1s subcomponent Calcium ion binding, serine-type endopeptidase activity, identical protein 
binding 
Unknown 
38 sp|P08697|A2AP_HUMAN Alpha-2-antiplasmin Endopeptidase inhibitor activity, protein homodimerization activity, serine-
type endopeptidase inhibitor activity, protease binding 
Secreted 
39 sp|P01871|IGHM_HUMAN Ig mu chain C region  Antigen binding Secreted, cell membrane 
40 sp|Q96PD5|PGRP2_HUMAN N-acetylmuramoyl-L-alanine amidase N-acetylmuramoyl-L-alanine amidase activity, peptidoglycan binding, zinc 
ion binding, peptidoglycan receptor activity 
Secreted, membrane 
41 sp|P06681|CO2_HUMAN Complement C2 Metal ion binding, serine-type endopeptidase activity  
42 sp|P35858|ALS_HUMAN Insulin-like growth factor- 
binding protein complex acid labile subunit 
Insulin-like growth factor binding Secreted › extracellular 
space 
43 sp|P02652|APOA2_HUMAN Apolipoprotein A-II Apolipoprotein receptor binding, cholesterol transporter activity, high-
density lipoprotein particle binding, high-density lipoprotein particle 
receptor binding, lipase inhibitor activity, lipid transporter activity, 
phosphatidylcholine-sterol O-acyltransferase activator activity, 
phospholipid binding, protein homodimerization activity, cholesterol 
binding, lipid binding, phosphatidylcholine binding, protein 
heterodimerization activity 
Secreted 
44 sp|P13671|CO6_HUMAN Complement component C6 Complement activation, classical pathway Secreted 
45 sp|P01031|CO5_HUMAN Complement C5 Chemokine activity, receptor binding, endopeptidase inhibitor activity Secreted 
46 sp|P01019|ANGT_HUMAN Angiotensinogen Growth factor activity, serine-type endopeptidase inhibitor activity, 
superoxide-generating NADPH oxidase activator activity, type 1 
angiotensin receptor binding, hormone activity, type 2 angiotensin receptor 
binding 
Secreted 
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47 sp|P02741|CRP_HUMAN C-reactive protein Calcium ion binding, choline binding, complement component C1q 
binding, low-density lipoprotein particle binding, cholesterol binding 
Secreted 
48 sp|P05156|CFAI_HUMAN Complement factor I Metal ion binding, serine-type endopeptidase activity, scavenger receptor 
activity 
Secreted › extracellular 
space 
49 sp|P00738|HPT_HUMAN Haptoglobin Antioxidant activity, serine-type endopeptidase activity, hemoglobin 
binding 
Secreted 
50 sp|P02753|RET4_HUMAN Retinol-binding protein 4 Retinal binding, retinol transporter activity, retinol binding Secreted 
51 sp|P0DJI8|SAA1_HUMAN Serum amyloid A-1 protein G-protein coupled receptor binding, heparin binding Secreted 
52 sp|P02768|ALBU_HUMAN Serum albumin Antioxidant activity, copper ion binding, drug binding, pyridoxal phosphate 
binding, zinc ion binding, chaperone binding, DNA binding, fatty acid 
binding, toxic substance binding 
Secreted 
53 sp|P02760|AMBP_HUMAN Protein AMBP Calcium channel inhibitor activity, heme binding, protein 
homodimerization activity, serine-type endopeptidase inhibitor activity, 
small molecule binding, calcium oxalate binding, IgA binding 
Secreted 
54 sp|P00748|FA12_HUMAN Coagulation factor XII Misfolded protein binding, serine-type endopeptidase activity, serine-type 
aminopeptidase activity 
Secreted 
55 sp|P05546|HEP2_HUMAN Heparin cofactor 2 Endopeptidase inhibitor activity, serine-type endopeptidase inhibitor 
activity, heparin binding 
Secreted › extracellular 
space 
56 sp|P07477|TRY1_HUMAN Trypsin-1 Metal ion binding, serine-type endopeptidase activity Secreted › extracellular 
space 
57 sp|P02775|CXCL7_HUMAN Platelet basic protein Glucose transmembrane transporter activity Secreted 
58 sp|P05452|TETN_HUMAN Tetranectin Calcium ion binding, heparin binding, carbohydrate binding, kringle 
domain binding 
Secreted 
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59 sp|P02747|C1QC_HUMAN Complement C1q subcomponent subunit C Complement activation, classical pathway Secreted 
60 sp|P18428|LBP_HUMAN Lipopolysaccharide-binding protein Lipopolysaccharide binding, receptor binding, lipoteichoic acid binding Secreted 
61 sp|P00736|C1R_HUMAN Complement C1r subcomponent Calcium ion binding, serine-type peptidase activity, serine-type 
endopeptidase activity 
Unknown 
62 sp|P01024|CO3_HUMAN Complement C3 C5L2 anaphylatoxin chemotactic receptor binding, endopeptidase inhibitor 
activity, receptor binding 
Secreted 
63 sp|P02745|C1QA_HUMAN Complement C1q subcomponent subunit A Cell-cell signaling, complement activation, classical pathway Secreted 
64 sp|P68871|HBB_HUMAN Hemoglobin subunit beta Heme binding, iron ion binding, oxygen transporter activity, hemoglobin 
binding, oxygen binding 
Cytosol 
65 sp|Q06033|ITIH3_HUMAN Inter-alpha-trypsin inhibitor heavy chain H3 Endopeptidase inhibitor activity, serine-type endopeptidase inhibitor 
activity 
Secreted 
66 sp|P29622|KAIN_HUMAN Kallistatin Serine-type endopeptidase inhibitor activity Secreted 
67 sp|P02743|SAMP_HUMAN Serum amyloid P-component Calcium ion binding, complement component C1q binding, unfolded 
protein binding, carbohydrate binding, virion binding 
Secreted 
68 sp|P07225|PROS_HUMAN Vitamin K-dependent protein S Calcium ion binding, endopeptidase inhibitor activity Secreted 
69 sp|P02671|FIBA_HUMAN Fibrinogen alpha chain Structural molecule activity Secreted 
70 sp|P03952|KLKB1_HUMAN Plasma kallikrein Serine-type endopeptidase activity Secreted 
71 sp|P69905|HBA_HUMAN Hemoglobin subunit alpha Heme binding, oxygen binding, iron ion binding, oxygen transporter 
activity 
Cytosol 
72 sp|O75636|FCN3_HUMAN Ficolin-3 Carbohydrate binding Secreted 
73 sp|P07357|CO8A_HUMAN Complement component C8 alpha chain Complement activation, alternative pathway Secreted, cell membrane 
74 sp|P22792|CPN2_HUMAN Carboxypeptidase N subunit 2 Enzyme regulator activity Secreted 
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75 sp|P68133|ACTS_HUMAN Actin, alpha skeletal muscle ADP binding, myosin binding, structural constituent of cytoskeleton, ATP 
binding 
Cytoplasm › cytoskeleton 
76 sp|P07358|CO8B_HUMAN Complement component C8 beta chain Complement activation, alternative pathway Secreted 
77 sp|Q6UXB8|PI16_HUMAN Peptidase inhibitor 16 Peptidase inhibitor activity Membrane 
78 sp|P26927|HGFL_HUMAN Hepatocyte growth factor-like protein Serine-type endopeptidase activity Secreted 
79 sp|P02654|APOC1_HUMAN Apolipoprotein C-I Fatty acid binding, phosphatidylcholine binding, phosphatidylcholine-sterol 
O-acyltransferase activator activity, phospholipase inhibitor activity, lipase 
inhibitor activity 
Secreted 
80 sp|P05543|THBG_HUMAN Thyroxine-binding globulin Hormone binding, serine-type endopeptidase inhibitor activity Secreted 
81 sp|P32119|PRDX2_HUMAN Peroxiredoxin-2 Antioxidant activity, thioredoxin peroxidase activity Cytoplasm 
82 sp|P02746|C1QB_HUMAN Complement C1q subcomponent subunit B Complement activation, classical pathway Secreted 
83 sp|P00740|FA9_HUMAN Coagulation factor IX Calcium ion binding, serine-type endopeptidase activity Secreted 
 
 
